docetaxel anhydrous has been researched along with Metastase in 918 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 64 (6.97) | 18.2507 |
| 2000's | 273 (29.74) | 29.6817 |
| 2010's | 520 (56.64) | 24.3611 |
| 2020's | 61 (6.64) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, Y; Li, Z; Liu, G; Ma, Y; Wang, C; Wang, S | 1 |
| Chen, Y; Guo, W; He, Y; Krimm, I; Li, Y; Liu, M; Mi, D; Pei, H; Shao, T; Wang, P; Wang, X; Yi, Z; Zhang, Y | 1 |
| Ahmed, ME; Andrews, JR; Bold, MS; Bryce, AH; Dundar, A; Jimbo, M; Karnes, RJ; Kendi, AT; Kwon, ED; Lowe, VJ | 1 |
| Blanchet, P; Brureau, L; Gourtaud, G; Roux, V; Sadreux, Y; Senechal, C; Vestris, PG | 1 |
| Deveci Ozkan, A; Guney Eskiler, G; Kaleli, S; Sahin, E | 1 |
| Beijnen, JH; Huitema, ADR; van Eijk, M; van Werkhoven, E; Vermunt, MAC; Wilthagen, EA | 1 |
| Alekseev, B; Crawford, ED; Cruz, F; Fizazi, K; Fu, C; Hussain, M; Joensuu, H; Kopyltsov, E; Kuss, I; Li, R; Maughan, BL; Méndez-Vidal, MJ; Montesa-Pino, Á; Park, CH; Parnis, F; Saad, F; Smith, MR; Sternberg, CN; Suzuki, H; Tammela, TLJ; Thiele, S; Tombal, B; Uemura, M; Utriainen, T; Ye, D | 1 |
| Chen, ML; Chuu, CP; Ho, CH; Huang, HL; Lai, CJ; Lin, YH; Liu, CH | 1 |
| Bianchi, A; Fukuokaya, W; Kawada, T; Kimura, T; Kramer, G; Laukhtina, E; Majdoub, M; Mori, K; Petrov, P; Pradere, B; Quhal, F; Rajwa, P; Shariat, SF; von Deimling, M; Yanagisawa, T | 1 |
| George, DJ | 1 |
| Cheng, H; Huang, X; Lang, T; Li, Y; Liu, Y; Wang, G; Yin, Q; Zheng, Z | 1 |
| Li, J; Liang, X; Shen, Q; Sun, L; Yang, J; Zhang, J; Zuo, T | 1 |
| Ali, A; Amos, CL; Attard, G; Beesley, S; Birtle, A; Brawley, CD; Brown, J; Calvert, J; Capaldi, L; Chowdhury, S; Clarke, NW; Cook, A; Cross, W; Dearnaley, DP; Douis, H; Gale, J; Gibbs, S; Gilbert, D; Gillessen, S; Hoyle, A; Ingleby, FC; James, ND; Jones, RJ; Langley, RE; Lydon, A; MacNair, A; Malik, Z; Mason, MD; Matheson, D; Millman, R; Nikapota, A; O'Sullivan, JM; Omlin, A; Parikh, O; Parker, CC; Parmar, MKB; Protheroe, A; Ritchie, AWS; Rudman, S; Rush, H; Russell, JM; Simms, M; Srihari, NN; Sydes, MR; Tanguay, JS; Tolan, S; Wagstaff, J; Wallace, J; Wylie, J; Zarkar, A | 1 |
| Arai, Y; Habuchi, T; Hatakeyama, S; Narita, S; Ohyama, C; Okamoto, T | 1 |
| Barrack, ER; Gupta, N; Hwang, C; Maahs, L; Reddy, PV; Sanchez, BE; Van Harn, M | 1 |
| Balestra, A; Droz-Perroteau, C; Fizazi, K; Fourrier-Reglat, A; Guiard, E; Joly, F; Jove, J; Lacueille, C; Lamarque, S; Moore, N; Oudard, S; Rouyer, M; Tubach, F | 1 |
| Ali, AA; Alqhtani, H; Balkrishnan, R; de Lima Lopes, G; Diaby, V; Ko, Y; Palacio, S; van Boemmel-Wegmann, S; Wang, CY | 1 |
| Calomino, N; Cherri, S; Farsi, M; Fiaschi, AI; Francini, E; Francini, G; Marrelli, D; Miano, ST; Petrioli, R; Rovello, F; Savelli, V; Vernillo, R | 1 |
| Assenholt, J; Hansen, TF; Madsen, JS; Osther, PJS; Zedan, AH | 1 |
| Ahmed, ME; Andrews, JR; Bryce, AH; Karnes, RJ; Kwon, E | 1 |
| Gao, WQ; Li, L; Liu, L; Liu, Y; Tong, Y; Wang, F | 1 |
| Almassi, N; Carducci, MA; Chen, YH; DiPaola, RS; Dreicer, R; Garcia, JA; Hearn, JWD; Hobbs, B; Jarrard, DF; Li, H; Reddy, CA; Reichard, CA; Sharifi, N; Sweeney, CJ | 1 |
| Cookson, MS; Parker, DC | 1 |
| He, Q; He, S; Hong, X; Lei, Y; Li, J; Li, Q; Li, Y; Liang, Y; Liu, N; Ma, J; Wang, Y; Yang, X; Zhang, P; Zhao, Y | 1 |
| Chan, KKW; Earle, CC; Eisen, A; Gong, IY; Trudeau, ME; Yan, AT | 1 |
| von Amsberg, G | 1 |
| Bossé, D; Canil, C; Koczka, K; Kushnir, I; Mallick, R; Ong, M; Reaume, NM | 1 |
| Merseburger, AS; von Amsberg, G | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Galsky, MD; Martini, A; Montorsi, F; Oh, WK; Pfail, J | 1 |
| Csizmarik, A; Keresztes, D; Küronya, Z; Nagy, N; Nyirády, P; Riesz, P; Szarvas, T; Váradi, M | 1 |
| Assi, T; Farhat, F; Kattan, C; Kattan, J; Rassy, E | 1 |
| Aragon-Ching, JB; Dreicer, R | 1 |
| Ahn, MJ; Burtness, B; Cheng, JD; Chirovsky, DR; Cohen, EEW; Dinis, J; Ellison, MC; Harrington, KJ; Le Tourneau, C; Licitra, LF; Mach, N; Machiels, JH; Mehra, R; Soria, A; Soulières, D; Swaby, RF | 1 |
| Baston, C; Gingu, C; Guler-Margaritis, SS; Preda, A; Sinescu, I | 1 |
| Bismarck, E; Hammerer, P; Merseburger, AS; Schrader, AJ | 1 |
| Azad, AA; Kwan, EM | 1 |
| Kogure, A; Ochiya, T; Prieto-Vila, M; Shimomura, I; Takahashi, RU; Usuba, W; Yamamoto, Y | 1 |
| Eterović, D; Omrčen, T; Vrdoljak, E | 1 |
| Abraham, P; Gricar, J; Shankaran, V; Zhang, Y | 1 |
| Feng, J; Lei, G; Li, H; Li, Q; Li, W; Restuccia, E; Shao, Z; Sun, T; Wang, X; Xu, B; Yin, Y; Zhang, H; Zhang, Q; Zheng, H | 1 |
| Hamilou, Z | 1 |
| Ahmed, ME; Alamiri, J; Alom, M; Andrews, JR; Haloi, R; Higa, J; Jeffrey Karnes, R; Joshi, V; Kwon, E; Motterle, G; Shah, PH | 1 |
| Al Harthy, M; Arlen, PM; Bilusic, M; Chun, G; Cordes, L; Couvillon, A; Dahut, WL; Dawson, NA; Figg, WD; Gulley, JL; Hankin, A; Karzai, FH; Kim, JW; Lee, MJ; Lee, S; Madan, RA; Marte, JL; Owens, H; Peer, CJ; Petrylak, DP; Rosner, I; Steinberg, SM; Theoret, MR; Tomita, Y; Trepel, JB; Williams, M; Yuno, A | 1 |
| Hao, C; Jia, Y; Li, S; Meng, W; Tong, Z; Xie, X; Zhang, J | 1 |
| Aberlenc, A; Bawa, O; Chauchereau, A; Farace, F; Faugeroux, V; Honore, A; Lacroix, L; Laplace-Builhe, C; Marty, V; Oulhen, M; Pawlikowska, P; Pommier, AL; Rouffiac, V; Scoazec, JY; Tayoun, T | 1 |
| Iwamoto, H; Izumi, K; Kadomoto, S; Kadono, Y; Kano, H; Makino, T; Mizokami, A; Naito, R; Shigehara, K; Shimada, T; Yaegashi, H | 1 |
| Anzellini, D; De Sanctis, V; Marinelli, L; Massaro, M; Montalto, A; Osti, MF; Reverberi, C; Valeriani, M | 1 |
| Benelli, A; Campodonico, F; De Censi, A; Ennas, M; Foppiani, L; Grillo-Ruggieri, F; Introini, C; Piccardo, A; Schiavone, C; Squillace, L; Zanardi, S; Zigoura, E | 1 |
| Alajati, A; Alimonti, A; Antonarakis, ES; Attanasio, G; Borrelli, C; Brina, D; Colucci, M; D'Ambrosio, M; De Marzo, AM; Dettwiler, S; Egger, G; Elia, AR; Garcia-Escudero, R; Guccini, I; Losa, M; Moch, H; Moor, AE; Mosole, S; Pasquini, E; Pernigoni, N; Revandkar, A; Rinaldi, A; Rüschoff, JH; Sheibani-Tezerji, R; Troiani, M; Wild, P | 1 |
| de Wit, R; Freedland, S; Tombal, B | 1 |
| Pienta, KJ; Reyes, DK; Rowe, SP; Sheikhbahaei, S | 1 |
| Hervonen, P; Huttunen, T; Jekunen, A; Kataja, V; Kautio, AL; Kellokumpu-Lehtinen, PL; Klintrup, K; Leskinen, M; Luukkaa, M; Marttila, T; Pulkkanen, K; Utriainen, T | 1 |
| Brown, J; Cunningham, J; Gatenby, R; Peeters, R; Staňková, K; Thuijsman, F; Viossat, Y | 1 |
| Bahl, A; Birtle, AJ; Crabb, SJ; Downs, N; Dunkley, D; Elliott, T; Griffiths, G; Jagdev, S; Jones, RJ; Khoo, V; Kumar, S; Light, M; Martin, K; Marwood, E; Northey, J; Robinson, A; Rooney, C; Salinas-Souza, C; Shaw, E; Stephens, C; Sundar, S; Westbury, C; Whitehead, A; Wilding, S | 1 |
| Avcı, S; Kırca, M; Ozpolat, B; Soylu, H; Ustunel, I | 1 |
| Aziz, MIA; Cheng, LJ; Lim, EH; Loke, L; Ng, K; Pearce, F | 1 |
| Chou, CW; Cummings, BS; Finnerty, MC; Ingram, LM; Mansoura, M | 1 |
| Ali, A; Amos, C; Attard, G; Brawley, CD; Calvert, J; Clarke, NW; Cook, A; Dearnaley, D; Douis, H; Gillessen, S; Haran, ÁM; Hoyle, A; James, ND; Mason, MD; Parker, CC; Parmar, MKB; Sydes, MR | 1 |
| Garrison, LP; Jiao, B | 1 |
| Bender, BC; Friberg, LE; Krishnan, SM; Laarif, SS; Quartino, AL | 1 |
| Crehange, G; Geoffrois, L; Gravis, G; Hennequin, C; Kleinclauss, F; Limat, S; Morgans, AK; Nerich, V; Oudard, S; Pelloux-Prayer, R; Schiele, P; Thiery-Vuillemin, A | 1 |
| Girgis-Gabardo, A; Gwynne, WD; Hassell, JA; Shakeel, MS | 1 |
| Bilen, MA; Brown, JT; Carthon, B; Caulfield, S; Kucuk, O; Lafollette, J; Liu, Y; Moore, M; Nazha, B; Russler, G; Smith, KER; Wan, L; Yantorni, L | 1 |
| Biggart, S; Cole, A; Grey, A; Hounsell, AR; Jain, S; McGarry, CK; Mitchell, D; O'Sullivan, JM; Prise, KM; Turner, PG | 1 |
| Akdeniz, N; Bayoğlu, İV; Bilgetekin, İ; Bilir, C; Çınkır, HY; Demirci, A; Demirci, U; Gül, D; Gülbağcı, B; Hacıbekiroğlu, İ; Koca, S; Öksüzoğlu, B; Varım, C | 1 |
| Arik, Z; Gürler, F; Güven, DC; İlhan, A; Kurt İnci, B; Öksüzoğlu, B; Özdemir, N; Özet, A; Sütçüoğlu, O; Turhan, O; Yalçin, Ş; Yazici, O; Yildiz, F | 1 |
| Brunotte, SJ; Ganser, A; Ivanyi, P; Kappler, P; Morgan, MA; Reuter, CWM | 1 |
| Cicero, G; DE Luca, R; Dieli, F; Dorangricchia, P | 1 |
| Han, X; He, W; Lv, Y; Qin, C; Xin, X; Yang, L; Yang, X; Yin, L; Zhang, L | 1 |
| Arranz, JA; Climent, MÁ; Gironés, R; Torregrosa, MD; Vázquez, S | 1 |
| Bergin, ART; de Souza, P; Hovey, E; Lloyd, A; Marx, G; Parente, P; Rapke, T | 1 |
| Andika, R; Ariwicaksono, SC; Hafizar, H; Hidianingsih, S; Hotasi, SL; Patandung, R; Rahardjo, HE; Rahman, F; Sembiring, MGA | 1 |
| Cheng, W; Ghosh, R; Gong, J; Kumar, AP; Li, L; Li, X; Wang, J; Xie, J; Zhang, J; Zhang, Y; Zhang, Z | 1 |
| Aoyagi, E; Kimura, T; Kitamura, S; Mitsui, Y; Miyamoto, H; Muguruma, N; Nakagawa, T; Okamoto, K; Rokutan, K; Takayama, T; Tanahashi, T | 1 |
| Chen, M; Du, Z; Goodin, S; He, Y; Huang, H; Li, D; Wang, H; Wu, X; Yu, L; Zhang, K; Zheng, X | 1 |
| Allende, D; Fadare, O; Forscher, C; Roma, AA; Rutgers, JK | 1 |
| Albers, P; Goebell, PJ; Grimm, MO; Klier, J; König, F; Machtens, S; Ohlmann, CH; Schostak, M; Schrader, AJ | 1 |
| Alshaker, H; Chao, Y; Cooper, C; Pchejetski, D; Srivats, S; Wang, Q | 1 |
| Alshaker, H; Böhler, T; Chao, Y; Cooper, C; Pchejetski, D; Srivats, S; Wang, Q | 1 |
| Burugu, S; Chen, B; Gao, D; Gelmon, KA; Kos, Z; Leung, S; Liu, S; Nielsen, TO; Parulekar, WR; Shepherd, L; Virk, S | 1 |
| Bianchini, D; de Bono, J; Gilman, A; Hall, E; IJzerman, M; Kolinsky, M; Lorente, D; Mateo, J; Mehra, N; Miranda, M; Omlin, A; Payne, H; Perez, R; Pezaro, C; Porta, N; Ravi, P; Rescigno, P; Terstappen, L; Tunariu, N | 1 |
| Beerlage, HP; Bloemendal, HJ; Boerma, MO; Bos, MMEM; Coenen, JLLM; Cordia, I; de Vos, AI; de Wit, R; Geenen, MM; Gerritsen, WR; Hendriks, MP; Peters, FPJ; Polee, MB; Spermon, R; Tick, LW; Uyl-de Groot, CA; van de Wouw, AJ; van den Berg, P; van den Bergh, ACM; van den Bosch, J; van den Eertwegh, AJM; van Moorselaar, RJA; Westgeest, HM | 1 |
| Boher, JM; Culine, S; Fizazi, K; Gravis, G; Habibian, M; Joly, F; Marino, P; Oudard, S; Sfumato, P | 1 |
| Boccardo, F; Messina, C; Messina, M | 1 |
| Scott, LJ | 1 |
| Beresford, MJ; Jefferies, ER; Sarmah, P; Thompson, AL | 1 |
| Annala, M; Beja, K; Beltran, H; Chedgy, EC; Collins, CC; Donoghue, A; Eastham, J; Fazli, L; Gleave, ME; Halabi, S; Mo, F; Morris, M; Sboner, A; Sigouros, M; Taplin, ME; Warner, EW; Wyatt, AW | 1 |
| Blasi, L; Cicero, G; De Luca, R; Dieli, F; Pavone, C; Pepe, A; Simonato, A | 1 |
| Alhasso, A; Carruthers, R; Cascales, A; Dodds, D; Glen, H; Jones, RJ; Lamb, C; Laskey, J; MacLeod, N; Marashi, H; McKay, S; Neilson, S; Rulach, RJ; Russell, JM; Sadoyze, A; Sidek, N; Venugopal, B; Wallace, J; White, L | 1 |
| Chan, ALF; Leung, HWC; Leung, JH; Muo, CH | 1 |
| Ahn, C; Cheedella, N; Choy, H; Dowell, JE; Gerber, DE; Hughes, RS; Iyengar, P; Nedzi, L; Pulipparacharuvil, S; Timmerman, RD; Tumati, V; Wardak, Z; Westover, KD | 1 |
| Eisterer, W; Fridrik, MA; Greil, R; Gruenberger, B; Hejna, M; Huemer, F; Keil, F; Thaler, J; Trommet, V; Ulmer, H; Weiss, L; Wöll, E | 1 |
| Ohlmann, CH | 1 |
| Bhindi, B; Boorjian, SA; Chandrasekar, T; Farrell, AM; Goldberg, H; Karnes, RJ; Klaassen, Z; Kulkarni, GS; Satkunasivam, R; Wallis, CJD | 1 |
| Bowen, K; Carlile, DJ; Eberhardt, WEE; Fischer, JR; Fülöp, A; Girotto, G; Jänne, PA; Kilgour, E; Kohlmann, A; Lago, S; Lishkovska, P; Lovick, S; Maciel, C; Mariani, G; McKeown, A; Ostoros, G; Smit, E; Smith, P; Soria, JC | 1 |
| Baciuchka, M; Berdah, JF; Beuzeboc, P; Boher, JM; Bousquet, G; Culine, S; Dauba, J; Delva, R; Deplanque, G; Eymard, JC; Ferrero, JM; Fizazi, K; Foulon, S; Gravis, G; Habibian, M; Hasbini, A; Joly, F; Kouri, CE; Krakowski, I; Laguerre, B; Latorzeff, I; Lavaud, P; Legoupil, C; Linassier, C; Machiels, JP; Mourey, L; Oudard, S; Platini, C; Pouessel, D; Priou, F; Ravaud, A; Rolland, F; Soulié, M; Suc, E; Tergemina-Clain, G; Théodore, C; Tubiana-Mathieu, N; Zanetta, S | 1 |
| Aoun, F; Assi, T; Bakouny, Z; El Rassy, E; Kattan, J; Sleilaty, G | 1 |
| Gwin, WR; Hobeika, A; Lyerly, HK; Morse, MA; Qiao, G; Ren, J; Song, Q; Wang, X; Zhou, X | 1 |
| Boér, K; Dank, M; Dankovics, Z; Küronya, Z; Lahm, E; Maráz, A; Petrányi, Á; Révész, J; Ruzsa, Á; Szûcs, M; Valikovics, A; Vas, M | 1 |
| Carducci, MA; Chen, YH; Cooney, M; Dipaola, R; Dreicer, R; Eisenberger, M; Garcia, JA; Hahn, N; Harshman, LC; Hussain, M; Jarrard, D; Kohli, M; Liu, G; Picus, J; Plimack, ER; Shevrin, D; Sweeney, CJ; Vogelzang, NJ | 1 |
| Bhardwaj, S; Varma, S | 1 |
| Almawash, SA; Mahato, RI; Mondal, G | 1 |
| Choi, YJ; Kim, BS; Kim, HG; Kim, HS; Kim, KH; Lee, HJ; Lee, HY; Lee, JL; Lee, KH; Park, KH; Park, SH; Shin, DY; Song, HS | 1 |
| Bei, X; Cai, Y; Cheng, W; Hu, C; Huang, W; Jin, J; Li, H; Li, S; Lin, R; Liu, G; Liu, S; Ma, Y; Ou, Y; Pan, T; Rao, J; Wan, L; Wang, Z; Wen, X; Wu, N; Wu, W; Yan, J; Zhang, Q; Zhang, X; Zheng, P | 1 |
| Ci, X; Clermont, PL; Collins, CC; Dong, X; Gout, PW; Hao, J; Lin, D; Qu, S; Wang, Y; Wu, R; Xue, H | 1 |
| Carducci, MA; Chen, YH; Cooney, MM; DiPaola, RS; Dreicer, R; Eisenberger, M; Garcia, JA; Hahn, NM; Hussain, M; Jarrard, DF; Kohli, M; Kyriakopoulos, CE; Liu, G; Picus, J; Plimack, ER; Shevrin, DH; Sweeney, CJ; Vogelzang, NJ | 1 |
| Hong, JH | 1 |
| Boher, JM; Carducci, MA; Chen, YH; DiPaola, R; Dreicer, R; Eisenberger, MJ; Fizazi, K; Garcia, JA; Gravis, G; Habibian, M; Hussain, MHM; Jarrard, DM; Joly, F; Kohli, M; Liu, G; Oudard, S; Picus, J; Soulie, M; Sweeney, C; Vogelzang, NJ | 1 |
| Elkon, JM; Lin, J; Millado, KF; Millett, RL | 1 |
| Baciarello, G; Fizazi, K; Hamilou, Z | 1 |
| Boerner, J; Dobson, K; Fontana, J; Heath, E; Heilbrun, L; Li, J; Smith, D; Stark, K; Thakur, MK; Vaishampayan, U | 1 |
| Gourdin, T | 1 |
| de Reijke, TM; Poorthuis, MHF; van Moorselaar, RJA; Vernooij, RWM | 1 |
| Asano, Y; Fujita, H; Goto, W; Hirakawa, K; Kashiwagi, S; Morisaki, T; Ohira, M; Ohsawa, M; Takada, K; Takashima, T | 1 |
| Ali, A; Brown, M; Clarke, N; Elliott, T; Hart, CA; Hiew, K; Lau, M; Maddineni, S; Ramani, V; Sangar, V | 1 |
| Albiges, L; Bernard, B; Francini, E; Gray, KP; Harshman, LC; Kantoff, PW; Shaw, GK; Sweeney, CJ; Taplin, ME; Valença, L; Xie, W | 1 |
| Filleur, S; Jarvis, C; Martinez-Marin, D; Nelius, T; Sennoune, SR | 1 |
| Jones, RJ | 1 |
| Eisenberger, MA; Isaacsson Velho, P | 1 |
| Aguiar, P; Haaland, B; Lopes, G; Tan, PS | 1 |
| Bang, SM; Choi, IS; Choi, M; Kang, B; Kim, JH; Kim, JW; Kim, SH; Kim, YJ; Lee, JH; Lee, JO; Lee, JS; Lee, JY; Lee, KW; Suh, KJ | 1 |
| Ali, R; Chambers, C; Ghosh, S; North, S; Sawyer, M; Shivji, A | 1 |
| Alva, A; Anderson, J; Autio, KA; Dittamore, R; Dreicer, R; Garcia, JA; Graf, RP; Hart, LL; Milowsky, MI; Morris, MJ; Posadas, EM; Ryan, CJ; Scher, HI; Schreiber, NA; Summa, JM; Youssoufian, H | 1 |
| Al-Batran, SE; Behringer, D; Daum, S; Hacker, U; Ibach, S; Knödler, M; Körfer, J; Kullmann, F; Kunzmann, V; Lindhofer, H; Lordick, F; Schenk, M; Schroll, S; Stahl, M; Trojan, J | 1 |
| Fizazi, K; Hamilou, Z; Saad, F | 1 |
| Akaza, H; Buchan, NC; Chiong, E; Chung, BH; Davis, ID; Kanesvaran, R; Khochikar, M; Le Chuyen, V; Letran, J; Lojanapiwat, B; Murphy, DG; Ng, CF; Ong, T; Pu, YS; Saad, M; Schubach, K; Türkeri, L; Umbas, R; Williams, S; Ye, DW | 1 |
| Aghebati-Maleki, L; Atyabi, F; Jadidi-Niaragh, F; Jafari, R; Majidi Zolbanin, N; Majidi, J; Rafatpanah, H; Shanehbandi, D; Soltani Zangbar, MS; Yousefi, M | 1 |
| Amin, AL; Barnadas, A; Cortés, J; Fuentes-Rivera, H; García-Saenz, JA; Godwin, AK; Gómez, HL; González Del Val, R; González-Rivera, M; Heldstab, J; Jensen, RA; Jerez-Gilarranz, Y; Khan, QJ; Kimler, BF; Klemp, JR; Lehn, C; López-Tarruella, S; Mammen, JV; Márquez-Rodas, I; Martín, M; Massarrah, T; Monte-Millán, MD; Morales, DB; Moreno, F; O'Dea, AP; Palomero, MI; Pelaez-Lorenzo, B; Perou, CM; Picornell, AC; Prat, A; Sharma, P; Wagner, JL; Wang, YY | 1 |
| Astone, M; Beigh, FH; Deng, Y; Ferrari, MG; Ganaie, AA; Hoeppner, LH; Hussain, T; Konety, BR; Koochekpour, S; Maqbool, R; Morrissey, C; Murugan, P; Parray, AS; Saleem, M; Siddique, HR; Umbreen, S | 1 |
| Cristofanilli, M; DiNatale, A; Fatatis, A; Kaur, R; Meucci, O; Qian, C; Shen, F; Worrede-Mahdi, A; Zhang, Q | 1 |
| Du, X; He, Q; Hong, X; Lei, Y; Li, Y; Liu, N; Ma, J; Sun, Y; Tang, X; Wang, Y; Wen, X; Yang, X; Zhang, J; Zhang, P | 1 |
| Akaza, H; Butt, M; Castillo, L; Ecstein-Fraisse, EB; Facchini, G; Fava, S; Hitier, S; Karavasilis, V; Leung, KC; Pripatnanont, C; Procopio, G; Silva, A; Wheatley, D; Ӧzatılgan, A; Ӧzgüroḡlu, M | 1 |
| Gillessen, S; Mottet, N; Yu, EY | 1 |
| Cheng, S; Li, J; Pang, N; Qi, XR; Sun, A; Yang, Z | 1 |
| Ali, A; Alonzi, R; Amos, CL; Attard, G; Bahl, A; Birtle, A; Brawley, CD; Chowdhury, S; Clarke, NW; Cross, W; Dearnaley, DP; Din, O; Douis, H; Eswar, C; Gale, J; Gannon, MR; Gillessen, S; Gilson, C; Hoyle, AP; James, ND; Jones, RJ; Jonnada, S; Khaksar, S; Langley, RE; Lester, JF; Malik, ZI; Mason, MD; Matheson, D; Millman, R; O'Sullivan, JM; Parikh, OA; Parker, CC; Parmar, MKB; Pedley, ID; Pudney, DM; Ritchie, AWS; Russell, JM; Sheehan, DJ; Srihari, NN; Sydes, MR; Thalmann, GN; Tran, ATH | 1 |
| Aksoy, S; Aktas, BY; Alacacioglu, A; Aliyev, A; Artac, M; Basaran, G; Beypinar, I; Bilen, E; Bilici, A; Cabuk, D; Cetin, B; Cicin, I; Cil, T; Degirmencioglu, S; Demir, A; Demir, H; Demirci, U; Er, O; Erdur, E; Eren, T; Erturk, I; Esin, E; Evrensel, T; Gumusay, O; Haksoyler, V; Harputluoglu, H; Imamoglu, I; Kaplan, MA; Karaagac, M; Karadurmus, N; Kocer, M; Korkmaz, T; Kostek, O; Oksuzoglu, B; Olgun, P; Oyan, B; Ozdemir, O; Paydas, S; Pilanci, KN; Sakalar, T; Sakin, A; Seker, M; Sumbul, AT; Tanrikulu, E; Urun, Y; Yetisir, E; Yildirim, N; Yilmaz, H; Yumuk, PF | 1 |
| Duckham, BR; Gater, A; Grant, L; Ito, T; Ribbands, AJ | 1 |
| Cain, D; Chi, KN; Clark, SJ; de Bono, JS; Higano, CS; Horvath, LG; Jacobs, C; Lin, HM; Mahon, KL; Qu, W; Spielman, C; Stockler, MR | 1 |
| Harada, K; Hirayama, M; Irisawa, R; Kato, Y; Mae, K; Saito, M; Tsuboi, R | 1 |
| Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E | 1 |
| Davis, ID; Hamid, AA; Morris, MJ | 1 |
| Araujo, JC; Chi, KN; De Bono, JS; Dutta, S; Eisenberger, MA; Fizazi, K; George, DJ; Halabi, S; Higano, CS; Kelly, WK; Logothetis, C; Morris, MJ; Petrylak, DP; Quinn, DI; Rosenthal, M; Small, EJ; Tangen, CM; Tannock, IF; Thompson, IM | 1 |
| Haukland, E; Mannsåker, B; Nieder, C; Norum, J; Pawinski, A; Yobuta, R | 1 |
| Manjappa, AS; Ramachandra Murthy, RS | 1 |
| Carles, J; Gillessen, S; Heidenreich, A; Heinrich, D; Keizman, D; Miller, K; Nilsson, S; O'Sullivan, JM; Reeves, J; Saad, F; Seger, M; Wirth, M | 1 |
| Chi, C; Dong, B; Fan, L; Gong, Y; Ma, X; Pan, J; Wang, R; Xue, W; Yang, Y; Zheng, H; Zhu, Y | 1 |
| Bouvet, M; Chawla, SP; Endo, I; Higuchi, T; Hiroshima, Y; Hoffman, RM; Kawaguchi, K; Kiyuna, T; Kumamoto, T; Li, Y; Matsuyama, R; Miyake, K; Miyake, M; Murakami, T; Nelson, SD; Oshiro, H; Razmjooei, S; Singh, SR; Wangsiricharoen, S; Zhang, Z | 1 |
| Beijnen, JH; Bergman, AM; Crombag, MBS; de Vries Schultink, AHM; Huitema, ADR; Otten, HM; Schellens, JHM; van Doremalen, JGC | 1 |
| de Freitas, HM; Hadi, M; Hall, F; Ito, T; Kerr, C; Lanar, S; Lloyd, AJ; Nafees, B; Penton, J; Pham, TP | 1 |
| Attard, G; Casadio, V; Castro, E; Conteduca, V; De Giorgi, U; Farolfi, A; Gonzalez-Billalabeitia, E; González-Del-Alba, A; Gurioli, G; Hernando, S; Jayaram, A; Lolli, C; Marin-Aguilera, M; Maugeri, A; Medina, A; Mellado, B; Morales-Barrera, R; Olmos, D; Puente, J; Rodriguez-Vida, A; Romero-Laorden, N; Salvi, S; Scarpi, E; Schepisi, G; Vidal, MJM; Villa-Guzmán, JC; Wetterskog, D; Wingate, A | 1 |
| Beijnen, JH; Bergman, AM; Crombag, MBS; de Vries Schultink, AHM; Huitema, ADR; Otten, HM; Schellens, JHM; van Werkhoven, E | 1 |
| James, ND | 1 |
| Beith, J; De Boer, RH; Redfern, A; Truman, M; White, M; Woodward, N; Young, J | 1 |
| Chen, E; Evans, A; Hansen, AR; Joshua, AM; Knox, J; Prawira, A; Sridhar, SS; Tan, S; Tannock, IF; Templeton, A; Vera-Badillo, F; Wang, L; Wouters, BG | 1 |
| Battaglia, A; De Meerleer, G; Devos, G; Everaerts, W; Joniau, S; Moris, L; Tosco, L; Van den Broeck, T | 1 |
| Bowman, L; Cuyun Carter, G; Garon, EB; Lin Cui, Z; Pérol, M; Winfree, KB | 1 |
| Bögemann, M; Goebell, PJ; Hammerer, P; Machtens, S; Pfister, D; Schostak, M; Schwentner, C; Steuber, T; von Amsberg, G; Wülfing, C | 1 |
| Dutta, S; Halabi, S; Kelly, WK; Morris, MJ; Russell, C; Ryan, CJ; Small, EJ; Taplin, ME | 1 |
| Choi, SY; Joung, JY; Kim, CS; Kim, SH; Kwon, WA; Lee, JE; Lee, KH; Seo, HK | 1 |
| Hammerer, P; Manka, L | 1 |
| Al-Janadi, A; Bolton, S; Flaig, T; Heath, E; Heilbrun, L; Hussain, A; Ivy, SP; Lara, P; Liu, G; Mack, P; Mannuel, H; Monk, JP; Silbiger, D; Smith, D; Stella, P; Usman, M; Vaishampayan, U; Zurita, A | 1 |
| Gschwend, JE; Horn, T; Maisch, P; Retz, M; von Amsberg, G | 1 |
| Chapin, BF; Ranasinghe, WKB; Reichard, CA | 1 |
| Li, Z; Liu, S; Ren, Q; Shao, J; Wang, S; Yu, XF | 1 |
| Armstrong, CM; Cai, D; Chen, J; Chen, N; Dai, J; Guo, W; Liu, J; Liu, Z; Ni, Y; Nie, L; Shen, P; Sun, G; Yin, X; Zeng, H; Zhang, H; Zhang, M; Zhang, X; Zhao, J; Zhao, P; Zhu, S; Zhu, X | 1 |
| Abbas, F; Al Dousari, S; Al Hallaq, Y; Al Hamdani, N; Alameh, W; Ashou, R; Assaf, G; Bachir, B; Bitar, N; Bulbul, M; Dagher, C; Dbouk, H; El Khoury, C; El-Hajj, A; Faddoul, S; Farha, G; Farhat, F; Geara, F; Ghazal, H; Gillessen, S; Haidar, M; Hussain, HK; Ibrahim, K; Jabbour, M; Khauli, R; Mukherji, D; Nasr, R; Nemer, E; Omlin, A; Rabah, D; Said, R; Sakr, G; Sayyid, K; Shamseddine, A; Temraz, S; Wazzan, W; Youssef, B; Zouain, N | 1 |
| Bai, SB; Cheng, Y; Cui, H; Cui, MX; Liu, DZ; Liu, M; Mei, QB; Zhang, BL; Zhou, SY | 1 |
| Chan, A; Cortés, J; de Haas, SL; Delmar, PR; Dirix, LY; Miles, DW; Pivot, X; Provencher, L; Romieu, G; Scherer, SJ; Tomczak, P | 1 |
| Agarwal, A; Aljumaily, R; Covic, L; Kaimal, R; Kim, YB; Kuliopulos, A; Pradhan, RV; Sharifi, S; Tressel, SL; Zarwan, C | 1 |
| Adjei, A; Brenner, DE; Cease, KB; Daignault-Newton, S; Dy, GK; Elingrod, VL; Johnson, CS; Kalemkerian, GP; Muindi, JR; Ramnath, N; Stella, PJ; Troeschel, S; Trump, DL | 1 |
| Arnold, D; Dietz, A; Eberhardt, W; Gauler, TC; Gruenwald, V; Hennemann, B; Hofele, C; Jordan, WO; Keilholz, U; Knoedler, M; Matzdorff, A; Schroeder, M; Weissinger, F | 1 |
| Batra, SK; Johansson, SL; Mimeault, M | 1 |
| Argiris, A; Burtness, B; Forastiere, AA; Ghebremichael, M; Gilbert, J; Kolesar, JM; Lee, JW; Sachidanandam, K | 1 |
| Fleitas, T; Gómez-Codina, J; Martín, M; Martínez-Sales, V; Mesado, D; Montalar, J; Reganon, E; Reynés, G; Vila, V | 1 |
| Amadori, D; Baselga, J; Benyunes, MC; Clark, E; Cortés, J; Ewer, MS; Knott, A; Miles, D; Ross, G; Swain, SM | 1 |
| Gao, F; Luo, J; Sun, X; Sun, Z; Wang, H; Zhang, Y; Zhao, X; Zhong, B | 1 |
| Miller, K; Saad, F | 1 |
| Boy, D; Bruzzi, P; Ceccarelli, M; Cognetti, F; De Laurentiis, M; De Placido, S; Del Mastro, L; Durando, A; Fabi, A; Kazeem, G; La Torre, I; Mansutti, M; Marchi, P; Merlo, DF; Venturini, M | 1 |
| Chen, LB; Chen, YT; Cui, SY; De, W; Feng, B; Huang, GC; Huang, JY; Song, HZ; Wang, R | 1 |
| Allen, P; Buchholz, TA; Buzdar, AU; Gonzalez-Angulo, AM; Hortobagyi, GN; Hunt, KK; Kim, MM; Kuerer, HM; Litton, JK; Meric-Bernstam, F; Mittendorf, EA; Woodward, WA | 1 |
| Hotte, SJ; Loblaw, DA; Walker-Dilks, C; Winquist, E | 1 |
| Al-Batran, SE; Bichev, D; Haller, B; Homann, N; Lordick, F; Lorenzen, S; Luley, K; Pauligk, C; Schumacher, G; Schuster, T; Thuss-Patience, P | 1 |
| Chen, L; Chen, YX; Hao, LH; Jiang, XJ; Li, ZY; Lin, HZ; Song, MQ | 1 |
| Aragon-Ching, JB | 1 |
| Bellmunt, J; Fitzpatrick, JM; Jenkins, C; Merseburger, AS; Parker, C | 1 |
| D'Auria, G; Fabbri, MA; Frittelli, P; Massari, A; Moscetti, L; Natoli, G; Nelli, F; Ruggeri, EM | 1 |
| Aragon-Ching, J; Beatson, M; Chau, CH; Dahut, WL; Figg, WD; Gao, R; Gulley, JL; Madan, RA; Sissung, TM; Spencer, S; Steinberg, SM | 1 |
| Galsky, MD; Goyal, J; Hendricks, R; Pond, GR; Small, A; Sonpavde, G; Tsao, CK | 1 |
| Frear, M; Gong, C; Kwon, S; Malmstrom, R; Nguyen, N; Pon, V; Srinivas, S; Wilson, L; Zhong, L | 1 |
| Battaglia, M; Bettocchi, C; Ditonno, P; Fanelli, M; Galleggiante, V; Germinario, CA; Larocca, AM; Lucarelli, G; Maiorano, E; Rutigliano, M; Selvaggi, FP; Spilotros, M; Vavallo, A | 1 |
| Bahl, A; de Bono, JS; Devin, J; Gravis, G; Hansen, S; Kocak, I; Oudard, S; Ozgüroglu, M; Sartor, AO; Shen, L; Tombal, B | 1 |
| Adkins, D; Clark, J; Haddad, R; Jaffa, Z; Limaye, S; O'Neill, A; Posner, M; Riley, S; Zhao, S | 1 |
| Dahan, L; Dalban, C; Landi, B; Lepère, C; Mazard, T; Mitry, E; Pernot, S; Rougier, P; Samalin, E; Seitz, JF; Taieb, J; Turki, H; Vaillant, JN; Ychou, M; Zaanan, A | 1 |
| Blumenthal, GM; Chattopadhyay, S; Chi, B; Cortazar, P; Graham, L; Hughes, P; Ibrahim, A; Justice, R; King, KE; Liu, Q; Pazdur, R; Pilaro, AM; Rellahan, BL; Ringgold, K; Scher, NS; Song, P; Tang, S; Thomas, C; Tilley, A; Weinberg, WC | 1 |
| Hsu, HH; Huang, GS; Kao, HL; Lin, WC | 1 |
| Ramfidis, VS; Saif, MW; Syrigos, KN | 1 |
| Amagai, K; Hirai, S; Hironaka, S; Hirose, M; Hyodo, I; Mamiya, T; Matsuda, K; Moriwaki, T; Murashita, T; Nihei, T; Ohkawara, A; Ozeki, M; Sato, M; Soeda, A; Yamaguchi, T | 1 |
| Baselga, J; Clark, E; Cortés, J; Im, SA; Im, YH; Knott, A; Pivot, X; Ross, G; Swain, SM | 1 |
| Heidenreich, A; Pfister, D; Piper, C; Porres, D; Thissen, AK | 1 |
| Ahallal, Y; Barret, E; Bennamoun, M; Cathelineau, X; Cerruti, J; Durand, M; Galiano, M; Gaya, JM; Macek, P; Prapotnich, D; Ropert, S; Rozet, F; Sanchez-Salas, R | 1 |
| Burris, HA; Crown, J; DeSilvio, M; Diéras, V; Espie, M; Kennedy, MJ; Koch, KM; Kothari, D; Lau, MR; Marty, M; Tresca, P | 1 |
| Gustafson, DL; Hudachek, SF | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Baselga, J; Brewster, M; Cortés, J; Garg, A; Grincuka, E; Hauschild, M; Kudaba, I; Lum, BL; Marier, JF; Masuda, N; McNally, V; Nijem, I; Patel, T; Ross, G; Swain, SM; Trinh, MM; Visich, J | 1 |
| Cella, D; de Bono, JS; Fizazi, K; Gagnon, DD; Hao, Y; Haqq, CM; Harland, S; Kheoh, T; Logothetis, CJ; Molina, A; Scher, HI; Staffurth, J; Sternberg, CN | 1 |
| McCormack, PL | 1 |
| Hosono, MN; Kamo, R; Miki, Y; Ogino, R; Shimatani, Y; Tada, T; Tamiya, H; Tsutsumi, S | 1 |
| Chen, WW; Cheng, AL; Hsu, CH; Huang, TC; Lin, CC; Yeh, KH | 1 |
| Beer, TM; Harzstark, AL; Liu, G; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK | 1 |
| Dionysopoulos, D; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Kotoula, V; Kourea, HP; Koutras, AK; Papadimitriou, C; Papadopoulou, K; Pectasides, D; Samantas, E; Skarlos, DV; Zagouri, F | 1 |
| de Bono, JS; Fizazi, K; Flaig, TW; Goodman, OB; Kheoh, T; Li, J; Molina, A; Mulders, PF; Scher, HI; Suttmann, H | 1 |
| Ozdemir, O; Ozdemir, P; Ozhan, MH; Uluer, H; Veral, A | 1 |
| Attili-Qadri, S; Benita, S; Karra, N; Nassar, T; Nemirovski, A; Schwob, O; Talmon, Y | 1 |
| Horie, T; Ishibashi, Y; Mizumoto, K; Noso, Y; Yamagata, S | 1 |
| Amadori, D; Baselga, J; Clark, E; Knott, A; Miles, D; Ross, G; Semiglazov, V; Sunpaweravong, P; Swain, SM | 1 |
| Lin, J; Pan, W; Shi, H; Wu, H; Yu, H; Zhu, J | 1 |
| Boni, G; Borsò, E; Cianci, C; Federici, F; Francesca, F; Lorenzoni, A; Mariani, G; Mazzarri, S; Orlandini, C; Pastina, I; Ricci, S; Rubello, D; Selli, C | 1 |
| Chaigneau, L; Chelly, J; Fiteni, F; Limat, S; Meneveau, N; Monnot, T; Montcuquet, P; Nerich, V; Perrin, S; Pivot, X; Villanueva, C; Voidey, A | 1 |
| Chen, WT; Dong, H; Doty, S; Friedlander, TW; Gilbert, EG; Ngo, VT; Paris, PL; Premasekharan, G; Ryan, CJ; Weinberg, V; Zhao, Q | 1 |
| Bahl, A; Barber, J; Burnett, S; Carrington, B; Chester, JD; Cruickshank, C; Elliott, T; Hall, E; Harland, SJ; Nicholson, S; Pickering, L; Thomson, A; Waters, R | 1 |
| Bompas, E; Clarisse, B; Cojocarasu, O; Delva, R; Eymard, JC; Guillot, A; Houede, N; Joly, F; Leconte, A; Lheureux, S; Linassier, C; Mourey, L; Oudard, S; Ravaud, A; Ringensen, F; Sevin, E; Tubiana-Mathieu, N; Valenza, B; Vedrine, L | 1 |
| de Morrée, ES; de Wit, R; Mathijssen, RH; Moll, JM; Teubel, W; van Royen, ME; van Soest, RJ; van Weerden, WM; Wiemer, EA | 1 |
| Afonso, J; Antón Aparicio, LM; Campos, B; Fernández, O; Lázaro, M; León, L; Vázquez, S | 1 |
| Beijnen, JH; Helgason, HH; Huitema, AD; Koolen, SL; Kruijtzer, CM; Malingre, MM; Schellens, JH; Schot, ME; Smit, WM; Werkhoven, Ev | 1 |
| Barraclough, H; Cheng, R; Kim, JH; Orlando, M; Pereira, JR | 1 |
| Ando, T; Fujinami, H; Hosokawa, A; Kajiura, S; Mihara, H; Minemura, M; Nishikawa, J; Ogawa, K; Sugiyama, T; Ueda, A; Ueda, Y; Yoshita, H | 1 |
| Bahl, A; Castellano, D; Chen, I; Chow Maneval, E; Daugaard, G; Gschwend, J; Houede, N; Jones, R; Laestadius, F; Lechuga, MJ; Maurina, T; Michaelson, MD; Ostler, P; Ou, YC; Oudard, S; Paolini, J; Saad, F; Sengeløv, L; Stenzl, A; Ullèn, A; Wang, SL | 1 |
| Fan, Y; Li, J; Liao, Y; Peng, L; Wan, Y | 1 |
| Hanaoka, J; Hayama, M; Inoue, H; Kanai, O; Kataoka, Y; Kitamura, T; Kobayashi, T; Mio, T; Motoishi, M; Okamoto, K; Okamura, M; Oshio, M; Sawai, S; Tanaka, H | 1 |
| Abdi, E; Bonaventura, A; Craft, P; de Souza, P; Hill, A; Hovey, E; Lloyd, A; Marx, G; Michele, A; Parente, P; Rapke, T | 1 |
| Aragon-Ching, JB; El-Bahesh, E; Elkon, J; Gupta, K | 1 |
| Cho, JY; Chung, HC; Fujii, M; Hara, T; Hosaka, H; Imamura, H; Inokuchi, M; Kim, HK; Kim, YH; Koizumi, W; Lee, KH; Nakajima, T; Ogura, M; Okuno, T; Satoh, T; Takagane, A; Takeuchi, M; Tanabe, K; Tsuji, A; Yoshida, K | 1 |
| Chen, X; Deng, M; Li, M; Lv, S; Song, W; Sun, H; Tang, Z; Yu, H; Zhang, D; Zhang, Y | 1 |
| Gonda, T; Halmos, B; Melamed, J; Miller, G; Rotterdam, H; Seetharamu, N; Villanueva, G | 1 |
| Baciuchka, M; Berdah, JF; Beuzeboc, P; Bousquet, G; Dauba, J; Delva, R; Deplanque, G; El Kouri, C; Esterni, B; Eymard, JC; Ferrero, JM; Fizazi, K; Gravis, G; Habibian, M; Hasbini, A; Joly, F; Krakowski, I; Labourey, JL; Laguerre, B; Latorzeff, I; Linassier, C; Machiels, JP; Marino, P; Mourey, L; Oudard, S; Platini, C; Pouessel, D; Priou, F; Ravaud, A; Rolland, F; Soulie, M; Suc, E; Théodore, C; Zanetta, S | 1 |
| Bahl, A | 1 |
| Bell, MC; Braly, P; Childs, BH; Drake, RD; Einstein, MH; Herzog, TJ; Hines, JF; Monk, BJ; Roman, LD; Rose, PG; Secord, AA; Wenham, RM | 1 |
| Barranger, E; Bertheau, P; Bousquet, G; de Bazelaire, C; Ferreira, I; Feugeas, JP; Janin, A; Jourdan, N; Vercellino, L | 1 |
| Aparicio, LM; de Bono, JS; Fong, P; Gillessen, S; Hudes, GR; Pandha, HS; Petrylak, DP; Piulats, JM; Pollak, MN; Saad, F; Sandhu, SK; Scranton, J; Wang, T | 1 |
| Bayraktar, S; Blaya, M; Green, MR; Levi, J; Lopes, G; Macintyre, J; Mayo, C; Merchan, J; Rocha-Lima, CM; Silva, O; Soares, HP; Walker, G | 1 |
| Badarinath, S; Childs, BH; Keaton, MR; Schwartzberg, LS | 1 |
| Glimelius, B; Gubanski, M; Lind, PA | 1 |
| Baykara, M; Benekli, M; Buyukberber, S; Coskun, U; Dane, F; Demirci, U; Karaca, H; Ozdemir, NY; Ozkan, M; Ulas, A | 1 |
| Altavilla, A; Attard, G; Bianchini, D; de Bono, JS; Ferraldeschi, R; Grist, E; Lorente, D; Mateo, J; Ravi, P; Sideris, S; Smith, A; Wong, S; Zafeiriou, Z | 1 |
| Charalambous, E; Dimopoulos, MA; Dionysopoulos, D; Fountzilas, G; Kotoula, V; Koutras, A; Kouvatseas, G; Papandreou, CN; Papazisis, K; Pectasides, D; Pentheroudakis, G; Samantas, E; Zagouri, F | 1 |
| Bilici, A | 1 |
| Barni, S; Blasi, L; Cinieri, S; Colucci, G; De Vita, F; Fedele, P; Filippelli, G; Gebbia, N; Giotta, F; Lorusso, V; Maiello, E; Orlando, L; Pappagallo, GL; Pisconti, S; Riccardi, F; Verderame, F | 1 |
| Huang, SM; Li, JX; Lu, TX; Wen, BX | 1 |
| Hu, GQ; Hu, GY; Lin, JW; Liu, DB; Long, GX; Mei, Q; Yuan, XL; Zhou, XY | 1 |
| Balslev, E; Bartels, A; Bjerre, C; Bjerre, KD; Brünner, N; Ejlertsen, B; Jørgensen, CL; Nielsen, DL | 1 |
| Brock, MV; Guo, M; Herman, JG; Lu, Y; Wu, K; Yan, W; Yang, Y; Zhang, Z; Zhou, Y | 1 |
| Antonarakis, ES; Brodsky, RA; Park, JC; Pratz, CF; Tesfaye, A | 1 |
| Antón Aparicio, LM; Batista, N; Castellano, D; Esteban, E; Germà, JR; Luque, R; Maroto, P; Méndez-Vidal, MJ; Pérez-Valderrama, B; Sánchez-Hernández, A | 1 |
| Allyon, J; Deplanque, G; Dufour-Lamartinie, JF; Elaidi, R; Ferrero, JM; Houillier, P; Lerest, C; Mackenzie, S; Maruani, G; Maurina, T; Medioni, J; Oudard, S; Raymond, E; Renaux, S; Rodier, JM | 1 |
| Bellmunt, J; de Bono, JS; Efstathiou, E; Kheoh, T; Li, J; Loriot, Y; Molina, A; Montgomery, B; Ryan, CJ; Scher, HI; Tran, N | 1 |
| Li, J; Li, X; Liu, H; Liu, M; Wang, J; Xu, J; Yang, H; Zhang, Y | 1 |
| Pal, SK; Sartor, O | 2 |
| Blumenthal, GM; Chen, HY; He, K; Justice, R; Kazandjian, D; Keegan, P; Patel, M; Pazdur, R | 1 |
| Antonarakis, ES; Carducci, MA; Denmeade, SR; Eisenberger, MA; Nadal, R; Paller, CJ; Rahman, H; Schweizer, MT; Zhang, Z | 1 |
| Gordian, E; Quintero, C; Ramachandran, K; Reis, IM; Singal, R; Zhao, W | 1 |
| Basch, E; Bennett, CL; Carducci, M; Chen, RC; Dusetzina, SB; Frame, JN; Garrels, K; Hotte, S; Kattan, MW; Loblaw, DA; Oliver, TK; Raghavan, D; Rumble, RB; Saad, F; Taplin, ME; Virgo, KS; Walker-Dilks, C; Williams, J; Winquist, E; Wootton, T | 1 |
| Bergman, AM; Bos, MM; Coenen, JL; de Wit, R; Gelderblom, H; Hamberg, P; Lolkema, MP; Los, M; Ten Tije, AJ; van den Berg, P; van den Eertwegh, AJ; van Oort, IM; Westgeest, HM; Wissing, MD | 1 |
| Boukovinas, I; Briasoulis, E; Dimopoulos, MA; Fountzilas, G; Kalogera-Fountzila, A; Karavasilis, V; Klouvas, G; Kosmidis, P; Kotoula, V; Mavropoulou, P; Papandreou, CN; Pectasides, D; Syrigos, KN | 1 |
| Clarke, NW; De Bono, JS; Dearnaley, DP; Gale, J; Hetherington, J; Hoskin, PJ; James, ND; Jones, RJ; Laing, R; Lester, JF; Mason, MD; McLaren, D; Parker, CC; Parmar, MKB; Ritchie, AWS; Russell, JM; Spears, MR; Strebel, RT; Sydes, MR; Thalmann, GN | 1 |
| Antonia, S; Dees, EC; Han, H; Harvey, RD; Ismail-Khan, R; Jackson, E; Link, C; Minton, S; Neuger, T; Soliman, HH; Sullivan, DM; Vahanian, NN | 1 |
| Eppler, S; Gordon, M; Lum, BL; Redfern, CH; Trudeau, C; Xu, N | 1 |
| Agelaki, S; Boukovinas, I; Christophyllakis, Ch; Georgoulias, V; Kalbakis, K; Kalykaki, A; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Mavroudis, D; Vamvakas, L; Vardakis, N | 1 |
| Carducci, MA; Friedman, PN; Halabi, S; Hertz, DL; Jiang, C; Kelley, MJ; Kelly, WK; Mahoney, JF; McLeod, HL; Morris, MJ; Mulkey, FA; Owzar, K; Patel, JN; Ratain, MJ; Small, EJ | 1 |
| Hou, C; Jiang, Y; Liu, Y; Sun, B; Yang, N; Zhang, H; Zheng, J; Zuo, P | 1 |
| Fujimura, T; Fukuhara, H; Hattori, M; Homma, Y; Igawa, Y; Kakutani, S; Kume, H; Miyazaki, H; Nagata, M; Nakagawa, T; Niimi, A; Taguchi, S | 1 |
| Akaza, H; Imanaka, K; Nakatani, T; Nishiyama, T; Ozono, S; Satoh, T; Tanabe, K; Terai, A; Uemura, H; Yokomizo, A | 1 |
| Fahrbach, K; Griebsch, I; Kaiser, R; Martin, A; Mellemgaard, A; Popat, S; Reck, M; Rizzo, M | 1 |
| Hirakawa, K; Kashiwagi, S; Kawajiri, H; Noda, S; Onoda, N; Takashima, T | 1 |
| Chen, LK; Hu, ZH; Huang, Y; Liu, JL; Ma, Y; Ma, YX; Wei, CL; Wu, X; Xu, F; Xue, C; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY; Zou, BY | 1 |
| Chen, C; Chmielowski, B; Ernst, S; Gonzalez, R; Jie, F; Keating, A; Kudchadkar, R; Redman, BG; Steinberg, J; Weber, J | 1 |
| Aggarwal, RR; Alumkal, J; Beer, TM; Graff, JN; Herrera, I; Higano, C; Lin, AM; Nordquist, LT; Ryan, CJ; Small, EJ; Taplin, ME; Weinberg, VK | 1 |
| Adkins, D; Bauman, JE; Beauregard, P; Bowles, DW; Hausman, D; Jimeno, A; Levy, B; Rudin, CM; Schnadig, I; Seetharamu, N; Shirai, K; Spira, A; Walker, L; Weissman, C | 1 |
| Agarwal, N; Antonarakis, ES; Azad, A; Batten, JA; Cheng, HH; Chi, KN; Galsky, MD; Gulati, R; Heath, EI; Leiter, A; Montgomery, RB; Nadal, R; Pal, SK; Rehman, HT; Twardowski, P; Vaishampayan, UN; Yu, EY | 1 |
| Eppler, S; Gordon, MS; Han, K; Lum, BL; Redfern, CH; Trudeau, C; Xu, N | 1 |
| Albert, S; Antoine, M; Banal, A; Baril, P; Belloc, JB; Benetkiewicz, M; Bonnetain, F; Céruse, P; Chabolle, F; Chibaudel, B; de Gramont, A; Gatineau, M; Housset, M; Lacau St Guily, J; Lacave, R; Lefevre, M; Moukoko, R; Périé, S; Soussan, P | 1 |
| Babacan, NA; Deveci, K; Kacan, T; Sancakdar, E; Seker, A; Seker, MM; Turesin, AK; Yilmaz, A | 1 |
| Baselga, J; Benyunes, MC; Campone, M; Ciruelos, E; Clark, E; Cortés, J; Ferrero, JM; Heeson, S; Kim, SB; Ro, J; Ross, G; Schneeweiss, A; Semiglazov, V; Swain, SM | 1 |
| Andergassen, U; Eiber, M; Gschwend, JE; Hatzichristodoulou, G; Heck, MM; Kehl, V; Krause, BJ; Nawroth, R; Rack, B; Retz, M; Souvatzoglou, M; Thalgott, M | 1 |
| Anderson, SA; Azad, AA; Bazov, J; Bell, RH; Chi, KN; Collins, CC; Gleave, ME; Haegert, A; Le Bihan, S; McConeghy, B; Paris, P; Shukin, R; Small, EJ; Thomas, G; Volik, SV; Wang, Y; Wyatt, AW; Youngren, J | 1 |
| Bakkum-Gamez, JN; Behbakht, K; Hensley, ML; Mannel, RS; Michael, H; Miller, A; O'Malley, DM | 1 |
| Berry, W; McNamara, M | 1 |
| Akazawa, Y; Funakoshi, T; Mima, H; Niki, T; Tagawa, H; Taniguchi, Y | 1 |
| Al-Batran, SE; Burmester, M; Hinke, A; Hofheinz, RD; Hozaeel, W; Hübner, A; Koenigsmann, M; Kuhl, R; Linsse, B; Pauligk, C; Tauchert, FK; Wiegand, J; Windemuth-Kieselbach, C; Zur Hausen, G | 1 |
| Barile, C; Basso, U; Buti, S; Caffo, O; De Vivo, R; Facchini, G; Fratino, L; Galligioni, E; Gernone, A; Lo Re, G; Lodde, M; Maines, F; Pappagallo, GL; Perin, A; Sacco, C; Sava, T; Veccia, A; Zustovich, F | 1 |
| Cao, P; Do, T; Ernsting, MJ; Gill, B; Hedley, D; Hoang, B; Li, SD; Lohse, I; Pintilie, M; Undzys, E | 1 |
| Bergh, J; Foukakis, T; Giorgetti, C; Hedayati, E; Jacobsson, H; Lindström, LS; Lövrot, J; Sandqvist, P; Xie, H | 1 |
| Hernandez-Aya, LF; Hussain, M | 1 |
| Cui, Y; Ma, T; Ma, W; Xiao, P; Zhang, H; Zhou, C; Zu, S | 1 |
| Chopra, S; Rashid, P | 1 |
| Kawakami, H; Nakagawa, K; Nishina, S; Nonagase, Y; Okabe, T; Sakiyama, T; Tamura, T; Ueda, S | 1 |
| Andergassen, U; Eiber, M; Gschwend, JE; Heck, MM; Kehl, V; Krause, BJ; Kronester, C; Nawroth, R; Rack, B; Retz, M; Souvatzoglou, M; Thalgott, M | 1 |
| Bianco, V; Fiaschi, AI; Francini, E; Laera, L; Petrioli, R; Ponchietti, R; Roviello, G | 1 |
| Fu, L; Huang, W; Li, H; Liang, Z; Liu, R; Luo, R; Wu, J; Xiao, X; Xie, F; Zhao, P; Zhu, X; Zhu, Y | 1 |
| Fiaschi, AI; Francini, E; Laera, L; Petrioli, R; Ponchietti, R; Roviello, G | 1 |
| Golstov, AA; Hirayama, T; Karanika, S; Karantanos, T; Kurosaka, S; Li, L; Park, S; Tanimoto, R; Thompson, TC; Wang, J; Yang, G | 1 |
| Hata, A; Hattori, Y; Imamura, F; Kaneda, T; Katakami, N; Kumagai, T; Morita, S; Negoro, S; Nishimura, T; Nishino, K; Okuda, C; Satouchi, M; Tachihara, M; Urata, Y; Yokota, S | 1 |
| Fujino, Y; Hirakawa, M; Hirata, K; Kagawa, M; Kato, J; Katsuki, S; Kobune, M; Kubo, T; Mitsui, Y; Miyamoto, H; Miyoshi, J; Nobuoka, T; Ohnuma, H; Okuda, T; Osuga, T; Sagawa, T; Sato, Y; Takahashi, Y; Takaoka, T; Takayama, T; Takimoto, R | 1 |
| Carducci, MA; Chen, YH; DiPaola, RS; Dwyer, AJ; Gulley, JL; Madan, RA; McNeel, DG | 1 |
| Cai, YL; Guo, W; He, Y; Hong, CS; Hu, YJ; Ji, T; Lee, JJ; Li, J; Myers, JN; Ren, GX; Sun, J; Tu, WY; Wang, LZ; Wang, YA; Wang, ZH; William, WN; Xu, LQ; Yang, WJ; Ye, WM; Yin, QM; Zhang, CP; Zhang, ZY; Zhong, LP; Zhu, HG; Zhuang, Z | 1 |
| Cui, YQ; Geng, Q; Li, J; Lin, HC; Liu, L; Yan, MX; Yao, M; Yu, T; Zhang, FL; Zhu, MX | 1 |
| Fujita, S; Hata, A; Iwasaku, M; Katakami, N; Korogi, Y; Mori, M; Morita, S; Namba, Y; Nishino, K; Nishiyama, A; Okuyama, T; Otsuka, K; Takeshita, J; Uchida, J; Yoshioka, H | 1 |
| Ahn, JH; Chung, HC; Im, SA; Im, YH; Jung, KH; Kang, SY; Kim, JH; Kim, SB; Park, HS; Ro, J; Song, HS; Yoo, C | 1 |
| Crawford, ED; Higano, CS; Hussain, M; Petrylak, DP; Shore, ND | 1 |
| Bonomi, M; Ceresoli, GL; De Vincenzo, F; Sauta, MG; Zucali, PA | 1 |
| Beer, TM; Graff, JN | 2 |
| Cai, J; Ding, H; Gu, X; Huang, H; Li, M; Wang, Q; Wang, Y; Xu, P; Yang, L; Yang, Q; Zhang, S; Zhu, J | 1 |
| De Laurentiis, M; Mustacchi, G | 1 |
| Baker, H | 1 |
| Bergman, AM; Bos, MM; Chitu, D; de Morrée, ES; de Wit, R; Goey, SH; Hamberg, P; Mathijssen, RH; Nieuweboer, AJ; van der Meer, N; van Soest, RJ | 1 |
| Ahn, S; Byun, SS; Hong, SK; Jeong, SJ; Jo, JK; Kim, KB; Lee, S; Lee, SE | 1 |
| Arlen, PM; Donahue, RN; Farsaci, B; Folio, LR; Grenga, I; Gulley, JL; Heery, CR; Ibrahim, NK; Jochems, C; Koenig, K; Madan, RA; Marté, JL; McMahon, S; Mohebtash, M; Murray, JL; Schlom, J; Steinberg, SM | 1 |
| Dreicer, R | 1 |
| Armstrong, AJ; Li, J | 1 |
| Audenet, F; Basset, V; Branchereau, J; de La Taille, A; Flamand, V; Lebdai, S; Lebret, T; Murez, T; Neuzillet, Y; Ploussard, G | 1 |
| Bertaglia, V; Buttigliero, C; Di Maio, M; Fiori, C; Porpiglia, F; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
| Alesini, D; Basso, U; Caffo, O; Campadelli, E; Conteduca, V; D'Angelo, A; De Giorgi, U; Donini, M; Ermacora, P; Fratino, L; Gasparro, D; Giordano, M; Lo Re, G; Lolli, C; Maines, F; Massari, F; Messina, C; Procopio, G; Ratta, R; Veccia, A; Verderame, F; Zagonel, V | 1 |
| Altavilla, A; Bracarda, S; Carlini, P; Caserta, C; Chioni, A; De Angelis, V; Derosa, L; Felici, A; Galli, L; Hamzaj, A; Pastina, I; Rossi, M; Scali, S; Sisani, M | 1 |
| Plow, EF; Sossey-Alaoui, K | 1 |
| Chang, K; Dai, B; Jia, ZW; Kong, YY; Li, GX; Qu, YY; Wang, Y; Ye, DW | 1 |
| Bellmunt, J; Davis, ID; de Bono, JS; De Porre, P; Fizazi, K; Griffin, TW; Kheoh, T; Molina, A; Mulders, PF; Oudard, S; Protheroe, A; Rathkopf, DE; Ryan, CJ; Saad, F; Scher, HI; Schrijvers, D; Small, EJ; Smith, MR; Taplin, ME; Yu, MK | 1 |
| Albany, C; Sonpavde, G | 1 |
| Antonarakis, ES; Dzinic, SH; Freeman, S; Heath, EI; Heilbrun, LK; Li, X; Liu, G; Sheng, S; Smith, D; Stein, M; Thakur, MK; Vaishampayan, U | 1 |
| Albiges, L; Beuzeboc, P; Boher, JM; Culine, S; Delva, R; Deplanque, G; Ferrero, JM; Fizazi, K; Gravis, G; Habibian, M; Joly, F; Krakowski, I; Laguerre, B; Latorzeff, I; Mourey, L; Oudard, S; Priou, F; Rolland, F; Soulié, M; Théodore, C | 1 |
| Buhari, SA; Chng, WJ; Hartman, M; Iau, P; Lee, SC; Loh, M; Miao, H; Sapari, NS; Soong, R; Tan, SH | 1 |
| de Boer, JP; de Jong, MA; Driessen, CM; Gelderblom, H; Kaanders, JH; Melchers, WJ; Rasch, CR; Tesselaar, ME; van der Graaf, WT; van Herpen, CM; Verbist, BM | 1 |
| Chowdhury, S; Gilson, C; Sydes, MR | 1 |
| Chang, CC; Chen, RJ; Chiou, HY; Hsieh, CC; Hsieh, CI; Lien, YC; Tai, CJ; Tzao, C; Wang, CK; Wu, CH; Wu, HC | 1 |
| Alzouebi, M; Amos, C; Attard, G; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Clarke, NW; Cook, A; Cross, W; de Bono, J; Dearnaley, DP; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; James, ND; Jones, RJ; Laing, R; Mason, MD; Matheson, D; McKinna, F; McLaren, DB; Millman, R; O'Sullivan, JM; Parikh, O; Parker, CC; Parmar, MK; Peedell, C; Protheroe, A; Ritchie, AW; Robinson, AJ; Russell, JM; Spears, MR; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Sydes, MR; Thalmann, G; Tolan, S; Tsang, D; Wagstaff, J | 1 |
| Collard, O; De Laroche, G; Falk, AT; Fournel, P; Guillot, A; Magné, N; Merrouche, Y; Méry, B; Moriceau, G; Pacaut, C; Trone, JC | 1 |
| de Bono, J; de Wit, R; Liewen, H; Meisel, A; Sartor, O; Stenner-Liewen, F; Vogt, DR; von Felten, S | 1 |
| Ghiorghiu, D; Jänne, PA; Mann, H | 1 |
| Bruce, J; De Porre, P; Gonzalez, MD; Kheoh, T; Lim, EA; Maul, S; Nanus, DM; Peng, W; Petrylak, DP; Posadas, EM; Smit, JW; Tagawa, ST; Tran, N | 1 |
| Antonarakis, ES; Denmeade, SR; Luber, B; Teply, BA | 1 |
| Fleming, MT; Gibbons, JA; Khondker, Z; Morris, MJ; Novotny, W; Ouatas, T; Peterson, AC; Rathkopf, DE; Scher, HI | 1 |
| Crabb, SJ; Davda, R; Hughes, S; Jones, R; Payne, H; Troup, J | 1 |
| Arrieta, O; Cappuzzo, F; Carter, GC; Ciuleanu, TE; Dakhil, S; Garon, EB; Goksel, T; Karaseva, N; Kim, JH; Kowalyszyn, RD; Lee, P; Lewanski, CR; Park, K; Pérol, M; Pikiel, J; Prabhash, K; Reck, M; Syrigos, KN; Thomas, M; Yurasov, S; Zimmermann, A | 1 |
| Cislo, P; Coleman, RE; Nilsson, S; O'Sullivan, JM; Parker, C; Reuning-Scherer, J; Sartor, O; Shan, M; Vogelzang, NJ; Zhan, L | 1 |
| Barbolosi, D; Ciccolini, J; Freyer, G; Iliadis, A; Meille, C | 1 |
| Carrera, G; Fernández, P; Gaba, L; García-Recio, S; Jiménez, N; Marín-Aguilera, M; Mellado, B; Paré, L; Pereira, MV; Prat, A; Reig, Ò | 1 |
| Attard, G; Bianchini, D; de Bono, JS; Dearnaley, DP; Ferraldeschi, R; Jayaram, A; Kolinsky, MP; Lorente, D; Mateo, J; Mehra, N; Parker, C; Perez-Lopez, R; Reid, A; Rescigno, P; Sideris, S; Smith, AD; Sumanasuriya, S; Tunariu, N; Zafeiriou, Z | 1 |
| Miller, RE; Sweeney, CJ | 1 |
| Hoshino, S; Iwasaki, K; Osaka, Y; Ota, Y; Suda, T; Tachibana, S; Tsuchida, A | 1 |
| Blumenthal, G; He, K; Kazandjian, D; Keegan, P; Libeg, M; Mushti, S; Pazdur, R; Suzman, DL | 1 |
| Eto, M; Inokuchi, J; Kiyoshima, K; Koga, H; Naito, S; Shiga, KI; Shiota, M; Takeuchi, A; Tatsugami, K; Yamaguchi, A; Yokomizo, A | 1 |
| Thoma, C | 1 |
| Barbolosi, D; Freyer, G; Guitton, J; Hénin, E; Iliadis, A; Meille, C; You, B | 1 |
| Choi, HG; Jeong, JH; Kim, JO; Thapa, RK; Yong, CS; Youn, YS | 1 |
| Chen, Z; Gera, L; Kucuk, O; Li, X; Mamouni, K; Wu, D; Zhang, S | 1 |
| Albanell, J; Campone, M; Chang, JC; de Haas, SL; Dewar, JA; Fumoleau, P; Garcia-Saenz, JA; Limentani, SA; Martin, M; Patre, M; Strasak, A; Xu, J | 1 |
| DI, LJ; Jiang, HF; Li, HP; Liang, X; Lin, XL; Shao, B; Song, GH; Wan, FL; Wang, CY; Wang, LN; Yan, Y; You, MN; Yuan, YH | 1 |
| Li, Q; Wen, F; Wheeler, JRC; Wu, YF; Zheng, HR | 1 |
| Bisbjerg, R; Daugaard, G; Kongsted, P; Lindberg, H; Sengeløv, L; Svane, IM | 1 |
| Francini, E; Sweeney, CJ | 1 |
| Amadori, D; Attard, G; Calistri, D; Casadio, V; Conteduca, V; De Giorgi, U; Gurioli, G; Lolli, C; Martignano, F; Salvi, S; Scarpi, E; Schepisi, G; Testoni, S | 1 |
| Almouzni, G; Cottu, P; Gentien, D; Gurard-Levin, ZA; Marangoni, E; Pancaldi, V; Pommier, Y; Postel-Vinay, S; Reyes, C; Sousa, FG; Valencia, A; Wilson, LO | 1 |
| Adamo, V; Barni, S; Boccardo, F; Bruno, M; Caffo, O; Caserta, C; Chiuri, VE; De Giorgi, U; De Vincenzo, F; De Vivo, R; Derosa, L; Dinota, A; Facchini, G; Fratino, L; Grassi, P; Messina, C; Mosca, A; Porcu, L; Procopio, G; Ricotta, R; Santini, D; Scavelli, C; Surace, G; Susi, M; Tartarone, A; Verzoni, E; Zaniboni, A | 1 |
| Cui, S; Hu, X; Liao, N; Liu, D; Luo, R; Sun, Q; Wang, X; Xu, B; Yu, S; Zhang, Q; Zheng, H | 1 |
| Cheng, HH; Gulati, R; Montgomery, RB; Mostaghel, EA; Nelson, PS; Schweizer, MT; Yu, EY | 1 |
| Deng, J; Fan, R; Gao, X; Guo, G; Li, X; Tong, A; You, C; Zhang, X; Zheng, Y; Zhou, L | 1 |
| Adams, J; Chang, EH; Leung, PK; Nemunaitis, J; Nunan, R; Pirollo, KF | 1 |
| Gill, HS; Mody, MD; Saba, NF | 1 |
| de Bono, JS; De Porre, P; Fizazi, K; Flaig, TW; Kheoh, T; Li, J; Mulders, PFA; Rathkopf, DE; Ryan, CJ; Saad, F; Shore, ND; Small, EJ; Smith, MR; Todd, MB | 1 |
| Galsky, MD; Oh, WK; Tsao, CK | 1 |
| Gschwend, J; Miller, K; Ohlmann, CH | 1 |
| Andre, V; Enas, N; Gueorguieva, I; Ribba, B; Tate, SC | 1 |
| Tran, N; Wong, HL; Xue, HY | 1 |
| An, X; Cao, Y; Chen, T; Deng, Y; Han, H; Shi, Y; Teng, X; Xue, C; Yang, W; Zhou, F | 1 |
| Aogi, K; Dalal, R; Gao, L; Ibrahim, A; Iwata, H; Masuda, N; Sasaki, Y; Xu, Y; Yoshikawa, R | 1 |
| Alavi, S; Deng, M; Duensing, S; Hagedorn, S; Kirfel, J; Konantz, M; Kristiansen, G; Lengerke, C; Perner, S; Queisser, A; Schaefer, T; Vogel, W; von Mässenhausen, A; Wang, H | 1 |
| Bristow, R; Joshua, AM; Milosevic, MF; Smith, AD; Truong, M; Yip, P | 1 |
| Gao, X; Hu, C; Li, K; Lu, L; Lu, M; Mao, Y; Peng, S; Qiu, J; Si-Tu, J; Wang, D | 1 |
| Chen, YT; Cheng, YT; Chiang, PH; Chuang, YC; Hsu, CC; Kang, CH; Lee, WC; Luo, HL; Shen, YC | 1 |
| Albiges, L; Audenet, F; Barthelemy, P; Beuzeboc, P; Fléchon, A; Gravis, G; Irani, J; Linassier, C; Oudard, S; Rebillard, X; Richaud, P; Rouprêt, M; Rozet, F; Thiery Vuillemin, A; Timsit, MO; Vincendeau, S | 1 |
| Adkins, D; Axelrod, R; Dakhil, S; Debruyne, PR; Dong, J; Kornek, G; Murugappan, S; O'Brien, P; Oliner, KS; Pant, S; Wirth, LJ | 1 |
| Bolton, D; Corfield, J; Crozier, J; Joshua, AM; Lawrentschuk, N | 1 |
| Alibhai, SM; Aziz, S; Breunis, H; Manokumar, T; Timilshina, N | 1 |
| Biswas, A; Ghosh, S; Jana, B; Mohapatra, S; Mondal, P; Saha, A | 1 |
| Gao, B; Guo, LJ; Hao, S; Jiang, Y; Luo, DL; Tian, WG; Zhang, S; Zhang, XH | 1 |
| Lin, DW; Yu, EY | 1 |
| Alumkal, JJ; Beer, TM; Graff, JN | 1 |
| Choi, HY; Il Seo, S; Jeon, HG; Jeon, SS; Jeong, BC; Kim, JH; Kwon, GY; Lee, HM; Lim, JE; Song, W | 1 |
| Andor, G; Bergqvist, M; Bondarenko, I; Grechanaya, E; Harmenberg, J; Holgersson, G; Jerling, M; Klockare, M; Maximovich, A; Thureson, M | 1 |
| Agarwal, N; Agarwal, P; Baisre, A; Goldstein, IM; Hansberry, DR; Kavi, A | 1 |
| Albiges, L; Attard, G; Bianchini, D; de Bono, J; Fizazi, K; Loriot, Y; Massard, C; Mateo, J; Mehra, N; Petrylak, DP; Pezaro, C; Ryan, CJ; Shen, L; Varga, A | 1 |
| Bernard, B; Carducci, MA; Chen, YH; Mitchell, EP; Muralidhar, V; Nguyen, PL; Pettaway, CA; Sridhar, SS; Sweeney, CJ | 1 |
| Adkins, D; Daly, K; Ley, J; Oppelt, P; Wildes, TM | 1 |
| Fujisaki, S; Sakurai, K; Takashina, M; Takayama, T; Tomita, R | 1 |
| Fujisawa, M; Furuse, H; Hara, T; Miyake, H; Ozono, S; Sugiyama, T; Tamura, K | 1 |
| Elo, LL; Hirvonen, O; Jyrkkiö, S; Laitinen, T; Mahmoudian, M; Rautakorpi, L; Seyednasrollah, F | 1 |
| Andersen, R; Borch, TH; Ellebaek, E; Hansen, M; Iversen, TZ; Kongsted, P; Lindberg, H; Met, Ö; Sengeløv, L; Svane, IM | 1 |
| Bloemendal, HJ; Bouman-Wammes, EW; de Klerk, JMH; van den Eertwegh, AJM; van Dodewaard-de Jong, JM; Verheul, HMW | 1 |
| Chlopicki, S; Denslow, A; Gebicki, J; Maciejewska, M; Marcinek, A; Nowak, M; Switalska, M; Wietrzyk, J | 1 |
| Bozkaya, Y; Demirci, NS; Doğan, M; Erdem, GU; Yazıcı, O; Zengin, N | 1 |
| Kitamura, S; Kuga, Y; Miwata, T; Mouri, T; Nishida, T; Sakimoto, H | 1 |
| Ahn, JH; Chung, HC; Im, SA; Im, YH; Jung, KH; Kim, J; Kim, SB; Lee, KS; Park, HS; Ro, J; Sohn, BS; Song, HS | 1 |
| Agelaki, S; Agelidou, A; Boukovinas, I; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kotsakis, A; Mavroudis, D; Polyzos, A; Souglakos, J; Vamvakas, L; Ziras, N | 1 |
| Cheng, T; Ernst, S; Karakiewicz, P; North, S; Perrotte, P; Ruether, D; Saad, F; Winquist, E | 1 |
| Blackwell, K; Bullock, K | 1 |
| Andersson, M; Azambuja, E; Balil, A; Crown, JP; Dolci, S; Francis, P; Gelber, RD; Gnant, M; Gutierrez, J; Láng, I; Nordenskjöld, B; Pestalozzi, BC; Piccart-Gebhart, M; Quinaux, E; Viale, G | 1 |
| Korski, K; Lamperska, K; Mackiewicz, A; Wysocki, PJ; Zaluski, J | 1 |
| Bukowski, RM; Dreicer, R; Elson, P; Mekhail, T; Olencki, T; Roman, S; Tamaskar, I | 1 |
| Berthold, DR; De Dosso, S | 1 |
| Al-Batran, SE; Atmaca, A; Clemens, MR; Fritz, M; Hartmann, JT; Hofheinz, R; Homann, N; Jäger, E; Mahlberg, R; Pauligk, C; Probst, S; Rethwisch, V; Seipelt, G; Sievert, M; Stoehlmacher, J | 1 |
| Davidson, NE; Goldstein, LJ; Martino, S; O'Neill, A; Perez, EA; Shulman, LN; Sparano, JA | 1 |
| Beardsley, EK; Chi, KN | 1 |
| Choi, IK; Kim, AR; Kim, JS; Kim, YH; Koo, BH; Lee, JB; Oh, SC; Park, KH; Seo, JH; Shin, SW; Sung, HJ | 1 |
| Anderson, J; Clarke, NW; Dearnaley, DP; Dwyer, J; James, ND; Mason, MD; Masters, J; Morgan, RC; Parmar, MK; Popert, RJ; Sanders, K; Stansfeld, J; Sydes, MR | 2 |
| Guo, QS; Liu, ZF; Song, SP; Wang, MY; Wu, N; Yang, XG; Zhang, XQ | 1 |
| Sternberg, CN | 1 |
| Bonny, MA; Clausse, M; D'Hondt, L; Dopchie, C; Duck, L; Filleul, B; Honhon, B; Jousten, P; Kerger, J; Machiels, JP; Marcelis, L; Mazzeo, F; Moxhon, AM; Tombal, B; Verhoeven, D; Verschaeve, V | 1 |
| Georgoulias, V; Mavroudis, D; Saloustros, E | 1 |
| Armstrong, AJ; Creel, P; George, DJ; Gockerman, JP; Haley, S; Hurwitz, H; Jaffe, TA; Moore, C; Petros, W; Sleep, D; Turnbull, J; Yenser, S | 1 |
| Dafni, U; Fountzilas, G; Fragkoulidi, A; Fragoulakis, V; Galani, E; Grimani, I; Maniadakis, N | 1 |
| Kim, JH; Lee, YC | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Kumazawa, T; Narita, S; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Yuasa, T | 1 |
| Amadori, D; Cecconetto, L; Dall'agata, M; Dazzi, C; Frassineti, GL; Milandri, C; Nanni, O; Oliverio, G; Pasquini, E; Passardi, A; Zoli, W; Zumaglini, F | 1 |
| Ebetino, FH; Lowik, CW; Papapoulos, SE; van Beek, ER; van Wijngaarden, J | 1 |
| Gouverneur, E; Grgic, A; Kamradt, J; Kirsch, CM; Lehmann, J; Nestle, U; Pinkert, J; Stöckle, M; Suttmann, H; Zwergel, U | 1 |
| Cottrell, W; Dranitsaris, G; Hopkins, S; Spirovski, B | 1 |
| Bayo, J; Bernabé, R; Fernández, A; Fernández-Freire, A; Fuentes, J; Lomas, M; Moreno, A; Rodríguez, A; Ruiz, M; Salvador, J | 1 |
| Lebret, T; Méjean, A; Timsit, MO | 1 |
| Guntinas-Lichius, O; Klussmann, JP; Rühlow, S; Veelken, F | 1 |
| Bareschino, M; Colantuoni, G; Falanga, M; Ferrara, ML; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Palazzolo, G; Rossi, A; Rossi, E; Schettino, C | 1 |
| Blaszkowsky, LS; Clark, JW; Earle, CC; Enzinger, PC; Fidias, P; Fuchs, CS; Kulke, MH; Mayer, RJ; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Vincitore, MM; Zhu, AX | 1 |
| Chia, S; Dent, S; Eisenhauer, EA; Ellard, S; Ellis, PM; Gelmon, K; Powers, J; Seymour, L; Vandenberg, T; Walsh, W | 1 |
| Cobb, P; Houts, AC; Schwartzberg, LS; Stepanski, EJ; Walker, MS | 1 |
| Burgess, LJ; Demetriou, GS; Jordaan, JP; Moodley, SD; Nosworthy, AL; Raats, J; Ruff, P; Vorobiof, DA; Werner, ID | 1 |
| Andoh, J; Aogi, K; Ikeda, T; Katsumata, N; Masuda, N; Minami, H; Sano, M; Shibata, T; Tabei, T; Takashima, S; Watanabe, T | 1 |
| Arena, MG; Di Lauro, L; Fattoruso, SI; Giacinti, L; Giannarelli, D; Lopez, M; Sergi, D | 1 |
| Economopoulos, T; Floros, T; Gouveris, P; Kamposioras, K; Karageorgopoulou, S; Koumarianou, A; Papatsibas, G; Papaxoinis, G; Pectasides, D; Pectasides, E; Psyrri, A; Tountas, N; Xiros, N | 1 |
| Cho, BC; Choi, EC; Choi, HJ; Keum, KC; Kim, JH; Kim, SH; Lee, YJ; Shin, SJ | 1 |
| Kunitoh, H; Saijo, N; Takeuchi, M | 1 |
| Johnson, MM; Jones, D; Logothetis, CJ; Mathew, P; Tu, SM; Wong, FC | 1 |
| Ahmad, A; Ali, S; Banerjee, S; Kong, D; Rahman, KM; Sakr, WA; Wang, Z | 1 |
| Bhar, P; Cheporov, S; Clawson, A; Gradishar, WJ; Krasnojon, D; Makhson, AN; Manikhas, GM | 1 |
| Bachelot, T; Cretin, J; de la Fouchardière, C; Goubely, Y; Hardy-Bessard, AC; Largillier, R; Orfeuvre, H; Paraiso, D; Pujade-Lauraine, E; Slama, B | 1 |
| Gillis, A; Leyssens, B; Lobelle, JP; Mombaerts, I; Paridaens, R; Wildiers, H | 1 |
| Anderson, DM; Bernath, AM; Gamini, SS; Hillman, DW; Niedringhaus, R; Northfelt, DW; Palmieri, F; Perez, EA; Salim, M; Stella, PJ; Tan, WW | 1 |
| Asmar, L; Bernold, D; Berry, WR; Boehm, KA; Fleming, MT; Galsky, MD; Hutson, TE; Periman, PO; Sonpavde, G; Weckstein, D; Zhan, F | 1 |
| Argiris, A; Axelrod, R; Brockstein, B; Buchanan, A; Forastiere, A; Ghebremichael, M; Hahn, K; Kolesar, J; Pins, M | 1 |
| Beuselinck, B; Dirix, L; Kains, JP; Paridaens, R; Wildiers, H; Wynendaele, W | 1 |
| Ando, M; Eguchi, K; Fujiwara, Y; Hozumi, Y; Inoue, K; Masuda, N; Miura, S; Mizutani, M; Nakagami, K; Noguchi, S; Ohashi, Y; Saito, M; Sano, M; Shinkai, T; Tsukamoto, F; Watanabe, T | 1 |
| Dahut, WL; Figg, WD; Ning, YM | 1 |
| Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Makatsoris, T; Papadimitriou, CA; Papakostas, P; Zagouri, F | 1 |
| Bertucci, F; Charafe-Jauffret, E; Deblock, M; Esterni, B; Extra, JM; Gilabert, M; Gonçalves, A; Houvenaeghel, G; Jacquemier, J; Tarpin, C; Viens, P | 1 |
| Bae, SH; Baek, JH; Do, YR; Kim, JY; Kim, MK; Lee, KH; Park, KU; Ryoo, HM; Song, HS | 1 |
| Bartsch, R; Brodowicz, T; Gerges, DA; Inbar, M; Pawlega, J; Spanik, S; Timcheva, C; Tomova, A; Tzekova, V; Wiltschke, C; Zielinski, CC | 1 |
| Cho, SH; Cho, YJ; Go, SI; Hwang, YS; Jeong, YY; Kang, JH; Kim, HC; Kim, HG; Kim, SH; Lee, GW; Lee, JD | 1 |
| Benedict, A; Cameron, DA; Corson, H; Jones, SE | 1 |
| Alanko, T; Asola, R; Bono, P; Hahka-Kemppinen, M; Huuhtanen, R; Joensuu, H; Kellokumpu-Lehtinen, P; Kokko, R; Leinonen, M; Pyrhönen, S; Sailas, L; Sunela, K; Turpeenniemi-Hujanen, T; Utriainen, M; Wigren, T | 1 |
| Alici, S; Benekli, M; Buyukberber, S; Camci, C; Coskun, U; Dane, F; Gumus, M; Kalender, ME; Kaya, AO; Ozturk, B; Sevinc, A; Uncu, D; Yaman, E; Yildiz, R | 1 |
| Bidard, FC; Brain, E; de Cremoux, P; Delaloge, S; Giachetti, S; Marty, M; Mathiot, C; Pierga, JY | 1 |
| Aulino, J; Baumann, J; Burkey, B; Chung, CH; Cmelak, AJ; Gilbert, J; Hatakeyama, H; Muldowney, NJ; Murphy, BA; Netterville, J; Parker, J; Shyr, Y; Sinard, R; Slebos, RJ; Yarbrough, WG | 1 |
| Bentzen, L; Buch-Hansen, TZ; Hansen, S; Hoeyer, M; Jensen, NV; Saxe, C; Sengeloev, L | 1 |
| Dentchev, T; Dueck, AC; Fitch, TR; Geeraerts, LH; Graham, DL; Gross, HM; Hillman, DW; Kahanic, SP; Le-Lindqwister, NA; Liu, H; Palmieri, FM; Patel, TA; Perez, EA | 1 |
| Abrial, C; Barthomeuf, C; Bayet-Robert, M; Chollet, P; Durando, X; Gachon, F; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Planchat, E | 1 |
| Begbie, S; Boyce, A; de Souza, P; Harvie, R; Khasraw, M; Lim, V; Marx, G; McCowatt, S; Parnis, F; Pavlakis, N; Underhill, C | 1 |
| Gelmon, K; Mackey, J; Martin, M; McCarthy, N; Pinter, T; Rupin, M; Youssoufian, H | 1 |
| Harris, LD; Pettaway, CA; Song, R | 1 |
| Alvarado, GC; Bedikian, AY; Camacho, LH; Hwu, P; Kim, KB; McIntyre, S; Papadopoulos, NE; Yoon, C | 1 |
| Adema, AD; Fichtner, I; Laan, AC; Myhren, F; Peters, GJ; Sandvold, ML; Verheul, HM | 1 |
| Armstrong, AJ; de Wit, R; Eisenberger, M; George, DJ; Halabi, S; Tannock, IF | 1 |
| Chang, H; Choi, HJ; Chung, HC; Kim, JH; Kim, SI; Kim, YT; Koo, JS; Moon, YW; Park, BW; Park, S; Roh, JK; Sohn, JH | 1 |
| Alumkal, J; Beer, TM; Eilers, KM; Ryan, C; Ryan, CW; Sun, J | 1 |
| Fumoleau, P; Le Corroller Soriano, AG; Marino, P; Martin, AL; Protière, C; Roché, H; Siani, C; Spielmann, M; Viens, P | 1 |
| Hirata, K; Kato, J; Kida, M; Kobune, M; Miyanishi, K; Niitsu, Y; Ohnuma, H; Ohta, H; Okubo, S; Sagawa, T; Sato, T; Sato, Y; Shintani, N; Takahashi, Y; Takayama, T; Takimoto, R; Tanaka, S; Yamaguchi, K | 1 |
| Armstrong, AJ; George, DJ | 1 |
| Fukushima, M; Ishiguro, H; Kanai, M; Kitano, T; Matsumoto, S; Mio, T; Misawa, A; Niimi, M; Nishimura, T; Sasaki, T; Tada, H; Teramukai, S; Yanagihara, K; Yasuda, H; Yoshimura, K | 1 |
| Blohmer, JU; Friese, K; Hilfrich, J; Kleine-Tebbe, A; Koelbl, H; Kuemmel, S; Lichtenegger, W; Morack, G; Schmid, P; Sommer, H; Wischnewsky, MB | 1 |
| Gridelli, C; Pallis, AG | 1 |
| Hillner, BE; Smith, TJ | 1 |
| Chu, FM; Dreicer, R; Foster, B; Fracasso, PM; Lang, Z; Picus, J | 1 |
| Aitini, E; Baconnet, B; Barbato, A; Bighin, C; Colucci, G; Crinò, L; Del Mastro, L; Garrone, O; Mansutti, M; Marini, G; Olmeo, N; Paccagnella, A; Puglisi, F; Venturini, M | 1 |
| Brighenti, M; Buti, S; Dalla Chiesa, M; Donati, G; Lazzarelli, S; Passalacqua, R; Rovere, RK; Tomasello, G | 1 |
| Anand, A; Dzik-Jurasz, A; Hu, J; Rathkopf, D; Ross, RW; Scher, HI; Tanaka, E; Wong, BY; Woo, MM; Yang, W | 1 |
| Beuzeboc, P; Eymard, JC; Ferrero, JM; Gravis, G; Joly, F; Krakowski, I; Oudard, S; Priou, F; Theodore, C; Thill, L; Zannetti, A | 1 |
| Bergougnoux, L; Bidard, FC; de Cremoux, P; Degeorges, A; Delva, R; Etienne-Grimaldi, MC; Mathiot, C; Milano, G; Pierga, JY; Pivot, X; Veyret, C | 1 |
| Allegrini, G; Andreuccetti, M; Cascinu, S; Cortesi, E; Falcone, A; Fontana, E; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Mentuccia, L; Merlano, M; Salvatore, L; Vasile, E | 1 |
| Kanzaki, M; Maeda, M; Matsumoto, K; Miyoshi, S; Takano, Y; Teshima, S; Wakita, T; Yoshinouchi, S | 1 |
| Biganzoli, L; Conte, P; Diéras, V; Glaspy, J; Guarneri, V; Miles, D; Robert, N; Smith, I; Taran, T; Thomssen, C | 1 |
| Ajiboye, AS; Arlen, PM; Chen, X; Dahut, WL; Figg, WD; Gulley, JL; Parnes, HL; Price, DK; Steinberg, SM; Woo, S; Wright, JJ; Zhu, W | 1 |
| Davis, TH; Dragnev, KH; Hardin, SB; Pipas, JM; Rigas, JR | 1 |
| Andre, F; Berrada, N; Broglio, K; Chan, S; Hortobagyi, GN; Mackey, JR; Nabholtz, JM; Pusztai, L | 1 |
| Ansari, RH; Benson, AB; Catalano, P; O'Dwyer, PJ; Powell, M; Sun, W | 1 |
| Hozumi, Y; Masuda, N; Mitsuyama, S; Mukai, H; Murakami, S; Ohashi, Y; Ohmura, T; Takashima, T; Watanabe, T; Yajima, T | 1 |
| Ohdan, H; Suzuki, T; Tanabe, K; Tokumoto, N; Yamamoto, H; Yoshida, K | 1 |
| Chan, A; Chlistalla, A; Cortés, J; Delozier, T; Dirix, LY; Harbeck, N; Miles, DW; Pivot, X; Provencher, L; Puglisi, F; Romieu, G; Schneeweiss, A; Sohn, JH; Steger, GG; Tomczak, P; Wardley, AM | 1 |
| Akay, BN; Akyol, A; Buyukcelik, A; Unlu, E | 1 |
| Araki, K; Doi, T; Fuse, N; Hayashi, R; Kawashima, M; Kiyota, N; Minami, H; Minashi, K; Ogino, T; Ohtsu, A; Okano, S; Tahara, M; Yoshino, T; Zenda, S | 1 |
| Harita, S; Hiraki, A; Hiraki, S; Hotta, K; Kamei, H; Kanazawa, S; Kiura, K; Matsuo, K; Nogami, N; Segawa, Y; Shibayama, T; Sugimoto, K; Tabata, M; Takata, I; Takemoto, M; Takigawa, N; Tanimoto, M; Ueoka, H; Watanabe, Y; Yonei, T | 1 |
| Aggarwal, S; Goel, G; Jauhri, M; Negi, A | 1 |
| Foster, J; Lee, J; Urba, S; Worden, F; Zhang, J | 1 |
| Drouin, SJ; Houédé, N; Rouprêt, M; Wallerand, H | 1 |
| Jotoku, H; Taguchi, K; Tamura, M; Watanabe, K; Yamamoto, M | 1 |
| Kaley, K; Penney, R; Saif, MW; Syrigos, K | 1 |
| Fotiou, S; Gennatas, C; Gennatas, S; Michalaki, V | 1 |
| Ang, MK; Chowbay, B; Gao, F; Leong, SS; Lim, WT; Ngeow, J; Tan, EH; Toh, CK | 1 |
| Beretov, J; Chen, H; Cozzi, PJ; Delprado, WJ; Hao, J; Li, Y; Madigan, MC; Russell, PJ; Xiao, W | 1 |
| Akiyama, H; Endo, I; Fujii, S; Kameda, K; Kimura, J; Kito, F; Kosaka, T; Kunisaki, C; Makino, H; Morita, S; Ono, HA; Oshima, T; Takagawa, R; Takahashi, M | 1 |
| Chang, HM; Kang, YK; Kim, BS; Kim, TW; Oh, ST; Ryu, MH; Yoo, C; Yook, JH | 1 |
| Aguilar-Mahecha, A; Alsawafi, Y; Basik, M; Buchanan, M; Gaboury, L; Hassan, S; Jahan, K; Mourskaia, AA; Muller, WJ; Salvucci, O; Siegel, PM | 1 |
| Han, B; Kang, WK; Kim, JA; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| El Bary, NM; El Halim Mohamed Abu Hamar, A; El Shebiney, M; Mansour, S; Maria, A; Sadaka, E | 1 |
| Dreicer, R; Elson, P; Garcia, JA; Hutson, TE; Shepard, D | 1 |
| Chao, Y; Chen, JS; Chen, LT; Lee, KD; Li, CP; Lin, PC; Lu, CH; Su, WP; Tsai, HJ; Yen, CJ | 1 |
| Ansari, RH; Brufsky, A; Cavalheiro, J; Chen, SC; De La Cruz Vargas, JA; Fein, LE; Gill, JF; Hart, LL; Kim, SB; Obasaju, CK; Orlando, M; Russell, CA; Schwartzberg, LS; Seidman, AD; Stein, RS; Stewart, JF; Tai, DF; Zhao, L | 1 |
| Buyse, M; Crown, J; Eiermann, W; Forbes, J; Fumoleau, P; Jagiello-Gruszfeld, A; Mackey, JR; Martin, M; Mrsic-Krmpotic, Z; Pegram, MD; Pienkowski, T; Press, MF; Riva, A; Roche, H; Rolski, J; Sauter, G; Slamon, DJ; Taupin, H; Valero, V; von Minckwitz, G | 1 |
| Georgoulias, V; Kaklamanis, L; Lagoudaki, E; Mavroudis, D; Papadaki, C; Souglakos, J; Stathopoulos, E; Tryfonidis, K; Trypaki, M; Tsaroucha, E | 1 |
| Capanu, M; Ilson, DH; Jhawer, M; Kelsen, DP; Lefkowitz, RA; Robinson, E; Shah, MA | 1 |
| Creemers, GJ; de Graaf, H; de Munck, L; Erjavec, Z; Schröder, CP; Smit, WM; Stouthard, JM; Vader, W; van Bochove, A; van Deijk, G; Westermann, AM; Willemse, PH | 1 |
| Hillemanns, P; Kramer, F; Park-Simon, TW; Rinnau, F; Schippert, C | 1 |
| Che, L; DI, Lj; Jia, J; Jiang, Hf; Liang, X; Ren, J; Song, Gh; Wang, Xl; Yang, Hb; Yu, J; Zhang, J; Zhou, Xn; Zhu, Yl | 1 |
| Botti, G; D'Aiuto, G; De Maio, E; de Matteis, A; Di Bonito, M; Di Maio, M; Di Rella, F; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rinaldo, M; Rossi, E; Thomas, R | 1 |
| Ballestrero, A; Bergaglio, M; Bertolotti, F; Brema, F; Canobbio, L; Cinzia, N; Folco, U; Mencoboni, M; Murialdo, R; Parodi, M; Pastorino, G; Simoni, C; Vaira, F | 1 |
| Bracarda, S; Logothetis, C; Oudard, S; Sternberg, CN | 1 |
| Enomoto, Y; Fujimura, T; Fukuhara, H; Homma, Y; Ishikawa, A; Kume, H; Nishimatsu, H; Suzuki, M | 1 |
| Arango, BA; Burgos-Tiburcio, A; Raez, LE; Santos, ES | 1 |
| Alhasso, A; Ansari, A; Ansari, J; Glaholm, J; Hussain, SA; Mahmood, R | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Maita, S; Narita, S; Numakura, K; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H | 1 |
| Bruno, R; Claret, L; Frances, N; Iliadis, A | 1 |
| Cetnar, J; Eickhoff, J; Liu, G; LoConte, NK; McFarland, TA; McNeel, D; Wilding, G | 1 |
| Corrado, G; di Stefano, A; Ferrandina, G; Lucidi, A; Margaritora, S; Piraino, A; Salutari, V; Scambia, G | 1 |
| Chang, PM; Chang, SY; Chang, YF; Chen, MH; Hwang, WS; Su, WC; Tsao, CJ; Tzeng, CH; Yang, MH | 1 |
| Collins, IM; Thomas, DM | 1 |
| Bontenbal, M; Bos, MM; Braun, HJ; Creemers, GJ; Erdkamp, FL; Hamberg, P; Klijn, JG; Loosveld, OJ; Muller, EW; Portielje, JE; Pruijt, JF; Schmitz, PI; Seynaeve, C; Smit, WM; Stouthard, JM; van Deijk, GA; van der Stelt-Frissen, IN | 1 |
| Abali, H; Aksoy, S; Budakoglu, B; Kos, FT; Odabaş, H; Oksuzoglu, B; Ozdemir, N; Uncu, D; Zengin, N | 1 |
| Eastwood, A; Epstein, D; Fox, D; Rodgers, M; Soares, M; Yang, H | 1 |
| Al-Batran, SE; Altmannsberger, HM; Atmaca, A; Bruch, HP; Homann, N; Jäger, E; Luley, K; Noack, F; Pauligk, C; Werner Kraus, T | 1 |
| Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E | 1 |
| Cheng, CY; Cherng, SH; Huang, XY; Liao, FT; Sheu, GT; Wu, MF; Wu, WJ; Yang, TY | 1 |
| Harrington, JA; Jones, RJ | 1 |
| Amadori, D; Baconnet, B; Barbato, A; Barone, C; Bordonaro, R; Comella, G; Gasparini, G; Gattuso, D; Gebbia, V; Milandri, C; Nanni, O; Salvagni, S; Saracchini, S; Serra, P | 1 |
| Andrieu, JM; Bats, AS; Eme, D; Hofmann, H; Huchon, C; Le Frere-Belda, MA; Lecuru, F; Levy, E; Medioni, J; Oudard, S | 1 |
| Agostini, C; Bachelot, T; Bajard, A; Boisseau, M; Coeffic, D; Dramais, D; Ferri-Dessens, RM; Guastalla, JP; Kaphan, R; Oprea, C; Perol, D; Provencal, J; Ray-Coquard, I | 1 |
| Comans, EF; Greuter, HN; Hendrikse, NH; Herder, GJ; Lammertsma, AA; Lubberink, M; Mooijer, MP; Rijnders, AY; Rizvi, SN; Schuit, RC; Smit, EF; van der Veldt, AA; van Lingen, A; Windhorst, AD; Yaqub, M | 1 |
| Benedetti, G; Chang, HT; Ciruelos, E; Duenne, AA; Miles, DW; Passos-Coelho, JL; Pivot, X; Schneeweiss, A; Thomssen, C; Verma, S; von Moos, R | 1 |
| Fujisawa, M; Harada, K; Miyake, H; Sakai, I; Terakawa, T | 1 |
| Berry, S; Chi, K; Czaykowski, P; Eigl, B; Gleave, M; Hotte, S; Lattouf, JB; Mukherjee, SD; North, S; Pollak, M; Saad, F; Winquist, E; Wood, L | 1 |
| Blackford, A; Chung, K; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, RC; Flores, EI; Kinsman, K; Laheru, D; Le, DT; Oliver, GR; Wilfong, LS; Zheng, L | 1 |
| Chen, I; Chow Maneval, E; George, DJ; Harmon, CS; Hutson, TE; Kozloff, M; Liu, G; Logothetis, CJ; Mathew, P; Shore, ND; Wang, SL; Wilding, G; Zurita, AJ | 1 |
| Aapro, M; Bhar, P; Gradishar, W; Tjulandin, S | 1 |
| Abbruzzese, JL; Carlson, PJ; Dakik, HK; Fogelman, DR; Moskovic, DJ; Qiao, W; Tamm, EP; Wolff, RA | 1 |
| Blum, JL; Hennessy, BT; Leonard, R; O'Shaughnessy, J | 1 |
| Hongo, F; Iwata, T; Kamoi, K; Kawauchi, A; Miki, T; Okihara, K; Takaha, N; Takeuchi, I; Ueda, T; Yamada, T; Yano, K | 1 |
| Cals, L; Curtit, E; Dohollou, N; Facchini, T; Gligorov, J; Grangé, V; Jaubert, D; Levy, E; Lortholary, A; Maille, N; Nouyrigat, P; Pivot, X | 1 |
| Chung, C; Frankel, P; Gu, L; Hurria, A; Kane, SE; Koczywas, M; Lau, SK; Leong, L; Luu, T; Martel, CL; McNamara, M; Morgan, R; Ruel, C; Russell, CA; Somlo, G | 1 |
| de Bono, JS; Massard, C; Michels, RM; Sartor, O | 1 |
| Aoki, A; Baba, Y; Imoto, K; Kamiryo, Y; Kaneda, Y; Konishi, M; Matsuda, K; Matsuyama, H; Nasu, T; Sakano, S; Shimabukuro, T; Suga, A; Takai, K; Yamamoto, M; Yamamoto, N; Yoshihiro, S | 1 |
| Ernsting, MJ; Li, SD; MacCallum, NW; Tang, WL | 1 |
| Andersson, M; Bjerre, KD; Cold, S; Jakobsen, EH; Jørgensen, CL; Kamby, C; Møller, S; Nielsen, DL; Stenbygaard, L; Sørensen, PG | 1 |
| Belfiglio, M; Fanizza, C; Ficorella, C; Iacobelli, S; Natoli, C; Tinari, N | 1 |
| García-Estevez, L; Gil, M; Ramos, M; Sánchez-Rovira, P; Servitja, S; Tusquets, I; Vázquez-Estevez, S; Velasco, A; Virizuela, JA | 1 |
| Bougnoux, P; Champeroux, P; Chevalier, S; Goupille, C; Kornfeld, S; Lebeau, J; Mahéo, K; Martel, E; Maurin, A; Pinet, A; Richard, S; Tranquart, F; Vibet, S | 1 |
| Kumar, A; Manjappa, AS; Megraj Khandelwal, VK; Mishra, AK; Monkkonen, J; Ramachandra Murthy, RS; Ramanlal Chaudhari, K; Ukawala, M | 1 |
| Baselga, J; Benyunes, MC; Clark, E; Cortés, J; Hegg, R; Im, SA; Im, YH; Kim, SB; Knott, A; Pedrini, JL; Pienkowski, T; Roman, L; Ross, G; Swain, SM | 1 |
| Bi, CP; Chang, TH; Chen, MK; Lai, GM; Lin, JT; Liu, MT; Wang, JW | 1 |
| Bollag, DT; Caralt, M; Cortés, J; Cortes-Funes, H; Delaloge, S; Miles, DW; Pierga, JY; Pritchard, KI | 1 |
| Dok, Y; Hamakawa, T; Kurokawa, Y; Miyata, H; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
| Jeet, V; Khatri, A; Russell, PJ; Verma, ND | 1 |
| Treshalina, EM; Yakunina, MN | 1 |
| Gallardo, HF; Gregor, P; Huang, QD; Morris, MJ; Rasalan, TS | 1 |
| Arranz, JÁ; Cassinello, J; Climent, MA; García-Donas, J; González del Alba, A; León-Mateos, L; Mellado, B; Méndez-Vidal, MJ; Pérez-Valderrama, B; Piulats, JM; Sánchez-Hernández, A | 1 |
| Hayashi, K; Kuramochi, H; Nakamura, T; Narumiya, K; Ota, M; Sato, T; Shirai, Y; Yamamoto, M | 1 |
| Barron, R; Edelsberg, J; Kartashov, A; Lyman, G; Weycker, D | 1 |
| Georgoulias, V; Kalbakis, K; Karachaliou, N; Kouroussis, Ch; Mavroudis, D; Papakotoulas, P; Poppis, E; Tryfonidis, K; Vardakis, N | 1 |
| Akaza, H; Arai, Y; Fujita, R; Hashine, K; Hoshi, S; Kakehi, Y; Kanayama, HO; Miki, T; Miura, T; Mizokami, A; Nishimura, K; Nonomura, K; Nonomura, N; Ogawa, O; Ozono, S | 1 |
| Bouchez, LC; Cho, CY; Dubrovska, A; Elliott, J; Kularatne, SA; Reddy, VA; Salamone, RJ; Schepotin, IB; Schultz, PG; Stakhovsky, AE; Telegeev, GD; Trussell, C; Wang, Y; Watson, J; Yan, F | 1 |
| Ishiguro, A; Itoh, J; Kawasaki, H; Kijima, H; Kudoh, Y; Matsumoto, Y; Saijo, Y; Shimaya, S; Takahata, T; Tanaka, S | 1 |
| Che, L; Di, L; Dong, N; Jia, J; Jiang, H; Ren, J; Song, G; Wang, C; Wang, X; Wang, Z; Yu, J; Zheng, X; Zhou, X; Zhu, B | 1 |
| Al-Asady, R; Al-Hussaini, M; Khader, J; Salah, S; Salem, A; Yousef, Y | 1 |
| Anderson, R; Balkrishnan, R; Camacho, F; Kamal, AH; Kimmick, G; Wei, W | 1 |
| Aoki, T; Furukawa, H; Goto, Y; Imamoto, H; Imano, M; Kobayashi, K; Miki, H; Peng, YF; Takiuchi, H; Tamura, S; Tsujinaka, T | 1 |
| Hasegawa, H; Kubo, H; Miyahara, M; Nishiyama, M; Tada, K; Yamashita, Y | 1 |
| Armstrong, AJ; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA | 1 |
| Anan, K; Arime, I; Chijiiwa, K; Fujii, T; Hara, S; Imamura, S; Inoue, H; Ishikawa, E; Mitsuyama, S; Nishimura, R; Ohchi, T; Ohkido, M; Ohno, S; Oikawa, T; Shimada, K; Tamura, K; Tanaka, M; Taniguchi, H; Yano, H | 1 |
| Bender, E | 1 |
| Haruma, K; Higashida, M; Hirabayashi, Y; Hirai, T; Hiratsuka, J; Kubota, H; Matsumoto, H; Murakami, H; Nakamura, M | 1 |
| Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N | 1 |
| Fukuoka, M; Katakami, N; Kudoh, S; Kurata, T; Matsui, K; Mitsudomi, T; Nishimura, Y; Saka, H; Senba, H; Tada, H | 1 |
| Antonarakis, ES; Carducci, MA; Eisenberger, MA; Goyal, J; Huang, P; Nuhn, P; Oh, D; Tyagi, P | 1 |
| Bhar, P; Cheporov, S; Clawson, A; Gradishar, WJ; Iglesias, J; Krasnojon, D; Makhson, AN; Manikhas, GM; McGuire, JR | 1 |
| Fujisawa, M; Harada, K; Miyake, H; Muramaki, M; Sakai, I | 1 |
| Bian, L; Cao, Y; Huang, H; Jiang, Z; Song, S; Wang, T; Wu, S; Zhang, S | 1 |
| Canon, JL; Clausse, M; D'Hondt, L; Duck, L; Kerger, J; Machiels, JP; Mardjuadi, F; Medioni, J; Moxhon, A; Musuamba, F; Oudard, S | 1 |
| Ahn, MJ; Cho, IS; Heo, DS; Hwang, DW; Jang, JS; Ji, JH; Kang, JH; Kim, SB; Park, JC; Park, K; Shin, SW; Sohn, CH; Sun, JM; Yun, T | 1 |
| Cornfeld, M; Eisenberger, M; Hudes, G; Puchalski, TA; Qi, M; Qin, X; Reddy, M; Tagawa, ST; Whang, YE | 1 |
| Hervonen, P; Kellokumpu-Lehtinen, P; Tulijoki, T | 1 |
| Bazan, F; Chaigneau, L; Compagnat, F; Dobi, E; Limat, S; Nerich, V; Perrin, S; Pivot, X; Villanueva, C; Voidey, A | 1 |
| Beretov, J; Chang, L; Cozzi, PJ; Graham, PH; Hao, J; Hung, TT; Kearsley, JH; Khatri, A; Li, Y; Madigan, MC; Power, CA; Xiao, W | 1 |
| Armstrong, AJ; Chi, KN; de Bono, JS; de Wit, R; Fizazi, K; Flaig, TW; Fléchon, A; Fleming, M; Hainsworth, JD; Hirmand, M; Mainwaring, P; Miller, K; Mulders, P; Saad, F; Scher, HI; Seely, L; Selby, B; Shore, ND; Sternberg, CN; Taplin, ME | 1 |
| Bang, YJ; Han, HS; Han, SW; Han, W; Im, SA; Jeon, YK; Kim, JH; Kim, JS; Kim, JW; Kim, TY; Kim, YJ; Noh, DY; Oh, DY; Park, IA | 1 |
| Blay, JY; Bompas, E; Cioffi, A; Collin, F; Cupissol, D; Delcambre, C; Duffaud, F; Floquet, A; Isambert, N; Jimenez, M; Pautier, P; Penel, N; Piperno-Neumann, S; Rey, A | 1 |
| Akyol, M; Bayoglu, IV; Can, A; Demir, L; Dirican, A; Erten, C; Kucukzeybek, Y; Medeni, M; Somali, I; Tarhan, MO | 1 |
| Bian, XJ; Dai, B; Shen, YJ; Xie, HY; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y | 1 |
| Aksoy, S; Altundag, K; Sendur, MA | 1 |
| Heidenreich, A; Pfister, D | 1 |
| Chen, W; Gao, Z; Huang, W; Jin, M; Li, Y; Liu, J; Yang, F | 1 |
| Berthold, DR; Betticher, DC; Brauchli, P; Bubendorf, L; Cathomas, R; Cotting, D; Droege, C; Gillessen, S; Jaggi, R; Klingbiel, D; Pless, M; Rothermundt, C; Schiess, R; Siciliano, D; von Moos, R; Winterhalder, R | 1 |
| Frances, N; Iliadis, A; Marouani, H; Mercier, C; Woloch, C | 1 |
| Dimitroulis, D; Felekouras, E; Griniatsos, J; Karatzas, T; Karavokyros, J; Kontzoglou, K; Mantas, D; Nikiteas, N; Polyzos, A; Polyzos, K; Syrigos, K; Tsavaris, N; Vafiadis, I | 1 |
| Berry, WR; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA | 1 |
| Alifrangis, C; Coombes, RC; Emson, M; Mackie, D; Palmieri, C; Shipway, D; Tat, T; Watson, V | 1 |
| Belardelli, F; Borghi, P; Buoncervello, M; Gabriele, L; Romagnoli, G; Spadaro, F; Toschi, E | 1 |
| Aldrighetti, D; Amadori, D; Bouko, Y; Canon, JL; Cardoso, F; Dirix, L; Giorgetti, C; Kern, KA; Machiels, JP; Usari, T; Verkh, L | 1 |
| Ben Reguiga, M; Bonhomme-Faivre, L; Bouquet, C; Farinotti, R | 1 |
| Aydogan, F; Aykan, F; Disci, R; Ekenel, M; Keskin, S; Kilic, L; Saglam, S; Sakar, B; Sen, F; Yıldız, I | 1 |
| Chen, Y; Cui, Y; Feng, Y; Li, Q; Liu, T; Wang, Y; Yu, Y | 1 |
| Abdelkhalek, SE; Hamed, RH | 1 |
| Bogdanova, N; Dawkins, F; de Boer, CJ; Dirix, L; Heidenreich, A; Rawal, SK; Schrijvers, D; Stenzl, A; Szkarlat, K; Wang, G; Welslau, M | 1 |
| Dai, B; Kong, YY; Ma, CG; Qu, YY; Yang, WY; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL | 1 |
| Cleeland, C; de Bono, JS; Fizazi, K; Gagnon, DD; Hao, Y; Haqq, CM; Kheoh, T; Mainwaring, P; Molina, A; North, S; Rothman, M; Scher, HI; Sternberg, CN | 1 |
| Cai, RG; Ding, XY; Fan, Y; Li, Q; Ma, F; Wang, JY; Xu, BH; Yuan, P; Zhang, P | 1 |
| Birtle, A | 1 |
| Agelaki, S; Agelidou, M; Chelis, L; Christophylakis, Ch; Georgoulias, V; Kentepozidis, N; Kotsakis, A; Papakotoulas, P; Samonis, G; Soultati, A; Vamvakas, L; Zafiriou, Z | 1 |
| Che, L; Di, L; Jia, J; Jiang, H; Liang, X; Lyerly, HK; Ren, J; Song, G; Wan, F; Wang, X; Yan, Y; Yu, J; Zhang, J; Zhou, X; Zhu, Y | 1 |
| Ardizzoni, A; Bisagni, G; Boni, C; De Matteis, A; Gamucci, T; Gnoni, R; Gori, S; Moretti, G; Musolino, A; Nuzzo, F; Panebianco, M; Passalacqua, R | 1 |
| Bianchi, GV; Chu, YW; Dirix, L; Guardino, E; Hurvitz, SA; Kocsis, J; Lu, J; Ng, V; Perez, EA; Song, C; Tong, B; Vinholes, J | 1 |
| Ligibel, JA; Winer, EP | 1 |
| Perez, EA; Qu, G | 1 |
| Chan, AT; Chiu, SK; Ho, WM; Johnson, PJ; Kwan, WH; Lam, KC; Leung, TW; Mo, FK; Mok, TS; Tse, KK; Yeo, W | 1 |
| Friedrichs, K; Hölzel, F; Jänicke, F | 1 |
| Bourhis, J; Faivre, S; Monnerat, C; Raymond, E; Temam, S | 1 |
| Burian, M; Cartellieri, M; Fiebiger, W; Formanek, M; Gedlicka, C; Kornek, GV; Kornfehl, J; Marks, B; Selzer, E | 1 |
| Bang, YJ; Boudraa, Y; Daglish, B; Heo, DS; Jacques, C; Kang, WK; Kang, YK; Kim, HC; Kim, NK; Kim, WS; Zuber, E | 1 |
| Ansari, R; Einhorn, LH; Fata, F; McClean, JW; Miller, KD; Porcu, P; Sledge, GW; Soule, SE; Zon, R | 1 |
| Campos, B; Carrete, N; Constenla, M; Garcia-Arroyo, R; Lorenzo, I; Palacios, P | 1 |
| Bucana, C; Dinney, CP; Fan, D; Fidler, IJ; Huang, SF; Karashima, T; Kedar, D; Killion, JJ; Kim, SJ; Lee, AT; Mian, B; Shepherd, D; Sweeney, P | 1 |
| Asola, R; Ekholm, E; Hinkka, S; Korpela, J; Mali, P; Pyrhönen, S; Salminen, E; Varjo, P; Varpula, M | 1 |
| Breidenbach, M; König, E; Kurbacher, C; Mallmann, P; Schwonzen, M | 1 |
| Azli, N; Bisset, D; Kaye, SB; Ramazeilles, C; Riva, A; Roché, H; Terret, C; Twelves, CJ; Vasey, PA; Vernillet, L | 1 |
| Benezery, K; Lagrange, JL; Magné, N; Namer, M; Otto, J | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Fountzilas, G; Gogas, H; Kosmidis, P; Mylonakis, N; Samonis, G; Skarlos, DV; Stathopoulos, G | 1 |
| Assadourian, S; Bonneterre, J; Fargeot, P; Guastalla, JP; Monnier, A; Namer, M; Roché, H | 1 |
| Besse, B; Spano, JP | 1 |
| Aapro, M; O'Shaughnessy, J; Twelves, C | 1 |
| Miles, D; Seidman, AD; von Minckwitz, G | 1 |
| Antman, K; Brafman, L; Fine, R; Nelsen, C; Petrylak, DP; Shriberg, L; Talbot, S; Tiersten, AD; Troxel, A; Vahdat, L | 1 |
| Chikazawa, M; Fukata, S; Inoue, K; Shuin, T; Yoshikawa, C | 1 |
| Aglietta, M; Alabiso, O; Capaldi, A; Choa, G; Donadio, M; Faggiuolo, R; Minischetti, M; Montemurro, F; Salomone, A; Sperti, E; Vietti-Ramus, G | 1 |
| Azli, N; Boudraa, Y; Cocquyt, V; Georgoulias, V; Hausmaninger, H; Paridaens, R; Ramazeilles, C; Samonnig, H; Van Aelst, F; Wildiers, J; Willemse, P; Zielinski, C | 1 |
| Alba, E; Antón, A; Florián, J; Godes, MJ; Llanos, M; López-Vega, JM; Menéndez, M; Pelegri, A; Pérez-Carrión, R; Ribelles, N | 1 |
| Borsellino, N; Colombo, A; Ferrera, P; Gebbia, V; Marrazzo, A; Mauceri, G; Musso, M; Porretto, F; Testa, A; Tirrito, ML | 1 |
| Baick, CH; Chiou, JY; Fruehauf, JP; Mehta, RS; Nalcioglu, O; Su, MY; Wang, J; Yu, H | 1 |
| Glasmacher, A; Gorschlüter, M; Kleinschmidt, R; Mey, U; Schmidt-Wolf, IG; Ziske, C | 1 |
| Glaspy, J; Green, MD; Hackett, J; Holmes, FA; Kubista, E; Neumann, T | 1 |
| Aperis, G; Barbounis, V; Demiri, M; Drufakou, S; Efremidis, AP; Koumakis, G; Missitzis, J; Vassilomanolakis, M | 1 |
| Li, WL; Qin, YK; Yao, Q; Zhu, SW | 1 |
| Bauduceau, O; Bernard, O; Ceccaldi, B; Dourhte, LM; Hervé, R; Le Moulec, S | 1 |
| Fumoleau, P | 1 |
| Siderov, J | 1 |
| Ilersich, AL; Verma, S | 1 |
| Almanza, C; Amenedo, M; Gamazo, JL; Gómez-Martín, C; González-Ageitos, A; González-Quintas, A; Losada, G; Ramos, M; Romero, C; Togores, P | 1 |
| Airoldi, M; Bumma, C; Cattel, L; Marchionatti, S; Pedani, F; Recalenda, V; Tagini, V | 1 |
| Nabholtz, JM | 2 |
| Crown, J; Pegram, M | 1 |
| Ahiskali, R; Celikel, T; Ceyhan, BB; Duman, D; Duman, DG | 1 |
| Bessho, A; Eguchi, K; Harada, M; Harita, S; Hiraki, S; Hiraki, Y; Kamei, H; Kiura, K; Okimoto, N; Segawa, Y; Tabata, M; Takemoto, M; Takigawa, N; Tanimoto, M; Ueoka, H; Watanabe, Y | 1 |
| Haga, S; Hanyu, N; Karasawa, K; Katsui, K; Kimura, T; Kohno, M; Maebayashi, K; Mitsuhashi, N; Muramatsu, H; Nasu, S; Seki, K; Takahashi, I | 1 |
| Bernard-Marty, C; Cardoso, F; Piccart, MJ | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; D'Aiuto, G; De Rosa, V; Di Bonito, M; Frasci, G; Lapenta, L; Thomas, R; Vallone, P | 1 |
| Barbounis, V; Demiri, M; Efremidis, AP; Koumakis, G; Missitzis, J; Vassilomanolakis, M | 1 |
| Bardou, VJ; Bladou, F; Camerlo, J; Genre, D; Gravis, G; Macquart-Moulin, G; Maraninchi, D; Salem, N; Serment, G; Viens, P | 1 |
| Almanza, C; Ballesteros, P; Belón, J; Casal, J; Castellanos, J; Frau, A; Galán, A; Lizón, J; Llorca, C; Lorenzo, A; Machengs, I; Méndez, M; Morales, S; Moreno-Nogueira, JA; Oltra, A; Ramos, M | 1 |
| Busby, E; Carey, DE; Marques, MB; Reynolds, RE; Robert, F | 1 |
| Alexopoulos, A; Ardavanis, A; Georganta, C; Gerasimidis, G; Kandilis, K; Karamouzis, MV; Karydas, I; Rigatos, G; Stavrakakis, J; Stavrinides, H; Tryfonopoulos, D | 1 |
| Asai Go, Go; Fukuoka, M; Kaneda, H; Kurata, T; Nakagawa, K; Nogami, T; Tamura, K; Uejima, H | 1 |
| Allred, DC; Chang, JC; Elledge, RM; Granchi, T; Gutierrez, MC; Hilsenbeck, SG; Kalidas, M; Lucci, A; Mohsin, S; Scott, BG; Van Pelt, AE | 1 |
| Higuchi, S; Matsunaga, N; Ohdo, S; Sakaguchi, H; Shin, M; Tabuchi, M; Takeuchi, A; To, H | 1 |
| O'Shaughnessy, J | 1 |
| Hawkins, N; Jones, L; Richardson, G; Riemsma, R; Westwood, M; Wright, K | 1 |
| Peyromaure, M; Thiounn, N | 1 |
| Hopkins, U; Malik, U; Manalo, JM; Negassa, A; Novik, Y; Raff, JP; Rajdev, L; Sarta, C; Sparano, JA | 1 |
| Guillén Grima, F; Peñuelas Sánchez, I; Sánchez Lerma, B | 1 |
| D'hondt, R; Dumez, H; Paridaens, R; Pauwelyn, K; Thomas, J; Van Oosterom, AT; Wildiers, H | 1 |
| El Saghir, NS; Otrock, ZK | 1 |
| Julka, PK; Mukhopadhyay, P; Rath, GK; Sharma, DN | 1 |
| Arai, Y; Hoshi, S; Itoh, A; Ohyama, C; Okada, Y; Ono, K; Saito, S; Satoh, M; Sohma, F; Takeda, A; Yamashita, S; Yamato, T | 1 |
| Bradley, C; Crawford, SM; Dent, J; Dodwell, D; Humphreys, AC; Joffe, JK; Perren, TJ; Rodwell, S | 1 |
| Alexopoulos, A; Ardavanis, A; Georganta, C; Kandilis, K; Karamouzis, MV; Rigatos, G; Stavrakakis, J; Stavrinides, H | 1 |
| Calvo, I; Casado, V; Daz, M; Dómine, M; Estévez, LG; Jaén, A; León, A; Lobo, F; Miró, C; Rubio, G; Sánchez-Rovira, P | 1 |
| Dempsey, DT; Furukawa, S; Gupta, D; McClurken, JB; Piacentino, V; Ross, K; Stepnowski, D | 1 |
| Adrover, E; Alba, E; Amenedo, M; Balil, A; Barnadas, A; Casado, A; Fernández-Aramburo, A; Jara, C; Martín, M; Ramos, M; Sánchez-Rovira, P | 1 |
| Baena, JM; Burrilo, MA; Garcia, MJ; Illarramendi, J; Lorenzo, A; Machengs, I; Mayordomo, JI; Milla, A; Modolell, A; Morales, S; Sanz, J; Tres, A; Yubero, A | 1 |
| Amenedo, M; Firvida, JL; González, A; Losada, G; Ramos, M; Rodríguez, R; Salgado, M | 1 |
| Baldi, PL; Calista, F; Cannita, K; Cianci, G; DE Galitiis, F; DI Rocco, ZC; Ficorella, C; Marchetti, P; Morelli, MF; Natoli, C; Porzio, G; Ricevuto, E; Tinari, N | 1 |
| Berman, A; Brahim, JS; Chow, C; Figg, WD; Parr, AL; Sparreboom, A; Steinberg, SM; Swain, SM; Tan, AR; Yang, X; Zhai, S | 1 |
| Albanell, J; Antón, A; Barnadas, A; Baselga, J; Climent, MA; Estaun, N; Garcia-Conde, J; Guillem, V; Laurent, C; Lluch, A; Losa, I; Mayordomo, JI; Tabernero, J; Tisaire, JL; Vermorken, JB | 1 |
| Desjardins, P; Hirsh, V; Laberge, F; Langleben, A; Latreille, J; Samson, B; Whittom, R | 1 |
| Nortier, JW | 1 |
| Heys, SD; Hutcheon, AW; Sarkar, T | 1 |
| Au, HJ; Bodnar, DM; Joy, AA; Koski, SL; Mackey, JR; Scarfe, AG; Smith, SW; Smylie, MG; Soulieres, D; Tonkin, KS | 1 |
| Saeki, T; Takashima, S | 1 |
| Aboulafia, DM; Jacobs, AD; Otero, H; Picozzi, VJ | 1 |
| Caillaud, D; Clary, C; Clouet, P; Coudert, B; Couteau, C; D'Arlhac, M; Dabouis, G; Douillard, JY; Gervais, R; Le Groumellec, A; Maury, B; Monnier, A; Mornet, M; Rivière, A; Spaeth, D | 1 |
| Asaga, T; Fukuda, M; Fukuma, E; Hamaguchi, Y; Inaba, M; Ishida, K; Ishikawa, T; Ishiyama, A; Katayama, K; Shimada, H; Shimizu, S; Suda, T; Tokuda, Y | 1 |
| Besova, NS; Gorbunova, VA | 1 |
| Hribaschek, A; Lippert, H; Lueck, A; Meyer, F; Ridwelski, K | 1 |
| Nortier, JW; Rodenburg, CJ; Slee, PH; van Bochove, A | 1 |
| Hara, I; Kamidono, S; Miyake, H; Muramaki, M | 1 |
| Apostolikas, N; Barbounis, V; Chrissohoou, M; Demiri, M; Efremidis, AP; Koumakis, G; Panopoulos, C; Vassilomanolakis, M | 1 |
| Amin, P; Dawson, N; Dorsey, B; Engstrom, C; Guo, C; Hussain, A; Siegel, E | 1 |
| Allen, J; Hade, EM; Mrózek, E; Rhoades, CA; Shapiro, CL | 1 |
| Filatova, LV; Gershanovich, ML; Semiglazova, TIu | 1 |
| Antón, A; Chan, S; Cognetti, F; Conte, P; Extra, JM; Green, M; Grimes, D; Kennedy, J; Lluch, A; Maraninchi, D; Marty, M; Mauriac, L; Mayne, K; O'Byrne, K; Snyder, R; Tubiana-Hulin, M; Ward, C | 1 |
| Chin, K; Hatake, K; Inamura, K; Ito, Y; Kobayashi, T; Mishima, Y; Mizunuma, N; Nagasaki, E; Nishimori, H; Shinozaki, E; Takahashi, S; Terui, Y; Yokoyama, M | 1 |
| Carboni, R; Caristi, N; Chiofalo, G; La Torre, F; Mafodda, A; Maisano, R; Mare, M; Picciotto, M | 1 |
| Battelli, N; Boccetti, T; Bonsignori, M; Marcucci, F; Massacesi, C; Pilone, A; Rocchi, MB | 1 |
| Arena, MG; Belli, F; Carpano, S; Di Lauro, L; Giannarelli, D; Lopez, M; Paoletti, G | 1 |
| Badve, S; Campbell, RA; Kumar, S; Mehrotra, S; Murry, DJ; Nakshatri, H; Roman, Y; Sadaria, MR; Sheridan, C; Shortle, NH; Sweeney, CJ | 1 |
| Gligorov, J; Nabholtz, JM | 3 |
| Bang, YJ; Ham, HS; Hong, YS; Im, SA; Im, YH; Kim, KW; Kim, SB; Kim, TY; Kim, WK; Lee, J; Lee, KE; Lee, KH; Lee, MA; Lee, MH; Lee, NS; Lee, SN; Park, HS; Park, YH; Seo, JH; Song, HS | 1 |
| Bang, SM; Cho, EK; Chung, M; Lee, JH; Lee, WK; Park, SH; Shin, DB | 1 |
| Ahn, JH; Kang, YK; Kim, SB; Kun Kim, W; Lee, JS; Sohn, HJ | 1 |
| Addo, FK; Cole, JT; Fitch, TR; Flynn, PJ; Ingle, JN; Mailliard, JA; Perez, EA; Suman, VJ; Veeder, MH; Walsh, DJ | 1 |
| Booser, D; Esparza-Guerra, L; Hortobagyi, G; Montero, A; Murray, J; Rosales, M; Valero, V | 1 |
| G Oumlker, E; Rodenhuis, S | 1 |
| Keam, SJ; McKeage, K | 1 |
| Fumoleau, P; Levy, C | 1 |
| Antón, A; Arcusa, A; Bayo, JL; Calvo, L; Carrasco, E; Florián, J; Martín-Richard, M; Mayordomo, JI; Pelegrí, A; Vásquez, S; Virizuela, J | 1 |
| Arlen, PM; Beetham, P; Chen, C; Dahut, W; Feldman, J; Grosenbach, DW; Gulley, JL; Jones, E; Marte, J; Panicali, D; Parker, C; Pazdur, M; Schlom, J; Skarupa, L; Steinberg, SM; Tsang, KY | 1 |
| Ford, HE; Hall, M; Harries, M; Johnston, SR; Makris, A; Miles, DW; Miller, L; Smith, IE; Yap, YS | 1 |
| Cirillo, I; de Bruijn, P; de Jonge, MJ; Felici, A; Loos, WJ; Mathijssen, RH; Nooter, K; Verweij, J | 1 |
| Appenrodt, S; Guntinas-Lichius, O; Krug, B; Veelken, F | 1 |
| Asmar, L; Ilegbodu, D; Khandelwal, P; O'Shaughnessy, JA; Pluenneke, R; Sternberg, J | 1 |
| Botti, G; Chiodini, P; D'Aiuto, G; De Maio, E; de Matteis, A; Di Maio, M; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Normanno, N; Nuzzo, F; Pacilio, C; Perrone, F; Rossi, E | 1 |
| Bianco, AR; Caputo, F; Catalano, G; Ciardiello, F; Colantuoni, G; De Laurentiis, M; De Placido, S; De Vita, F; Diadema, MR; Gridelli, C; Orditura, M; Palmieri, G; Tortora, G; Troiani, T | 1 |
| Puhalla, S; Ramaswamy, B | 1 |
| Ajzensztejn, D; Hegde, VS; Lee, SM | 1 |
| Ahn, JS; Im, YH; Kang, JH; Kang, WK; Lee, J; Lee, SI; Lim, HY; Park, JO; Park, K; Park, KW; Park, YS | 1 |
| Allen, J; Hauger, M; Kendra, K; Merriman, N; Moore, T; Mrozek, E; Nadella, P; Ramaswamy, B; Rhoades, CA; Shapiro, CL; Villalona-Calero, M; Watson, H; Young, D | 1 |
| Arlen, PM; Gulley, JL; Pazdur, M; Rauckhorst, M; Skarupa, L | 1 |
| Bloomfield, D; James, ND; Luscombe, C | 1 |
| Amadori, D; Cecconetto, L | 1 |
| Farfan, N; Hamilton-Nelson, K; Lopes, G; Negret, LM; Raez, LE; Rocha-Lima, C; Roman, E; Rosado, MF; Santos, ES; Silva, O; Tolba, K | 1 |
| Bustam, A; Khoo, KS; Lehnert, M; Manzoor Zaidi, SH; Nair, R; Ngelangel, CA; Reece, WH; Song, S; Srimuninnimit, V | 1 |
| Birtle, A; Collins, R; Fenwick, E; Light, K; Norman, G; Palmer, S; Riemsma, R; Trowman, R | 1 |
| Baker, SD; Carducci, MA; Denmeade, SR; Eisenberger, MA; Elza-Brown, K; Pili, R; Rosenbaum, E; Schmidt, J; Sinibaldi, VJ; Walczak, J; Zahurak, M | 1 |
| Honda, J; Miyoshi, T; Seike, J; Tangoku, A; Umemoto, A; Yoshida, T | 1 |
| Barak-Wigler, N; Bexon, AS; Chan-Navarro, CA; Gorbounova, V; Harker, WG; Leonard, R; Maraninchi, D; McKendrick, JJ; O'Shaughnessy, J; Twelves, C; Vukelja, S | 1 |
| James, J; Miller, KD; Murry, DJ; Sidor, C; Sledge, GW; Storniolo, AM; Treston, AM | 1 |
| Ackermann, S; Beckmann, MW; Camara, O; Emons, G; Günthert, AR; Kiesel, L; Rensing, K; Schröder, W; Steiner, E | 1 |
| Albanell, J; Bosch, M; Campás, C; Codony-Servat, J; Dang, L; Domingo-Domenech, J; Filella, X; Gascon, P; Mellado, B; Montagut, C; Oliva, C; Rolfe, M; Ross, JS; Rovira, A; Tapia, M | 1 |
| Beijnen, JH; Bosch, TM; Doodeman, VD; Huitema, AD; Jansen, R; Jansen, RL; Schellens, JH; Smit, WM; Soesan, M; van Herpen, CM; Witteveen, E | 1 |
| Calabrò, F; Sternberg, CN | 1 |
| Agelaki, S; Argiraki, A; Christofillakis, Ch; Georgoulias, V; Kalykaki, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Souglakos, J; Tselepatiotis, E; Vamvakas, L; Vardakis, N | 1 |
| Baker, SD; Caravelli, J; Cutchall, K; D'Andrea, G; Fleming, MT; Gomez, J; Hudis, C; Hurria, A; Kelly, WK; Kris, MG; Miller, VA; Norton, L; Panageas, K; Scher, HI; Yeung, H | 1 |
| Alexandrescu, DT; Vaillant, J; Wiernik, PH | 1 |
| Sweeney, CJ | 1 |
| Chang, HK; Chen, JS; Liaw, CC; Lin, YC; Wang, HM; Yang, TS | 1 |
| Birtle, A; Collins, R; Fenwick, E; Light, K; Norman, G; Palmer, S; Perard, R; Riemsma, R; Trowman, R | 1 |
| Altieri, V; Autorino, R; Cancello, G; D'Armiento, M; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Figg, WD; Imbimbo, C; Longo, N; Mirone, V; Perdonà, S; Tortora, G | 1 |
| Amiconi, G; Blasio, AD; Candeloro, G; Cesta, A; Necozione, S; Rea, S; Recchia, F; Saggio, G | 1 |
| Andrade, R; Chabot, J; Desai, M; Fine, RL; Fogelman, DR; Guba, S; Schreibman, SM; Sherman, W; Strauss, J | 1 |
| Chang, HM; Chun, YJ; Kang, YK; Kim, BS; Kim, M; Kim, TW; Lee, JL; Lee, JS; Oh, ST; Ryu, MH; Yook, JH | 1 |
| Dent, S; Messersmith, H; Trudeau, M | 1 |
| Barbanti, G; De Rubertis, G; Francini, E; Francini, G; Manganelli, A; Marsili, S; Pascucci, A; Petrioli, R; Salvestrini, F; Sciandivasci, A | 1 |
| Andersson, E; Aulitzky, WE; Cai, F; Havelka, AM; Linder, S; Muerdter, TE; Olofsson, MH; Pan, Y; Schwarz, S; Shoshan, MC; Sonnenberg, M; Toi, M; Ueno, T; van der Kuip, H; Xu, R | 1 |
| Cescon, TP; Dennison, SK; Geyer, CE; Jacobs, SA; Raymond, JM; Seeger, J; Swain, SM; Wilson, JW; Wolmark, N | 1 |
| Blasinska-Morawiec, M; Bonneterre, J; Campone, M; Chatelut, E; Deporte-Fety, R; Douville, I; Ecochard, L; Koralewski, P; Leger, F; Longerey, B | 1 |
| Ewer, MS; O'Shaughnessy, JA | 1 |
| Gassiamis, A; Karabelis, A; Kosmas, C; Malamos, N; Mylonakis, N; Polyzos, A; Skopelitis, H; Tsakonas, G; Tsavaris, N | 1 |
| Baker, LH; Benjamin, RS; Fanucchi, M; Harmon, DC; Hensley, ML; Maki, RG; Okuno, SH; Patel, SR; Priebat, DA; Reinke, D; Samuels, B; Schuetze, SM; Thall, PF; Wathen, JK | 1 |
| Agostini, C; Bachelot, T; Cassier, PA; Chabaud, S; Cure, H; Guastalla, JP; Jacquin, JP; Martin, C; Orfeuvre, H; Peaud, PY; Pérol, D; Salles, B; Tigaud, JD; Trillet-Lenoir, V | 1 |
| Beer, TM; Dreicer, R; Fehrenbacher, L; Hannah, AL; Higano, CS; Hudes, G; Picus, J; Rarick, M; Saleh, M | 1 |
| Christophylakis, C; Georgoulias, V; Ignatiadis, M; Kalbakis, K; Kotsakis, A; Polyzos, A; Potamianou, A; Stathopoulos, GP; Tselepatiotis, E; Vamvakas, L | 1 |
| Ilson, DH | 1 |
| Ajani, JA; Boni, C; Chao, Y; Constenla, M; Fodor, M; Majlis, A; Marabotti, C; Moiseyenko, VM; Rodrigues, A; Tjulandin, S; Van Cutsem, E; Voznyi, E | 1 |
| Arena, MG; Di Lauro, L; Foggi, P; Lopez, M; Nunziata, C; Sperduti, I | 1 |
| Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, A; Prezerakos, P | 1 |
| Boku, N; Ebihara, M; Iida, Y; Onitsuka, T; Onozawa, Y; Zenda, S | 1 |
| Twelves, C | 1 |
| Harbeck, N; Kates, R; Mallmann, P; Nawroth, F; Ohlinger, R; Pantke, E; Thomas, A; Valter, M; Warm, M | 1 |
| Goh, PG; Hwang, SW; Jeong, HY; Kang, HM; Kang, SH; Kang, YS; Kim, JI; Kim, SH; Kwon, DS; Lee, BS; Moon, HS; Nam, KW; Seong, JK | 1 |
| Andreu, J; Cortés, J; Martínez, P; Montero, MA; Prat, A; Serrano, C | 1 |
| Baldazzi, V; Carini, M; Crisci, A; Giordano, C; Grifoni, R; Lapini, A; Neri, B; Pantaleo, P; Raugei, A; Vannini, L | 1 |
| Chang, HK; Chen, JS; Lin, YC; Shen, WC; Wang, HM | 1 |
| Aiba, K; Hatake, K; Hosoyama, H; Ito, Y; Katayama, K; Minowa, S; Mitsuhashi, J; Nishi, S; Noguchi, K; Oh-hara, Y; Shibata, H; Sugimoto, Y; Suzuki, R; Takahashi, S; Tsukahara, S | 1 |
| Bucana, CD; Cohen, L; Fidler, IJ; Johnson, MM; Jones, DM; Kim, SJ; Logothetis, CJ; Mathew, P; Meluch, AA; Morris, MJ; Oh, WK; Pagliaro, LC; Smith, L; Tannir, NM; Thall, PF; Troncoso, P; Tu, SM; Wen, S | 1 |
| Craig, M; Day, LL; Loberg, RD; Neeley, C; Pienta, KJ; Sargent, E; Snyder, LA; Wojno, K; Yan, L; Ying, C | 1 |
| Goh, BC; Lee, HS; Lee, SC; Soo, R; Sukri, N; Tham, LS; Wang, LZ; Wong, CI; Yong, WP | 1 |
| Armstrong, AJ; de Wit, R; Eisenberger, M; Garrett-Mayer, ES; Tannock, IF; Yang, YC | 1 |
| Radaideh, SM; Sledge, GW | 1 |
| O'Brien, ME | 1 |
| Fujii, S; Hayashi, R; Kawashima, M; Kiyota, N; Minami, H; Ogino, T; Ohtsu, A; Tahara, M | 1 |
| Baselga, J; De Rosa, F; Fettner, S; Jones, R; Rakhit, A; Trigo, JM; Twelves, C; Wright, T | 1 |
| Autorino, R; De Placido, S; Di Lorenzo, G; Figg, WD; Fossa, SD; Giordano, A; Giuliano, M; Imbimbo, C; Labianca, R; Longo, N; Mirone, V; Perdonà, S | 1 |
| de Wit, R | 1 |
| Chaladaj, A; Droz, JP | 1 |
| Abe, S; Iyama, S; Kato, J; Murase, K; Niitsu, Y; Okamoto, K; Sagawa, T; Sato, T; Sato, Y; Takahashi, S; Takayama, T | 1 |
| Bossi, A; Chauchereau, A; de Crevoisier, R; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Thuret, R | 1 |
| Bae, JM; Choi, IJ; Kim, CG; Kim, HK; Kim, NK; Kim, YW; Lee, JH; Lee, JS; Park, SR; Ryu, KW | 1 |
| Bisegna, R; Bratta, M; Candeloro, G; Di Staso, M; Necozione, S; Rea, S; Recchia, F; Tombolini, V | 1 |
| Marty, M; Pivot, X | 1 |
| Ahuja, H; Alberti, D; Attia, S; Blank, J; Eastman, M; Eickhoff, J; Glode, M; Horvath, D; Jumonville, A; Liu, G; Marnocha, R; McNeel, D; Shevrin, D; Staab, MJ; Straus, J; Wilding, G | 1 |
| Anderssona, M; Awadab, A; Barrett-Leec, P; Ellisd, P; Hupperetse, P; Jackischf, C; Kubistag, E; Lückh, HJ; Monnerati, C; Nitzj, U; Untchl, M | 1 |
| Cai, Y; Hong, X; Hu, X; Li, J; Ou, Z; Shen, Z; Wang, Z; Yang, X; Zhao, X | 1 |
| Amar, S; Perez, EA; Roy, V | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Karina, M; Kosmidis, P; Koutras, A; Maniadakis, N; Matsiakou, F; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Skarlos, D | 1 |
| Anand, A | 1 |
| Eisenhauer, EA; Trudeau, M | 1 |
| Ravdin, PM; Valero, V | 1 |
| Benner, S; Calayag, M; Fossella, FV; Glisson, B; Huber, M; Lee, JS; Lippman, S; Murphy, WK; Perez-Soler, R; Shin, DM | 1 |
| Abbruzzese, JL; Ajani, JA; Bready, B; Lassere, Y; Levin, B; Patt, Y; Pazdur, R; Soh, LT; Soo, E; Sugarman, S | 1 |
| Bellet, RE; Buzdar, AU; Esparza, L; Fonseca, GA; Fraschini, G; Holmes, FA; Hortobagyi, GN; Theriault, RL; Valero, V; Walters, RS | 1 |
| Bedikian, AY; Burris, HA; Buzaid, AC; Eckardt, JR; Eton, O; Jenkins, J; Legha, SS; Smetzer, L; Von Hoff, DD; Weiss, GR | 1 |
| Balmaceda, C; Baselga, J; Bruno, R; Crown, JP; Currie, V; Freilich, R; Gilewski, TA; Gollub, M; Hakes, TB; Hudis, CA; Lebwohl, DE; Norton, L; Raptis, G; Robles, M; Seidman, AD | 1 |
| Piccart, MJ | 1 |
| Delorme, F; Eisenhauer, EA; Higgins, BP; Letendre, F; Lofters, WS; Muldal, AM; Norris, BD; Trudeau, ME; Vandenberg, TA | 1 |
| Rougier, P | 1 |
| Azli, N; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Krakowski, I; Lentz, MA; Misset, JL; Murawsky, M; Pouillart, P; Riva, A; Roche, H | 1 |
| Piccart, M | 1 |
| Trudeau, ME | 2 |
| Kennedy, MJ | 1 |
| Diéras, V | 3 |
| Delorme, F; Janowska, A; Mackey, J; Nabholtz, JM; Noel, D; Paterson, A; Riva, A; Smylie, M | 1 |
| Azli, N; Delecroix, V; Féty, R; Fumoleau, P; Perrocheau, G | 1 |
| Von Hoff, DD | 1 |
| Valero, V | 1 |
| Antoine, E; Khayat, D | 1 |
| Bonneterre, J; Launois, RJ; Reboul-Marty, JM | 1 |
| Chan, S | 1 |
| Aapro, MS; Alaki, M; Bezwoda, WR; Deschênes, L; Douma, J; Drbal, J; Melnychuk, D; Murawsky, M; Nabholtz, JM; Rapoport, B; Riva, A; Rosso, R; Thuerlimann, B; Trillet-Lenoir, V; Vandenberg, TA | 1 |
| al-Tweigeri, T; Au, D; Delorme, F; Mackey, JR; Nabholtz, JM; Noel, D; Paterson, AH; Riva, A; Sansregret, E; Smylie, M | 1 |
| Aapro, MS | 2 |
| Clemons, M; Howell, A; Jayson, G; Leahy, M; Ranson, M; Valle, J | 1 |
| Rubens, RD | 1 |
| Dubbelman, R; Hiemstra, A; Lustig, V; Rodenhuis, S; ten Bokkel Huinink, WW | 1 |
| Cottu, PH; Espié, M; Extra, JM; Marty, M | 1 |
| Braguer, D; Briand, C; Kadi, A; Lehmann, M; Luis, J; Marvaldi, J; Pichard, V; Rognoni, JB | 1 |
| Bontenbal, M; de Wit, R; Klijn, JG; Seynaeve, C | 1 |
| Crown, J; Nabholtz, JM | 1 |
| Sparano, JA | 2 |
| Aapro, M | 1 |
| Crown, J | 3 |
| Mackey, J; Nabholtz, JM; Smylie, M; Tonkin, K | 1 |
| Pagani, O | 1 |
| Espie, M | 1 |
| Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Katsogridakis, K; Kotsakis, T; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Vlachonikolis, J | 1 |
| Miller, KD; Sledge, GW | 1 |
| Agelaki, S; Alexopoulos, A; Apostolaki, F; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kalbakis, K; Kosmas, C; Kourousis, C; Malamos, N; Mavroudis, D; Potamianou, A; Rigatos, G; Samonis, G; Sarra, E; Vlachonicolis, J | 1 |
| Buckner, CD; Franco, C; Hazelton, B; Moore, M; Schwartzberg, LS; Smith, R; Van Amburg, A; Weaver, CH; White, L; Zhen, B | 1 |
| Janowska-Wieczorek, A; Mackey, J; Nabholtz, JM; Smylie, M; Tonkin, K | 1 |
| Au, HJ; Au, R; Mackey, J; Morrish, D; Nabholtz, JM; Salter, E; Smylie, M; Tonkin, K | 1 |
| Agelaki, S; Alexopoulos, A; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kouroussis, C; Malamos, N; Mavroudis, D; Panagos, G; Papadouris, S; Potamianou, A; Samonis, G; Sara, E; Xydakis, E | 1 |
| Burris, HA | 1 |
| Ravdin, PM | 1 |
| Hortobagyi, GN | 1 |
| Blohmer, JU; Costa, SD; Dresel, V; Eidtmann, H; Gademann, G; Hilfrich, J; Jackisch, C; Kaufmann, M; Merkle, E; Raab, G; von Minckwitz, G | 1 |
| Bergman, M; Ekholm, E; Huhtala, S; Salminen, E | 1 |
| Alakl, M; Bodrogi, I; Buzzi, F; Chan, S; Crown, J; Duarte, R; Friedrichs, K; Gil Gil, M; González Mancha, R; Korec, S; Murawsky, M; Murray, E; Noel, D; Pintér, T; Richardson, G; Riva, A; Ronzoni, M; Simmonds, P; Van Belle, S; von Minckwitz, G; Vorobiof, D; Walpole, E; Yelle, L | 1 |
| Hayashi, K; Kuroi, K; Nagai, S; Toi, M; Tominaga, T | 1 |
| Budman, D; Kreis, W | 1 |
| Crown, JP | 1 |
| Bunnell, CA; Burstein, HJ; Clarke, KD; Garber, JE; Manola, J; Matulonis, UA; Parker, LM; Scheib, R; Shulman, LN; Winer, EP; Younger, J | 1 |
| Gagnon, GA; Sallah, S | 1 |
| Amano, G; Furuta, A; Harada, Y; Ikegaki, H; Kijima, G; Ohnuki, K; Ohuchi, N; Satomi, S; Yoshida, R | 1 |
| Brodowicz, T; Herscovici, V; Koestler, WJ; Steger, GG; Tomek, S; Vaclavik, I; Wiltschke, C; Zielinski, CC | 1 |
| Aita, P; Bearz, A; Boiocchi, M; Colussi, AM; Corona, G; Crivellari, D; Robieux, I; Sorio, R; Stocco, F; Toffoli, G | 1 |
| Adenis, A; Armand, JP; Baille, P; Blanc, C; Bonneterre, J; Clouet, P; de Forni, M; Dembak, M; Ducreux, M; Lebecq, A; Lefresne-Soulas, F; Rougier, P | 1 |
| Bergh, J; Blomqvist, C; Hakamies-Blomqvist, L; Luoma, M; Malmström, P; Mjaaland, I; Mouridsen, H; Ostenstad, B; Ottosson-Lönn, S; Pluzanska, A; Sjödin, M; Sjöström, J | 1 |
| Besenval, M; Boisdron-Celle, M; Delva, R; Gamelin, E; Lortholary, A; Maillard, P; Perard, D; Vernillet, L | 1 |
| Chang, HK; Chen, JS; Liaw, CC; Lin, YC; Wang, CH | 1 |
| Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wolf, M | 1 |
| Köhne, CH; Wilke, HJ; Wils, JA | 1 |
| Culine, S; Droz, JP | 1 |
| Al-Tweigeri, T; Azli, N; Mackey, JR; Nabholtz, JM; Noël, DR; North, S; Paterson, A; Riva, A; Smylie, M; Tonkin, K | 1 |
| Adachi, I; Ando, M; Katsumata, N; Nagata, K; Narabayashi, M; Watanabe, T | 1 |
| Georgoulias, VA | 1 |
| Milla, L; Milla-Santos, A; Rallo, L; Solano, V | 1 |
| Bojko, P; Borquez, D; Kasimir-Bauer, S; Mayer, S; Neumann, R; Seeber, S | 1 |
| Ambrosini, G; Antoine, EC; Azli, N; Benhammouda, A; Borg-Olivier, O; Chollet, P; Khayat, D; Mazen, MF; Monfardini, S; Ramazeilles, C; Riva, A; Sorio, R | 1 |
| Delozier, T; Fumoleau, P; Guastalla, JP; Kerbrat, P; Roché, H; Viens, P | 1 |
| Baker, M; Bradof, JE; Burris, HA; Erland, JB; Greco, FA; Grimaldi, M; Hainsworth, JD; Kalman, LA; Sullivan, T; Yardley, DA | 1 |
| Dieras, V; Perez, E; Valero, V | 1 |
| Bergaglio, M; Cognetti, F; Del Mastro, L; Donati, S; Frevola, L; Lionetto, R; Lunardi, G; Michelotti, A; Papaldo, P; Rosso, R; Sguotti, C; Venturini, M | 1 |
| Beuzeboc, P; Diéras, V; Laurence, V; Pierga, JY; Pouillart, P | 1 |
| Leyland-Jones, B; Smith, I | 1 |
| Carman, L; Colborn, D; Gutterman, L; Jones, J; Kuebler, JP; Larrimer, N; Laufman, LR; Moore, T; Patel, T; Pritchard, J; Roach, R; Segal, M; Spiridonidis, CH; Zangmeister, J | 1 |
| Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC | 1 |
| Blum, JL; Buzdar, A; Dieras, V; Horton, J; Lo Russo, PM; Osterwalder, B; Rutman, O | 1 |
| Bischoff, J; Forstpointner, R; Geuenich, S; Gutschow, K; Heinemann, V; Hiddemann, W; Kentenich, CH; Malekmohammadi, M; Sommer, H; Stemmler, HJ | 1 |
| Besova, NS; Bliumenberg, AG; Chekalova, MA; Gorbunova, VA; Khokhlova, SV; Kuznetsov, VV; Orel, NF; Poddubnyĭ, BK; Sinitsyna, ME; Smirnova, NB | 1 |
| Brugnatelli, S; Danova, M; De Bella, MT; Manuguerra, G; Palmeri, S; Riccardi, A; Vaglica, M | 1 |
| Clark, JW; Earle, CC; Fuchs, CS; Grossbard, ML; Grossman, SR; Kim, H; Kulke, MH; Mayer, RJ; Morgan, JA; Ryan, DP; Shivdasani, R | 1 |
| Arkad'eva, TV; Artamonova, EV; Davidenko, IS; Manziuk, LV; Poddubnaia, IV | 1 |
| Carles, J; Climent, MA; Garcia del Muro, X; Germá, JR; Gumá, J; Marcuello, E; Maroto, P; Parra, MS; Paz-Ares, L; Tisaire, JL | 1 |
| Bougnoux, Ph; Eymard, JC; Lotz, V; Mansouri, H; Namer, M; Spielmann, M; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Aihara, T; Kim, Y; Takatsuka, Y | 1 |
| Morere, JF | 1 |
| Booser, DJ; Cristofanilli, M; Frye, DK; Hortobagyi, GN; Rivera, E; Rosales, MM; Valero, V | 1 |
| Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S | 1 |
153 review(s) available for docetaxel anhydrous and Metastase
| Article | Year |
|---|---|
The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Network Meta-Analysis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2023 |
The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer.
Topics: Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms | 2020 |
[Treatment of metastatic, castration-resistant prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Germany; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Treatment Outcome | 2020 |
Docetaxel Rechallenge in Patients with Metastatic Prostate Cancer: A Comprehensive Review.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retreatment | 2020 |
Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Precision Medicine; Prostatic Neoplasms; Survival Rate | 2020 |
Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Hormones; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Treatment Outcome | 2020 |
[mHSPC-Therapie mit Apalutamid/ADT].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Thiohydantoins | 2020 |
The evolving options in metastatic castration-sensitive prostate cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2020 |
Management of Prostate Cancer with Systemic Therapy: A Prostate Cancer Unit Perspective.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Patient Care Management; Prostatic Neoplasms | 2021 |
The Role of Serotonin in Breast Cancer Stem Cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Docetaxel; Epithelial-Mesenchymal Transition; Female; Humans; Mice; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplastic Stem Cells; Phenotype; Receptors, Serotonin; Remission Induction; Serotonin; Sertraline; Signal Transduction | 2021 |
Aged patients with metastatic castration resistant prostate cancer: Should we treat with chemotherapy?
Topics: Aged; Antineoplastic Agents; Docetaxel; Geriatric Assessment; Humans; Male; Neoplasm Metastasis; Patient Selection; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report.
Topics: Androgen Antagonists; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2017 |
[Metastatic prostate cancer : Update: position paper for the use of chemotherapy].
Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Docetaxel; Early Medical Intervention; Evidence-Based Medicine; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2017 |
Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
Topics: Androgen Antagonists; Androstenes; Clinical Decision-Making; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Patient Selection; Progression-Free Survival; Prostatic Neoplasms; Time Factors; Treatment Outcome | 2018 |
Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant | 2017 |
Management of metastatic prostate cancer in the elderly: identifying fitness for chemotherapy in the post-STAMPEDE world.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Physical Fitness; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome | 2017 |
[Patients with metastatic prostate cancer : Recommendations for primary hormonal or chemohormonal therapy].
Topics: Androgen Antagonists; Combined Modality Therapy; Disease Progression; Docetaxel; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2017 |
Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Network Meta-Analysis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate | 2018 |
The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?
Topics: Abiraterone Acetate; Androgens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prostatic Neoplasms; Steroid Synthesis Inhibitors; Taxoids; Treatment Outcome | 2017 |
Pharmacokinetic/pharmacodynamic drug evaluation of enzalutamide for treating prostate cancer.
Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tumor Burden | 2018 |
Treatment of Castration-naive Metastatic Prostate Cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2017 |
Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2018 |
Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2017 |
Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Diphosphonates; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Treatment Outcome | 2018 |
Treatment of hormone-naïve metastatic prostate cancer.
Topics: Androgen Antagonists; Androstenes; Clinical Trials, Phase III as Topic; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2018 |
Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Asia, Eastern; Asia, Southeastern; Combined Modality Therapy; Consensus; Developing Countries; Docetaxel; Humans; Lymph Node Excision; Male; Neoplasm Metastasis; Oceania; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Risk Factors | 2019 |
What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations.
Topics: Abiraterone Acetate; Androgen Antagonists; Clinical Trials as Topic; Docetaxel; Humans; Infusions, Intravenous; Male; Medical Oncology; Neoplasm Metastasis; Practice Guidelines as Topic; Prostatic Neoplasms; Steroid Synthesis Inhibitors; Tubulin Modulators; Urology | 2019 |
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Black People; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; White People | 2019 |
Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events.
Topics: Adolescent; Adult; Aged; Androgen Antagonists; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Quality of Life; Young Adult | 2019 |
Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort.
Topics: Area Under Curve; Clinical Trials as Topic; Docetaxel; Humans; Incidence; Logistic Models; Male; Neoplasm Metastasis; Neoplasms; Neutropenia; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2019 |
Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Topics: Androgen Antagonists; Androstenes; Combined Modality Therapy; Docetaxel; Humans; Lymph Node Excision; Male; Metastasectomy; Neoplasm Metastasis; Prostatic Neoplasms; Standard of Care | 2019 |
[Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2019 |
[Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Treatment Outcome | 2019 |
[50 years of systemic therapy of urinary bladder cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Transitional Cell; Clinical Trials as Topic; CTLA-4 Antigen; Docetaxel; Humans; Immunotherapy; Neoplasm Metastasis; Programmed Cell Death 1 Receptor; Randomized Controlled Trials as Topic; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 2019 |
Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tissue Extracts | 2013 |
Perspectives on treatment of metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2013 |
Current, new and novel therapy for castration-resistant prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Disease Progression; Docetaxel; Humans; Male; Molecular Targeted Therapy; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Proteins; Receptor, ErbB-2; Taxoids; Trastuzumab | 2013 |
Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids | 2014 |
[A case of postoperative thymic carcinoma recurrence that was effectively treated with combination chemotherapy of nedaplatin and docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Recurrence; Taxoids; Thymoma | 2013 |
The Utility of Chemotherapy in the Treatment of Metastatic Prostate Cancer.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostate; Prostatic Neoplasms; Taxoids | 2016 |
Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
Topics: Alpha Particles; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Cancer Vaccines; Chlorides; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Taxoids; Tissue Extracts | 2013 |
Treatment options in patients with metastatic gastric cancer: current status and future perspectives.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Docetaxel; Epirubicin; Fluorouracil; Humans; Medical Oncology; Neoplasm Metastasis; Palliative Care; Pyrimidines; Quality of Life; Receptor, ErbB-2; Stomach Neoplasms; Taxoids; Trastuzumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.
Topics: Abiraterone Acetate; Androstadienes; Benzamides; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Practice Guidelines as Topic; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2014 |
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Mutation; Neoplasm Metastasis; Neoplasm Staging; Retreatment; Taxoids; Treatment Outcome | 2015 |
Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
Management of castration-resistant (advanced) prostate cancer (CRPC): rationale, progress and future directions.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Australia; Disease Progression; Docetaxel; General Practice; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids | 2015 |
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.
Topics: Abiraterone Acetate; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Young Adult | 2015 |
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Tissue Extracts | 2015 |
Role of chemotherapy in combination with hormonal therapy in first-line treatment of metastatic hormone-sensitive prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Hormones; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2015 |
The role of taxanes in triple-negative breast cancer: literature review.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Odds Ratio; Prostatic Neoplasms; Risk Factors; Taxoids; Time Factors; Treatment Outcome; Tumor Burden | 2016 |
Docetaxel for the treatment of bladder cancer.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Docetaxel; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Urinary Bladder Neoplasms | 2015 |
Chemotherapy for metastatic castrate-sensitive prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2016 |
Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids | 2016 |
The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoradiotherapy; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Immunotherapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2016 |
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.
Topics: Age Factors; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Evidence-Based Medicine; Health Status; Humans; Male; Neoplasm Grading; Neoplasm Metastasis; Patient Selection; Population Surveillance; Prednisone; Prostatic Neoplasms; Taxoids; Tumor Burden; Uncertainty | 2017 |
Understanding the role of new systemic agents in the treatment of prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Taxoids; Tissue Extracts | 2016 |
A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2016 |
Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Genes, erbB-2; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab | 2008 |
Docetaxel in the management of prostate cancer: current standard of care and future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Docetaxel; Drug Delivery Systems; Humans; Male; Neoadjuvant Therapy; Neoplasm Metastasis; Prostatic Neoplasms; Survival Rate; Taxoids | 2008 |
Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Epothilones; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Organoplatinum Compounds; Prostatic Neoplasms; Receptors, Vascular Endothelial Growth Factor; Taxoids; Testosterone; Thionucleotides | 2008 |
Paclitaxel and docetaxel in the treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2008 |
New avenues for second-line treatment of metastatic non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Metastasis; Pemetrexed; Quinazolines; Taxoids | 2009 |
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Europe; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; North America; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recurrence; South America; Survival Analysis; Taxoids; Tumor Burden | 2009 |
Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prednisone; Prognosis; Prostatic Neoplasms; Substance Withdrawal Syndrome; Taxoids; Treatment Outcome | 2010 |
Is age a negative prognostic factor for the treatment of advanced/metastatic non-small-cell lung cancer?
Topics: Age Factors; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Global Health; Humans; Immunosuppressive Agents; Lung Neoplasms; Neoplasm Metastasis; Prognosis; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Development of targeted therapy for squamous cell carcinomas of the head and neck.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Insulin-Like Growth Factor I; Neoplasm Metastasis; NF-kappa B; Proteasome Inhibitors; Recurrence; Taxoids; Vascular Endothelial Growth Factor A | 2011 |
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Forecasting; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Failure | 2011 |
Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids | 2011 |
Management of metastatic castration-resistant prostate cancer after first-line docetaxel.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Docetaxel; Hormones; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neovascularization, Pathologic; Orchiectomy; Prostatic Neoplasms; Salvage Therapy; Survival Analysis; Taxoids | 2011 |
Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Taxoids | 2011 |
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Radioisotopes; Taxoids; Tissue Extracts | 2011 |
Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Taxoids | 2012 |
Pertuzumab in HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; PubMed; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prognosis; Prostatic Neoplasms; Survival Rate; Taxoids | 2013 |
Trastuzumab/chemotherapy combinations in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Platinum Compounds; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2002 |
Gemcitabine and targeted therapy in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2002 |
Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Hematologic Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2002 |
End points for new agents in induction chemotherapy for locally advanced head and neck cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
[Radiation recall dermatitis after docetaxel and external beam radiotherapy. Report of two cases and review of the literature].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Paclitaxel; Radiodermatitis; Radiotherapy; Taxoids | 2002 |
[Gemcitabine and breast cancer].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Economics, Pharmaceutical; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Combination versus sequential single-agent therapy in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Research Design; Taxoids; Trastuzumab | 2002 |
Gemcitabine combined with docetaxel in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2003 |
Docetaxel-anthracycline combinations in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2003 |
Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2003 |
Use and abuse of taxanes in the management of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Bias; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Patient Selection; Randomized Controlled Trials as Topic; Substance-Related Disorders; Taxoids | 2003 |
Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Fluorouracil; Humans; Neoplasm Metastasis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; State Medicine; Survival Rate; Taxoids; Treatment Outcome; United Kingdom | 2004 |
[Docetaxel in combination with cisplatin for first-line treatment of locally advanced or metastatic non-small cell lung cancer: meta-analysis of randomized and controlled clinical trials].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Metastasis; Taxoids | 2004 |
Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2004 |
The role of taxanes in the treatment of breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemistry, Pharmaceutical; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2005 |
Docetaxel/trastuzumab combination therapy for the treatment of breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2005 |
Docetaxel in the treatment of breast cancer: current experience and future prospects.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Humans; Neoplasm Metastasis; Neoplasm Staging; Taxoids | 2005 |
Docetaxel in hormone-refractory metastatic prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Taxoids | 2005 |
Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasm Metastasis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Tubulin Modulators | 2006 |
The changing pattern of management for hormone-refractory, metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Palliative Care; Prednisolone; Prostatic Neoplasms; Spinal Cord Compression; Taxoids; Urologic Diseases | 2006 |
Gemcitabine and taxanes in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2006 |
A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
State-of-the-art management of metastatic disease at initial presentation or recurrence.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Taxoids; Urinary Bladder Neoplasms | 2006 |
A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.
Topics: Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Glucocorticoids; Humans; Male; Models, Economic; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Quality-Adjusted Life Years; Taxoids; Treatment Outcome; United Kingdom | 2007 |
Gemcitabine in the management of metastatic breast cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Heart Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2007 |
Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2008 |
Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Neoplasm Metastasis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Chemotherapy in hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Male; Multivariate Analysis; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nomograms; Predictive Value of Tests; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Survival Analysis; Taxoids | 2008 |
Management of metastatic prostate cancer: the crucial role of geriatric assessment.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Geriatric Assessment; Humans; Lymphatic Metastasis; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Palliative Care; Prednisone; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2008 |
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
Topics: Angiogenesis Inhibitors; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Taxoids; Vascular Endothelial Growth Factor A | 2008 |
Treatment of metastatic breast cancer: looking towards the future.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Medical Oncology; Neoplasm Metastasis; Paclitaxel; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
Taxoid compounds in breast cancer: current status and future prospects.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1995 |
Docetaxel delivers new management opportunities for gastrointestinal carcinomas.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Docetaxel; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Stomach Neoplasms; Taxoids | 1995 |
Treatment of advanced breast cancer: current status.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1996 |
Metastatic breast cancer.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Diphosphonates; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Gemcitabine; Humans; Imides; Intercalating Agents; Isoquinolines; Naphthalimides; Neoplasm Metastasis; Neoplasm Proteins; Organophosphonates; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Topoisomerase II Inhibitors; Treatment Outcome | 1996 |
The taxoids: same roots, different drugs.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids | 1997 |
Docetaxel in combination chemotherapy for metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
[A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Docetaxel; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Sensitivity and Specificity; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1997 |
Review of docetaxel/doxorubicin combination in metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1997 |
Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Synergism; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Metastasis; Nervous System Diseases; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 1997 |
Review of recent trials of chemotherapy for advanced breast cancer: the taxanes.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
The role of docetaxel in improving treatment outcomes in advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 1997 |
Prospects with docetaxel in the treatment of patients with breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
[Chemotherapy in metastasized breast carcinoma].
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Neoplasm Metastasis; Neoplasms, Second Primary; Paclitaxel; Palliative Care; Quality of Life; Survival Rate; Taxoids | 1998 |
Evolution in the treatment of advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1998 |
Taxanes in the treatment of breast cancer: a prodigy comes of age.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Neoplasm Proteins; Paclitaxel; Palliative Care; Survival Analysis; Taxoids; Tubulin; Vinca Alkaloids | 1999 |
A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Phase III randomized trials of docetaxel in patients with metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Mitomycin; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Vinblastine | 1999 |
Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Single-agent docetaxel (Taxotere) in randomized phase III trials.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Failure | 1999 |
Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Clinical Trials as Topic; Docetaxel; Doxorubicin; Heart; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Recent progress in the clinical development of docetaxel (Taxotere).
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Estramustine; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Expanding options in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Developments in the treatment of gastric cancer in Europe.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Taxoids | 2000 |
Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Palliative Care; Prednisolone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2000 |
Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids | 2001 |
Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Heart Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2001 |
Interaction between Herceptin and taxanes.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Heart Diseases; Humans; Mice; Mice, Nude; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Nervous System Diseases; Neutropenia; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptor, ErbB-3; Salvage Therapy; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays | 2001 |
Role of Herceptin in primary breast cancer: views from North America and Europe.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Interactions; Europe; Female; Humans; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; North America; Paclitaxel; Palliative Care; Pilot Projects; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Research Design; Safety; Survival Analysis; Tamoxifen; Taxoids; Trastuzumab; Treatment Outcome | 2001 |
421 trial(s) available for docetaxel anhydrous and Metastase
| Article | Year |
|---|---|
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgen Receptor Antagonists; Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Proportional Hazards Models; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyrazoles | 2022 |
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies | 2019 |
HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
Topics: Aged; Alleles; Androgen Antagonists; Disease Progression; Disease-Free Survival; Docetaxel; Genotype; Humans; Male; Middle Aged; Multienzyme Complexes; Neoplasm Metastasis; Progesterone Reductase; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Steroid Isomerases; Treatment Outcome | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Double-Blind Method; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2020 |
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyridines; Treatment Outcome | 2021 |
A randomized controlled Phase II trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Treatment Outcome; Vinorelbine | 2020 |
CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Body Composition; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Prospective Studies; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Psoas Muscles; Subcutaneous Fat; Tomography, X-Ray Computed | 2021 |
Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Retreatment; Taxoids; Treatment Outcome | 2020 |
Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Time Factors; United Kingdom | 2021 |
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Androgen Antagonists; Bone Neoplasms; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate; Prostatic Neoplasms | 2021 |
Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms; Radium; Treatment Outcome | 2021 |
The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Regression Analysis; Taxoids; Treatment Outcome | 2017 |
Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Docetaxel; Double-Blind Method; Fatigue; Humans; Male; Middle Aged; Modafinil; Neoplasm Metastasis; Prostatic Neoplasms; Surveys and Questionnaires; Taxoids | 2017 |
Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer: Microarray Analysis of Whole Human Genes.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Microarray Analysis; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Analysis; Taxoids; Tegafur; Treatment Outcome | 2017 |
Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry.
Topics: Aged; Aged, 80 and over; Disease-Free Survival; Docetaxel; Humans; Incidence; Male; Middle Aged; Neoplasm Metastasis; Netherlands; Pragmatic Clinical Trials as Topic; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Registries; Retrospective Studies; Treatment Outcome; Tubulin Modulators | 2018 |
Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; France; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Prostatic Neoplasms; Quality-Adjusted Life Years; Risk Factors; Taxoids; Time Factors; Treatment Outcome; Tumor Burden | 2017 |
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Radiosurgery; Radiotherapy, Adjuvant; Treatment Outcome | 2018 |
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Austria; Bevacizumab; Camptothecin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2017 |
SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Taxoids | 2017 |
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Belgium; Confidence Intervals; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; France; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Time Factors; Treatment Outcome | 2018 |
Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05).
Topics: Aged; Aged, 80 and over; Benzimidazoles; Biomarkers, Tumor; Docetaxel; Drug Administration Schedule; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinolones; Receptor, Fibroblast Growth Factor, Type 2; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Time Factors; Treatment Outcome | 2018 |
Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.
Topics: Administration, Intravenous; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Somatostatin; Treatment Outcome | 2018 |
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Diarrhea; Disease-Free Survival; Docetaxel; Fatigue; Humans; Male; Middle Aged; Nanoparticles; Nausea; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2018 |
Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer.
Topics: Adult; Aged; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; Docetaxel; Epithelial Cell Adhesion Molecule; Female; Fluorouracil; Gastrectomy; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Peritoneal Neoplasms; Stomach Neoplasms | 2018 |
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Radiotherapy; Standard of Care; Survival Analysis; Treatment Outcome | 2018 |
Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
Topics: Aged; Antineoplastic Agents; Disease-Free Survival; DNA; DNA Methylation; Docetaxel; Glutathione Transferase; Humans; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2019 |
Clinical Trials of Metastatic Castration-sensitive Prostate Cancer: Recent Progress and New Horizons.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radiotherapy; Steroid Synthesis Inhibitors; Tubulin Modulators | 2019 |
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Topics: Aged; Aged, 80 and over; Androstenes; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2019 |
Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE).
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Non-Randomized Controlled Trials as Topic; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab | 2019 |
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pantoprazole; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2019 |
Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Ramucirumab; Survival Analysis; Treatment Outcome; Young Adult | 2019 |
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Predictive Value of Tests; Receptor, ErbB-2; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pharmacogenetics; Polymorphism, Single Nucleotide; Steroid Hydroxylases; Survival Rate; Taxoids; Treatment Outcome; Vitamin D3 24-Hydroxylase | 2013 |
Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Time Factors; Treatment Outcome | 2013 |
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Drug Administration Schedule; ErbB Receptors; Fatigue; Female; Gefitinib; Genotype; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome | 2013 |
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Double-Blind Method; Female; Humans; Neoplasm Metastasis; Receptor, ErbB-2; Stroke Volume; Taxoids; Trastuzumab; Ventricular Dysfunction, Left | 2013 |
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Medical Futility; Middle Aged; Neoplasm Metastasis; Paclitaxel; Patient Compliance; Taxoids; Treatment Outcome | 2013 |
Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms; Survival; Survival Rate; Taxoids; Vitamin B Complex | 2013 |
Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Genotype; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Polymorphism, Single Nucleotide; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome; X-ray Repair Cross Complementing Protein 1 | 2013 |
Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Algorithms; Comorbidity; Disease-Free Survival; Docetaxel; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.
Topics: Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Pain; Pain Measurement; Palliative Care; Peripheral Nervous System Diseases; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Survival; Survival Rate; Taxoids; Treatment Outcome | 2013 |
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperidines; Quinazolines; Taxoids | 2013 |
A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Young Adult | 2014 |
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Neoplasm Metastasis; Placebos; Quality of Life; Receptor, ErbB-2; Surveys and Questionnaires; Survival; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Polyethylene Glycols; Quinazolines; Receptor, ErbB-2; Recombinant Proteins; Taxoids; Trastuzumab; Young Adult | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Interactions; Female; Humans; Middle Aged; Models, Biological; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2013 |
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.
Topics: Abiraterone Acetate; Adenocarcinoma; Androstadienes; Antineoplastic Agents; Chemotherapy, Adjuvant; Docetaxel; Humans; Male; Neoplasm Metastasis; Orchiectomy; Placebos; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires; Taxoids; Treatment Failure | 2013 |
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Epothilones; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2011 |
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Taxoids; Treatment Outcome; Viscera | 2014 |
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Penile Neoplasms; Survival Analysis; Taxoids; United Kingdom | 2013 |
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Etoposide; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Palliative Care; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Vinblastine; Vinorelbine | 2015 |
Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancer.
Topics: Administration, Oral; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclosporine; Docetaxel; Drug Monitoring; Female; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Taxoids; Treatment Failure; Vomiting | 2016 |
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Humans; Indoles; Kaplan-Meier Estimate; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Treatment Outcome | 2014 |
Acceptable but limited efficacy of capecitabine-based doublets in the first-line treatment of metastatic triple-negative breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Odds Ratio; Pilot Projects; Survival Analysis; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzhydryl Compounds; Breast Neoplasms; Docetaxel; Double-Blind Method; Fatigue; Female; Humans; Male; Middle Aged; Modafinil; Nausea; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Vomiting; Wakefulness-Promoting Agents | 2014 |
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Young Adult | 2014 |
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Docetaxel; Fatigue; Hot Flashes; Humans; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Physician-Patient Relations; Prostatic Neoplasms; Self-Assessment; Sexual Dysfunction, Physiological; Surveys and Questionnaires; Taxoids; Weight Gain; Weight Loss | 2014 |
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Taxoids | 2014 |
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Receptor, IGF Type 1; Taxoids | 2014 |
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2014 |
Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Taxoids; Trastuzumab | 2014 |
Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin).
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Quality of Life; Stomach Neoplasms; Surveys and Questionnaires; Taxoids; Treatment Outcome | 2014 |
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; ROC Curve; Survival Rate; Taxoids; Time Factors | 2014 |
Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Epothilones; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Proportional Hazards Models; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Single-arm, multi-centre phase II study of lobaplatin combined with docetaxel for recurrent and metastatic nasopharyngeal carcinoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclobutanes; Docetaxel; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Organoplatinum Compounds; Recurrence; Survival Rate; Taxoids | 2014 |
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Denmark; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2014 |
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Spain; Taxoids | 2014 |
Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Alkynes; Antineoplastic Combined Chemotherapy Protocols; Cholecalciferol; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Calcitriol; Taxoids; Treatment Outcome | 2014 |
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Survival Analysis; Taxoids | 2015 |
FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Docetaxel; Drug Approval; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Taxoids; Treatment Outcome; United States; United States Food and Drug Administration; Young Adult | 2014 |
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle Proteins; DNA Methylation; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Neoplasm Metastasis; Nuclear Proteins; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Quinazolines; Risk Factors; Taxoids; Treatment Outcome | 2014 |
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Cohort Studies; Disease-Free Survival; Docetaxel; Early Detection of Cancer; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Physical Fitness; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Taxoids; Treatment Outcome | 2015 |
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Monitoring; Female; Florida; Humans; Immunologic Factors; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Taxoids; Time Factors; Treatment Outcome; Tryptophan | 2014 |
Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Interactions; Electrocardiography; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab | 2014 |
Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast; Breast Neoplasms; Cohort Studies; Deoxycytidine; Docetaxel; Drug Monitoring; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Salvage Therapy; Survival Analysis; Taxoids | 2015 |
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arteries; Bevacizumab; Clinical Trials, Phase III as Topic; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prednisone; Prognosis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Thromboembolism; Venous Thromboembolism | 2015 |
A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Phase I dose-escalation study of aflibercept plus docetaxel in nasopharyngeal carcinoma and other solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Radiography; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Taxoids; Vascular Endothelial Growth Factor A | 2014 |
A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Naphthoquinones; Neoplasm Metastasis; Neoplasm Staging; Taxoids; Treatment Outcome | 2015 |
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Female; Gonanes; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Phosphoinositide-3 Kinase Inhibitors; Recurrence; Taxoids | 2015 |
Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Oropharyngeal Neoplasms; Taxoids; Treatment Outcome | 2015 |
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Double-Blind Method; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab | 2015 |
Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Cell Count; Docetaxel; Humans; Longitudinal Studies; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids | 2015 |
Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leiomyosarcoma; Middle Aged; Neoplasm Metastasis; Taxoids; Thrombocytopenia; Time Factors; Treatment Outcome; Uterine Neoplasms | 2015 |
Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Taxoids; Treatment Outcome | 2015 |
Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Cell Hypoxia; Cell Proliferation; Docetaxel; Female; Gene Expression Profiling; Humans; Indoles; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Prospective Studies; Pyrroles; Sunitinib; Taxoids; Tomography, X-Ray Computed | 2015 |
Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids; Young Adult | 2015 |
Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Precision Medicine; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2015 |
A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Platinum; Retreatment; Taxoids; Tegafur; Treatment Outcome | 2015 |
Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Cisplatin; Docetaxel; Drug Combinations; ErbB Receptors; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Trastuzumab | 2015 |
Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809).
Topics: Aged; Antibodies, Neoplasm; Antineoplastic Agents; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Docetaxel; Humans; Immunoglobulin G; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Mouth Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Radiotherapy; Surgical Procedures, Operative; Taxoids; Treatment Outcome; Young Adult | 2015 |
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome | 2015 |
Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cancer Vaccines; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Maryland; Membrane Glycoproteins; Middle Aged; National Cancer Institute (U.S.); Neoplasm Metastasis; Proportional Hazards Models; Risk Factors; Taxoids; Texas; Time Factors; Treatment Outcome; United States | 2015 |
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
Topics: Abiraterone Acetate; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Double-Blind Method; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retreatment; Survival Rate; Taxoids | 2016 |
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Docetaxel; HSP90 Heat-Shock Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome; Triazoles | 2016 |
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Outcome and Process Assessment, Health Care; Prostate; Prostatic Neoplasms; Radiography; Taxoids; Tumor Burden | 2016 |
High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; DNA Mutational Analysis; Docetaxel; Doxorubicin; Female; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids | 2015 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Early Termination of Clinical Trials; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Netherlands; Radiotherapy Dosage; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2016 |
Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial. [Corrected].
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrroles; Salvage Therapy; Sunitinib; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid | 2016 |
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Granulocyte Colony-Stimulating Factor; Humans; Kallikreins; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Male; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Neutrophils; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Severity of Illness Index; Taxoids; Time Factors; Treatment Outcome | 2016 |
Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (S
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Docetaxel; Double-Blind Method; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Placebos; Proto-Oncogene Proteins p21(ras); Research Design; Taxoids; Treatment Outcome; Young Adult | 2016 |
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2016 |
Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Docetaxel; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retreatment; Taxoids; Treatment Outcome | 2016 |
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Platinum; Proportional Hazards Models; Quality of Life; Ramucirumab; Retreatment; Taxoids; Treatment Outcome | 2016 |
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.
Topics: Aged; Bone Neoplasms; Combined Modality Therapy; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Radium; Standard of Care; Taxoids; Treatment Outcome | 2016 |
Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Models, Theoretical; Neoplasm Metastasis; Taxoids | 2016 |
TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oncogene Proteins, Fusion; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2016 |
Phase I Study of Docetaxel, Cisplatin, and 5-Fluorouracil Chemoradiotherapy for Local or Metastatic Esophageal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2016 |
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Approval; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nivolumab; Programmed Cell Death 1 Receptor; Taxoids; United States; United States Food and Drug Administration | 2016 |
Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Maximum Tolerated Dose; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2016 |
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Maytansine; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Trastuzumab | 2016 |
Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study.
Topics: Adult; Aged; Cohort Studies; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Female; Genes, p53; Humans; Liposomes; Male; Middle Aged; Nanoparticles; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Retreatment; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Asian People; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Female; Gingivitis; Half-Life; Humans; Japan; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Ramucirumab; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2016 |
PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Panitumumab; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2016 |
Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Podophyllotoxin; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2017 |
Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Dendritic Cells; Disease-Free Survival; Docetaxel; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Transplantation, Autologous; Treatment Outcome | 2017 |
A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Etidronic Acid; Humans; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2017 |
Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Prospective Studies; Taxoids; Time Factors; Treatment Outcome | 2009 |
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Pain; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Failure | 2008 |
Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Survival Rate; Taxoids; Temozolomide | 2008 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids | 2008 |
Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Taxoids | 2008 |
Docetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Recurrence; Salvage Therapy; Survival Analysis; Taxoids | 2009 |
Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Belgium; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estramustine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2008 |
A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Outcome | 2008 |
Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Greece; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quality-Adjusted Life Years; Survival Rate; Taxoids | 2009 |
Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids | 2008 |
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrazoles; Risk Factors; Sulfonamides; Taxoids; Treatment Outcome; Zoledronic Acid | 2009 |
A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Palliative Care; Quality of Life; Recurrence; Survival Analysis; Taxoids | 2009 |
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids | 2009 |
Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Clusterin; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Oligonucleotides, Antisense; Taxoids; Thionucleotides; Treatment Outcome | 2009 |
A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dibenzocycloheptenes; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Metastasis; Placebos; Quinolines; Recurrence; Taxoids | 2009 |
Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Taxoids; Time Factors; Treatment Failure; Treatment Outcome | 2009 |
Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Epirubicin; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Survival Rate; Taxoids | 2009 |
Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2009 |
Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Rate; Taxoids | 2009 |
Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Antineoplastic Agents; Cohort Studies; Combined Modality Therapy; Constipation; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Feasibility Studies; Humans; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Orchiectomy; Organometallic Compounds; Organophosphorus Compounds; Pain; Platelet Count; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Taxoids | 2009 |
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Breast Neoplasms; Confidence Intervals; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Probability; Risk Assessment; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2009 |
Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Polyethylene Glycols; Taxoids | 2009 |
A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Constriction, Pathologic; Docetaxel; Double-Blind Method; Female; Humans; Lacrimal Apparatus Diseases; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Ophthalmic Solutions; Taxoids; Treatment Outcome | 2010 |
N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Castration; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrroles; Quality of Life; Sunitinib; Taxoids; Time Factors; Treatment Failure | 2010 |
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cyclooxygenase 2; Docetaxel; Drug Administration Schedule; Female; Glucuronosyltransferase; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Vascular Endothelial Growth Factor A | 2009 |
Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Frail Elderly; Humans; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids | 2010 |
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Receptor, ErbB-2; Taxoids; Trastuzumab | 2010 |
Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2009 |
A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Squamous Cell; Neutropenia; Taxoids | 2010 |
Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperati
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Recurrence; Taxoids; Time Factors | 2010 |
Phase II study of a biweekly schedule of docetaxel and cisplatin in patients with metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Infections; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Survival Analysis; Taxoids | 2010 |
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Celecoxib; Cell Separation; Cyclophosphamide; Docetaxel; Early Detection of Cancer; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplastic Cells, Circulating; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Time Factors; Trastuzumab; Young Adult | 2010 |
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; NF-kappa B; Pyrazines; Recurrence; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Endpoint Determination; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Pain; Palliative Care; Prednisone; Prostatic Neoplasms; Survival Analysis; Taxoids | 2010 |
North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Taxoids; Treatment Outcome; United States | 2010 |
Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Curcumin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids; Time Factors; Treatment Outcome | 2010 |
Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Dose-Response Relationship, Drug; Glucuronidase; Humans; Male; Middle Aged; Neoplasm Metastasis; Oligosaccharides; Prostatic Neoplasms; Taxoids; Treatment Failure | 2010 |
TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Ramucirumab; Taxoids; Treatment Outcome | 2009 |
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Nomograms; Orchiectomy; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Estradiol; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Paclitaxel; Polyglutamic Acid; Prostatic Neoplasms; Taxoids | 2010 |
Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Docetaxel; Female; Humans; Lymph Nodes; Middle Aged; Models, Economic; Neoplasm Metastasis; Neoplasm Staging; Quality-Adjusted Life Years; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Taxoids; Tegafur; Treatment Outcome | 2010 |
Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2010 |
Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome | 2010 |
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Integrin alphaV; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2011 |
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxins; Disease Progression; Docetaxel; Doxorubicin; Female; Heart; Humans; Kaplan-Meier Estimate; Liposomes; Middle Aged; Neoplasm Metastasis; Stroke Volume; Taxoids; Trastuzumab; Ventricular Function, Left | 2010 |
Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Recombinant Proteins; Stomach Neoplasms; Taxoids; Treatment Outcome | 2011 |
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
Topics: Acetylation; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Fluorodeoxyglucose F18; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Panobinostat; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2010 |
Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Retreatment; Retrospective Studies; Taxoids; Treatment Outcome | 2010 |
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids; Treatment Outcome | 2010 |
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Humans; Ketoconazole; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Treatment Failure | 2010 |
A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2010 |
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Docetaxel; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Quality of Life; Survival Rate; Taxoids; Tegafur | 2010 |
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Docetaxel; Drug Administration Schedule; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Placebos; Taxoids | 2010 |
Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Taxoids; Tegafur; Young Adult | 2011 |
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Taxoids; Vindesine | 2010 |
Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Rate; Taxoids | 2010 |
A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2010 |
Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab | 2010 |
Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Palliative Care; Quality of Life; Taxoids; Treatment Failure | 2011 |
Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2011 |
Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Stomach Neoplasms; Taxoids; Young Adult | 2011 |
Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer.
Topics: Aged; Alopecia; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Prednisone; Prospective Studies; Prostatic Neoplasms; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Castration; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2011 |
A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 2010 |
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cross-Over Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Taxoids | 2011 |
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeu
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease-Free Survival; Docetaxel; Female; Gene Amplification; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2011 |
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Proportional Hazards Models; Quality of Life; Taxoids; Time Factors; Treatment Outcome | 2011 |
[Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Taxoids; Thiotepa | 2011 |
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids | 2011 |
Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Taxoids; Urologic Neoplasms; Vinblastine | 2011 |
A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Organoplatinum Compounds; Prognosis; Prostatic Neoplasms; Taxoids | 2013 |
Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2011 |
Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast c
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Genes, erbB-2; Humans; Immunotherapy; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Heart Failure; Humans; Liposomes; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2011 |
Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids | 2011 |
Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids | 2011 |
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms; Taxoids; Thionucleotides; Treatment Outcome | 2011 |
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids | 2012 |
Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Pelvic Neoplasms; Taxoids; Treatment Outcome | 2011 |
Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Heart; Humans; Liposomes; Middle Aged; Neoplasm Metastasis; Taxoids | 2011 |
A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Receptor, ErbB-2; Taxoids | 2011 |
Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Receptor, ErbB-2; Taxoids; Trastuzumab; Up-Regulation | 2012 |
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab; Ventricular Dysfunction, Left; Young Adult | 2012 |
Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Comorbidity; Docetaxel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Minor Surgical Procedures; Neoadjuvant Therapy; Neoplasm Metastasis; Placebos; Postoperative Hemorrhage; Taxoids | 2012 |
A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Prednisolone; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2013 |
Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids | 2012 |
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Prednisone; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2013 |
[Docetaxel in combination with epirubicin as the first-line chemotherapy for advanced and recurrent breast cancer: a multicenter phase II study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Recurrence; Taxoids | 2012 |
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fever; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Remission Induction; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Taxoids | 2012 |
The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Germany; Humans; Male; Neoplasm Metastasis; Orchiectomy; Patient Compliance; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation-Sensitizing Agents; Survival Rate; Taxoids; United States | 2012 |
Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2012 |
Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Niacinamide; Orchiectomy; Phenylurea Compounds; Pilot Projects; Prednisone; Prospective Studies; Prostatic Neoplasms; Pyridines; Sorafenib; Taxoids; Testosterone | 2012 |
A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Taxoids | 2012 |
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Docetaxel; Humans; Interleukin-6; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2013 |
No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2012 |
Increased survival with enzalutamide in prostate cancer after chemotherapy.
Topics: Aged; Androgen Receptor Antagonists; Antineoplastic Agents; Benzamides; Disease-Free Survival; Docetaxel; Double-Blind Method; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Seizures; Signal Transduction; Taxoids | 2012 |
Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; France; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leiomyosarcoma; Lenograstim; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Recombinant Proteins; Taxoids; Uterine Neoplasms | 2012 |
[Docetaxel plus prednisone versus mitoxantrone plus prednisone as first-line chemotherapy for metastatic hormone-refractory prostate cancer: long-term effects and safety].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2012 |
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; ErbB Receptors; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; PTEN Phosphohydrolase; Taxoids; Translational Research, Biomedical; Treatment Outcome | 2012 |
Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids | 2012 |
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Neutropenia; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Taxoids | 2012 |
A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Indoles; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrroles; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2013 |
Clinical outcome of docetaxel in advanced or metastatic endometrial cancer.
Topics: Adult; Aged; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Prospective Studies; Recurrence; Taxoids | 2012 |
A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate c
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Double-Blind Method; Humans; Integrin alphaV; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Placebos; Prednisone; Prostatic Neoplasms; Survival; Taxoids | 2013 |
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Castration; Docetaxel; Fatigue; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prednisone; Prostatic Neoplasms; Surveys and Questionnaires; Taxoids | 2013 |
Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms | 2013 |
Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2013 |
Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of su
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Docetaxel; Female; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Thiotepa | 2013 |
The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Compliance; Taxoids | 2013 |
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Maytansine; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Head and Neck Neoplasms; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Palliative Care; Recurrence; Survival Rate; Taxoids; Time Factors | 2002 |
Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Docetaxel; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Estramustine; Female; Humans; Microtubules; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival; Taxoids; Treatment Outcome; Venous Thrombosis | 2002 |
Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Incidence; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2002 |
Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Taxoids | 2002 |
Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2002 |
Docetaxel in combination with dacarbazine in patients with advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Docetaxel; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Skin Neoplasms; Survival Analysis; Taxoids | 2002 |
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infections; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Palliative Care; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Estramustine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Remission Induction; Survival Analysis; Taxoids | 2003 |
Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Gene Expression; Genes, erbB-2; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Taxoids; Trastuzumab | 2003 |
A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Taxoids | 2003 |
Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer: a GEICAM-9801 phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Palliative Care; Prospective Studies; Spain; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Phase I-II parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2003 |
Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Evaluation; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
[Clinical research of taxotere in treatment of metastatic breast cancer].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Budgets; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Neoplasm Metastasis; Ontario; Paclitaxel; Population Surveillance; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine; Women's Health | 2003 |
Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pulmonary Fibrosis; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Taxoids | 2003 |
Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Radiation Dosage; Radiation-Sensitizing Agents; Radiography; Taxoids; Treatment Outcome | 2003 |
Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Recombinant Proteins; Taxoids | 2004 |
Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; France; Humans; Infusions, Intravenous; Italy; Middle Aged; Neoplasm Metastasis; Taxoids | 2004 |
Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Enoxaparin; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2003 |
Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2004 |
Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiac Output; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Respiratory System; Survival Analysis; Survival Rate; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2004 |
Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Frail Elderly; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2004 |
Trastuzumab and docetaxel for metastatic breast cancer: an experience from a cancer centre in India.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease Progression; Docetaxel; Female; Humans; India; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2004 |
Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Liposomes; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Taxoids | 2004 |
Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Fever; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids; Treatment Outcome | 2004 |
Docetaxel plus fractionated cisplatin is a safe and active schedule as first-line treatment of patients with advanced non-small cell lung cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Taxoids; Time Factors | 2004 |
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Taxoids | 2004 |
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinases; Docetaxel; Enzyme Inhibitors; Female; Flavonoids; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Mouth Mucosa; Mucous Membrane; Neoplasm Metastasis; Phosphorylation; Piperidines; Retinoblastoma Protein; Taxoids; Time Factors; Tumor Suppressor Protein p53 | 2004 |
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Asthenia; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Europe; Female; Humans; Infusions, Intravenous; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neutropenia; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids | 2004 |
Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Foot; Hand; Humans; Middle Aged; Nail Diseases; Neoplasm Metastasis; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2004 |
Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2004 |
Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids | 2004 |
Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cross-Over Studies; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2005 |
A multicenter phase II study of docetaxel 60 mg/m2 as first-line chemotherapy in patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Japan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Health Status; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain Measurement; Pancreatic Neoplasms; Quality of Life; Severity of Illness Index; Taxoids | 2004 |
A phase I dose-escalating study of docetaxel plus folinic acid and 5-fluorouracil in anthracycline-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids | 2004 |
First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2005 |
Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Goserelin; Humans; Infusions, Intravenous; Injections, Intramuscular; Injections, Subcutaneous; Leuprolide; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2005 |
Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Heart; Humans; Liposomes; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids | 2005 |
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Evaluation; Female; Humans; Leukopenia; Middle Aged; Neoplasm Metastasis; Neutropenia; Receptor, ErbB-2; Taxoids; Trastuzumab | 2005 |
Low dose-intensity docetaxel in the treatment of pre-treated elderly patients with metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Humans; Neoplasm Metastasis; Taxoids | 2005 |
Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids | 2005 |
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Docetaxel; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Receptor, ErbB-2; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A; Vomiting | 2005 |
Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids; Time Factors | 2005 |
Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Phase I trial of dose-dense docetaxel and doxorubicin with or without sargramostim in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Taxoids; Treatment Outcome | 2005 |
Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Prodrugs; Prospective Studies; Remission Induction; Taxoids | 2005 |
Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids | 2005 |
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Androgens; Antigens; Antigens, Neoplasm; Antigens, Surface; Antineoplastic Agents, Phytogenic; Cancer Vaccines; Combined Modality Therapy; Cross-Over Studies; Disease-Free Survival; Docetaxel; Glutamate Carboxypeptidase II; Glycoproteins; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Mucin-1; Mucins; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome; Vaccination | 2006 |
A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome | 2006 |
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Half-Life; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Taxoids; Treatment Outcome | 2006 |
Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Quality of Life; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Taxoids | 2006 |
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Female; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptors, Estrogen; Taxoids; Treatment Outcome | 2006 |
Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Disease Progression; Docetaxel; Female; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Palliative Care; Stomach Neoplasms; Taxoids; Vomiting | 2007 |
Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2006 |
Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Male; Middle Aged; Models, Statistical; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Taxoids; Treatment Outcome | 2006 |
Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Failure | 2006 |
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Sulindac; Survival Analysis; Taxoids | 2006 |
Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.
Topics: 2-Methoxyestradiol; Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Estradiol; Fatigue; Female; Half-Life; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome; Tubulin Modulators; Urinalysis; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2007 |
Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids | 2007 |
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Survival; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; Interleukin-6; Lymph Nodes; Male; Middle Aged; Neoplasm Metastasis; NF-kappa B; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Statistics as Topic; Survival Analysis; Taxoids; Tumor Cells, Cultured | 2006 |
Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Smoking; Survival Analysis; Taxoids | 2007 |
ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Taxoids; Treatment Outcome | 2006 |
A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2007 |
Albumin-bound paclitaxel improves response rate vs docetaxel in metastatic breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2007 |
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Survivors; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Zoledronic Acid | 2007 |
A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Disease Progression; Docetaxel; Drug Delivery Systems; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Failure | 2008 |
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Disease Progression; Docetaxel; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Quinazolines; Taxoids; Treatment Outcome | 2007 |
Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; France; Humans; Middle Aged; Neoplasm Metastasis; Poland; Taxoids; Vinblastine; Vinorelbine | 2007 |
Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Taxoids | 2007 |
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Sarcoma; Taxoids; Treatment Outcome | 2007 |
A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Taxoids | 2008 |
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Epothilones; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2007 |
A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Taxoids | 2006 |
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease Progression; Docetaxel; Esophagogastric Junction; Female; Fever; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting | 2007 |
Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Greece; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Taxoids | 2007 |
Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Urologic Neoplasms; Urothelium | 2007 |
An open-labeled phase II trial of docetaxel in combination with cisplatin as first-line cytotoxic therapy for anthracycline-naive patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Taxoids | 2007 |
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Castration; Cohort Studies; Disease-Free Survival; Docetaxel; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Placebos; Prostatic Neoplasms; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Taxoids | 2007 |
A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Maximum Tolerated Dose; Midazolam; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neutropenia; Taxoids | 2008 |
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Kinetics; Male; Mitoxantrone; Neoplasm Metastasis; Nomograms; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Regression Analysis; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Quinazolines; Taxoids; Treatment Outcome | 2008 |
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bone Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Follow-Up Studies; Hormones; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2008 |
Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; CD4-CD8 Ratio; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Immunotherapy; Killer Cells, Natural; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; T-Lymphocytes; Taxoids | 2008 |
Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Calcium; Docetaxel; Double-Blind Method; Ergocalciferols; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2008 |
Biweekly docetaxel-containing chemotherapy may be the optimal schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Pilot Projects; Taxoids; Treatment Outcome | 2008 |
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab | 2009 |
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Drug Hypersensitivity; Drug Resistance; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Taxoids | 1995 |
Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms; Docetaxel; Drug Administration Schedule; Drug Eruptions; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1994 |
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Skin Neoplasms; Taxoids | 1995 |
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cimetidine; Dexamethasone; Diphenhydramine; Docetaxel; Drug Administration Schedule; Drug Hypersensitivity; Edema; Female; Humans; Injections, Intravenous; Leukopenia; Middle Aged; Neoplasm Metastasis; Paclitaxel; Premedication; Taxoids | 1996 |
Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 1996 |
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 1996 |
First-line treatment of metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Europe; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; North America; Paclitaxel; Taxoids | 1996 |
Docetaxel in combination with doxorubicin: a phase I dose-finding study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pilot Projects; Survival Rate; Taxoids | 1997 |
Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pilot Projects; Taxoids | 1997 |
Docetaxel combined with vinorelbine: phase I results and new study designs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Liver Neoplasms; Neoplasm Metastasis; Neutropenia; Paclitaxel; Research Design; Taxoids; Vinblastine; Vinorelbine | 1997 |
Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bacterial Infections; Breast Neoplasms; Cause of Death; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Fever; Heart Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Quality of Life; Remission Induction; Safety; Survival Rate; Taxoids; Thrombocytopenia | 1997 |
Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Constipation; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Mitomycins; Neoplasm Metastasis; Paclitaxel; Quality of Life; Remission Induction; Safety; Survival Rate; Taxoids; Thrombocytopenia; Vinblastine | 1997 |
Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fever; Heart Failure; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1997 |
[Taxotere: the first drug better than acrdiamycin, the most frequently used drug in the treatment of metastasized breast cancer. Phase III study shows a better response than standard treatment].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids | 1997 |
Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Mitomycin; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Vinblastine | 1998 |
Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Failure | 1998 |
Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1998 |
Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Taxoids | 1998 |
Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1998 |
[Breast cancer: new therapeutic strategies].
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Multiple; Female; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Taxoids; Treatment Outcome | 1998 |
Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lymphocyte Count; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Ventricular Function, Left | 1999 |
Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids | 1999 |
Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4 g/m2 of CY.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Taxoids | 1999 |
Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Ventricular Function, Left | 1999 |
Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
[Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids | 1999 |
Docetaxel administered on a weekly basis for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Fibrinogen; Fibrinolysis; Hemorrhage; Humans; Male; Neoplasm Metastasis; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Urokinase-Type Plasminogen Activator | 2000 |
[Clinical efficacy of low-dose weekly docetaxel combined with oral 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced or metastatic breast cancer: a pilot trial].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Floxuridine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Taxoids | 2000 |
Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer.
Topics: Adult; Anthracyclines; Antineoplastic Agents, Phytogenic; Austria; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Idarubicin; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 2000 |
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Docetaxel; Female; France; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Quality of Life; Taxoids | 2000 |
Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2000 |
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; Disease Progression; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Interstitial; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Stomatitis; Survival Analysis; Taxoids; Thiotepa; Thrombocytopenia; Transplantation Conditioning | 2000 |
Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Remission Induction; Survival Analysis; Taxoids | 2001 |
Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Failure | 2001 |
High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Epirubicin; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Survival Analysis; Taxoids | 2001 |
Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Survival Analysis; Taxoids | 2001 |
Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids | 2001 |
Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids | 2001 |
Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Taxoids | 2001 |
Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Sarcoma; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2001 |
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Failure | 2001 |
Weekly docetaxel (Taxotere) in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
[Efficacy and toxicity of a taxotere/cisplatin combination in first line chemotherapy in patients with disseminated ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; World Health Organization | 2002 |
A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2002 |
Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2002 |
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Phase II study of weekly docetaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Uracil | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
347 other study(ies) available for docetaxel anhydrous and Metastase
| Article | Year |
|---|---|
Antagonizing NOD2 Signaling with Conjugates of Paclitaxel and Muramyl Dipeptide Derivatives Sensitizes Paclitaxel Therapy and Significantly Prevents Tumor Metastasis.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Lewis Lung; Drug Synergism; Mice; Neoplasm Metastasis; Nod2 Signaling Adaptor Protein; Paclitaxel; Signal Transduction | 2017 |
Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin.
Topics: Animals; Antineoplastic Agents; Calcium-Binding Proteins; Cell Line, Tumor; Cell Movement; Drug Design; Epithelial-Mesenchymal Transition; Humans; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Muscle Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Structure-Activity Relationship; Triazoles; Xenograft Model Antitumor Assays | 2019 |
Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy.
Topics: Antineoplastic Agents; Carbon Radioisotopes; Docetaxel; Drug Monitoring; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prognosis; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies | 2022 |
Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
Topics: Androstenes; Antineoplastic Agents; Benzamides; Black People; Docetaxel; Guadeloupe; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Immunotherapeutic role of cabazitaxel treatment in the activation of TLR3 signalling in metastatic castration-resistant prostate cancer in vitro.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Humans; Immunotherapy; Interferon Regulatory Factor-3; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Signal Transduction; Taxoids; Toll-Like Receptor 3; Tumor Microenvironment | 2022 |
Active Targeting of P-Selectin by Fucoidan Modulates the Molecular Profiling of Metastasis in Docetaxel-Resistant Prostate Cancer.
Topics: Androgen Antagonists; Androgens; Cyclooxygenase 2; Docetaxel; Humans; Male; Neoplasm Metastasis; NF-kappa B; P-Selectin; Polysaccharides; Prostatic Neoplasms, Castration-Resistant | 2022 |
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
Topics: Abiraterone Acetate; Absorptiometry, Photon; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2019 |
In Vivo Environment-Adaptive Nanocomplex with Tumor Cell-Specific Cytotoxicity Enhances T Cells Infiltration and Improves Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Aspirin; CD8-Positive T-Lymphocytes; Cell Death; Cell Line, Tumor; Docetaxel; Endocytosis; Heparitin Sulfate; Humans; MCF-7 Cells; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Neoplasms; Polyethylene Glycols; Polyethyleneimine; Tissue Distribution | 2019 |
Coadministration of chemotherapy and PI3K/Akt pathway treatment with multistage acidity/CathB enzyme-responsive nanocarriers for inhibiting the metastasis of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Humans; Indazoles; Maleic Anhydrides; Mice; Nanoparticles; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Polyethyleneimine; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Proto-Oncogene Proteins c-akt; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2019 |
Validation and development of the CHAARTED criteria in patients with hormone-naïve metastatic prostate cancer: A multi-institutional retrospective study in Japan.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Japan; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies | 2020 |
Class III β-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer.
Topics: Aged; Biomarkers, Tumor; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome; Tubulin | 2019 |
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2019 |
A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan.
Topics: Ado-Trastuzumab Emtansine; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Docetaxel; Female; Humans; Lapatinib; Markov Chains; Middle Aged; Neoplasm Metastasis; Quality-Adjusted Life Years; Receptor, ErbB-2; Taiwan; Trastuzumab | 2020 |
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Prospective Studies; Stomach Neoplasms | 2020 |
Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Circulating MicroRNA; Docetaxel; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2020 |
Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Humans; Kallikreins; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2020 |
Proscillaridin A slows the prostate cancer progression through triggering the activation of endoplasmic reticulum stress.
Topics: Androgens; Animals; Apoptosis; Cell Movement; Disease Progression; Docetaxel; Endoplasmic Reticulum Stress; Humans; Male; Mice; Neoplasm Metastasis; Proscillaridin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2020 |
Circular RNA CRIM1 functions as a ceRNA to promote nasopharyngeal carcinoma metastasis and docetaxel chemoresistance through upregulating FOXQ1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Morphogenetic Protein Receptors; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Female; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Prognosis; RNA, Circular; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Follow-Up Studies; Humans; Maytansine; Middle Aged; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Trastuzumab | 2020 |
[Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms | 2020 |
Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer.
Topics: Aged; Antineoplastic Agents; Docetaxel; Dose-Response Relationship, Drug; Drug Monitoring; Granulocyte Colony-Stimulating Factor; Humans; Male; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Time-to-Treatment; Treatment Outcome | 2020 |
Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; United States | 2020 |
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Reported Outcome Measures; Quality of Life; Squamous Cell Carcinoma of Head and Neck | 2021 |
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer.
Topics: Administration, Intravenous; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms | 2020 |
Quercetin Inhibits Lef1 and Resensitizes Docetaxel-Resistant Breast Cancer Cells.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Caveolin 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lymphoid Enhancer-Binding Factor 1; MCF-7 Cells; Neoplasm Metastasis; Neoplasm Proteins; Quercetin; RNA, Small Interfering; Signal Transduction; Transforming Growth Factor beta; Vimentin | 2020 |
Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; United States | 2020 |
Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure | 2020 |
Exploitation of the chick embryo chorioallantoic membrane (CAM) as a platform for anti-metastatic drug testing.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Chick Embryo; Chorioallantoic Membrane; Cisplatin; Crizotinib; Docetaxel; Drug Screening Assays, Antitumor; Gefitinib; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms | 2020 |
Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Docetaxel; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Risk Factors; Signal Transduction; Taxoids | 2021 |
Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Neoplasms; Disease-Free Survival; Docetaxel; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Recurrence; Retrospective Studies; Tumor Burden | 2020 |
Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis.
Topics: Animals; Cellular Senescence; Docetaxel; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinases; Mice; Neoplasm Metastasis; Neoplasm Transplantation; PC-3 Cells; Prostatic Neoplasms; PTEN Phosphohydrolase; Tissue Inhibitor of Metalloproteinase-1 | 2021 |
Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2021 |
Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer.
Topics: Androstenes; Cell Proliferation; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Models, Theoretical; Neoplasm Metastasis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome; Tumor Burden | 2020 |
Antiandrogen abiraterone and docetaxel treatments affect Notch1, Jagged1 and Hes1 expressions in metastatic prostate cancer cells.
Topics: Androgen Antagonists; Androstenes; Cell Line, Tumor; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Jagged-1 Protein; Male; Neoplasm Metastasis; Prostatic Neoplasms; Receptor, Notch1; RNA, Messenger; Transcription Factor HES-1 | 2021 |
Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Cost-Benefit Analysis; Docetaxel; Female; Humans; Neoplasm Metastasis; Progression-Free Survival; Quality-Adjusted Life Years; Receptor, ErbB-2; Singapore; Trastuzumab | 2021 |
Identification of lipidomic profiles associated with drug-resistant prostate cancer cells.
Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Ferroptosis; Gene Expression Regulation, Neoplastic; Humans; Lipid Metabolism; Lipidomics; Lipids; Male; Middle Aged; Neoplasm Metastasis; Nuclear Proteins; Phosphatidate Phosphatase; Prostatic Neoplasms; Signal Transduction | 2021 |
The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Docetaxel; Female; Humans; Models, Economic; Neoplasm Metastasis; Quality-Adjusted Life Years; Receptor, ErbB-2; Reimbursement Mechanisms; Trastuzumab | 2021 |
Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2-negative breast cancer patients treated with docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Patient-Specific Modeling; Receptor, ErbB-2 | 2021 |
Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer.
Topics: Abiraterone Acetate; Cost-Benefit Analysis; Docetaxel; Hormones; Humans; Male; Markov Chains; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Therapies, Investigational; Treatment Outcome | 2021 |
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.
Topics: Androstenes; Black or African American; Docetaxel; Georgia; Health Status Disparities; Hormones; Humans; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies | 2021 |
Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prognosis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2021 |
Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophagogastric Junction; Female; Fluorouracil; Hematologic Diseases; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Stomach Neoplasms; Survival Analysis | 2022 |
Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients.
Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Limit of Detection; Male; Neoplasm Metastasis; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone | 2021 |
Cytosolic co-delivery of miRNA-34a and docetaxel with core-shell nanocarriers via caveolae-mediated pathway for the treatment of metastatic breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caveolae; Cell Line, Tumor; Cell Movement; Cytosol; Docetaxel; Drug Carriers; Drug Delivery Systems; Endocytosis; Humans; Mammary Neoplasms, Experimental; Mice; MicroRNAs; Nanoparticles; Neoplasm Metastasis; Rats; RNA Interference; RNA Stability; Spheroids, Cellular; Taxoids; Tissue Distribution | 2017 |
Combination of Nexrutine and docetaxel suppresses NFκB-mediated activation of c-FLIP.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Metastasis; NF-kappa B; Plant Extracts; Prostatic Neoplasms; Signal Transduction; Taxoids | 2017 |
The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Neoplasm Metastasis; Neoplasm Proteins; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
On Uterine Angiosarcomas: 2 Additional Cases.
Topics: Antineoplastic Agents; Carboplatin; Disease-Free Survival; Docetaxel; Fatal Outcome; Female; Hemangiosarcoma; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Metastasis; Paclitaxel; Uterine Neoplasms; Uterus | 2017 |
New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Female; Fingolimod Hydrochloride; Humans; Lymphopenia; Mice; Nanoparticles; Neoplasm Metastasis; Neoplasm Staging; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Drug Liberation; Humans; Lipids; Male; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Nanoparticles; Neoplasm Metastasis; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Prostatic Neoplasms | 2017 |
Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Lymphocytes, Tumor-Infiltrating; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Patient Selection; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; T-Lymphocytes, Cytotoxic; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2017 |
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.
Topics: Androstenes; Biomarkers, Tumor; Clinical Decision-Making; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Practice Patterns, Physicians'; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Surveys and Questionnaires; Taxoids; Treatment Outcome; Tubulin Modulators | 2018 |
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.
Topics: Androgen Receptor Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Combined Modality Therapy; Docetaxel; Gene Expression Regulation, Neoplastic; Genomics; Humans; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prostatectomy; Prostatic Neoplasms; Taxoids; Transcriptome | 2017 |
Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2017 |
Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Medical Oncology; Neoplasm Metastasis; Nivolumab; Quinazolines; Ramucirumab; Taxoids | 2017 |
Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Febrile Neutropenia; Gonadotropin-Releasing Hormone; Hospitalization; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; Time Factors | 2018 |
Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Docetaxel; Female; Humans; Markov Chains; Neoplasm Metastasis; Quality-Adjusted Life Years; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab | 2018 |
CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cytochrome P-450 CYP1A1; Docetaxel; Female; Genetic Markers; Humans; Liver Neoplasms; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Progression-Free Survival; Survival Analysis; Thiotepa | 2018 |
[Experience with cabazitaxel therapy for patients with metastatic castrate resistant prostate cancer in Hungary].
Topics: Age Factors; Aged; Biopsy, Needle; Cohort Studies; Disease-Free Survival; Docetaxel; Humans; Hungary; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Patient Safety; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Rare incidence of tumor lysis syndrome in metastatic prostate cancer following treatment with docetaxel.
Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Tumor Lysis Syndrome | 2018 |
Coadministration of Polymeric Conjugates of Docetaxel and Cyclopamine Synergistically Inhibits Orthotopic Pancreatic Cancer Growth and Metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Drug Liberation; Hedgehogs; Humans; Mice; Micelles; Microtubules; Neoplasm Metastasis; Pancreatic Neoplasms; Polymers; Proton Magnetic Resonance Spectroscopy; Taxoids; Veratrum Alkaloids | 2018 |
Salutaxel, a Conjugate of Docetaxel and a Muramyl Dipeptide (MDP) Analogue, Acts as Multifunctional Prodrug That Inhibits Tumor Growth and Metastasis.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Antineoplastic Agents; Cell Line; Cytokines; Docetaxel; Humans; Mice; Myeloid-Derived Suppressor Cells; Neoplasm Metastasis; Neoplasms; Nod1 Signaling Adaptor Protein; Prodrugs | 2018 |
Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Movement; Cell Proliferation; Docetaxel; Drug Synergism; Drugs, Chinese Herbal; Forkhead Box Protein M1; Humans; Lung Neoplasms; Male; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Prostatic Neoplasms; Transcriptome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Anti-Inflammatory Agents; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Female; Follow-Up Studies; Humans; Immunohistochemistry; Middle Aged; Multigene Family; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Taxoids; Trastuzumab; Treatment Outcome | 2018 |
Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Docetaxel; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Mutation; Neoplasm Metastasis; Predictive Value of Tests; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2019 |
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Registries; Retrospective Studies; Survival Rate; Time Factors | 2018 |
Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Eye Proteins; Humans; Macrophages; Male; Mice; Mice, SCID; Neoplasm Metastasis; Nerve Growth Factors; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; Recombinant Proteins; Serpins; Taxoids; Xenograft Model Antitumor Assays | 2018 |
Counterpoint: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Abiraterone.
Topics: Abiraterone Acetate; Antineoplastic Agents; Clinical Decision-Making; Docetaxel; Humans; Male; Neoplasm Metastasis; Patient Selection; Prostatic Neoplasms; Risk Factors; Steroid Synthesis Inhibitors; Taxoids; Time Factors; Treatment Outcome | 2018 |
Point: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Chemotherapy.
Topics: Abiraterone Acetate; Antineoplastic Agents; Clinical Decision-Making; Docetaxel; Humans; Male; Neoplasm Metastasis; Patient Selection; Prostatic Neoplasms; Risk Factors; Steroid Synthesis Inhibitors; Taxoids; Time Factors; Treatment Outcome | 2018 |
Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Treatment Outcome | 2018 |
Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2019 |
Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells
Topics: Animals; Aptamers, Nucleotide; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chitosan; CHO Cells; Cricetinae; Cricetulus; Docetaxel; Drug Liberation; Gene Expression Regulation, Neoplastic; Gene Silencing; Heparin; Humans; Mucin-1; Nanoparticles; Neoplasm Metastasis; Particle Size; Receptor, IGF Type 1; Receptors, Somatomedin; RNA, Small Interfering; Serum; Static Electricity | 2019 |
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Genes, BRCA1; Genes, BRCA2; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Black or African American; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Polycomb Repressive Complex 1; Prostatic Neoplasms; White People; Zebrafish | 2018 |
Impeding Circulating Tumor Cell Reseeding Decelerates Metastatic Progression and Potentiates Chemotherapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; CX3C Chemokine Receptor 1; Disease Progression; Docetaxel; Doxorubicin; Drug Synergism; Female; Humans; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Cells, Circulating; Prognosis; Small Molecule Libraries; Xenograft Model Antitumor Assays | 2018 |
Topics: Antineoplastic Combined Chemotherapy Protocols; Computational Biology; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Profiling; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Matrix Metalloproteinase 2; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; rab GTP-Binding Proteins; Sequence Analysis, DNA; Tissue Inhibitor of Metalloproteinase-2 | 2018 |
Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Registries; Treatment Outcome | 2018 |
Prior anti-CAFs break down the CAFs barrier and improve accumulation of docetaxel micelles in tumor.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Extracellular Fluid; Female; Humans; Mice; Mice, Inbred BALB C; Micelles; Microvessels; Neoplasm Metastasis; Neoplasms; Organ Specificity; ortho-Aminobenzoates; Spheroids, Cellular; Taxoids; Tissue Distribution; Tumor Microenvironment | 2018 |
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Practice Patterns, Physicians'; Prognosis; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult | 2019 |
Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Caregivers; Cross-Sectional Studies; Disease-Free Survival; Docetaxel; Europe; Humans; Male; Middle Aged; Neoplasm Metastasis; Patient Satisfaction; Prostatic Neoplasms; Quality of Life; Self Report | 2018 |
Collision tumour of extramammary Paget disease and melanoma.
Topics: Administration, Intravenous; Aged; Asian People; Docetaxel; Fatal Outcome; Humans; Keratin-7; Male; MART-1 Antigen; Melanoma; Neoplasm Metastasis; Neoplasms, Second Primary; Paget Disease, Extramammary; Scrotum; Skin Neoplasms; Tubulin Modulators | 2019 |
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Italy; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Liver Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Progression-Free Survival; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Treatment Failure | 2019 |
Initiation of Systemic Therapy During the Last 30 Days of Life in Patients With Metastatic Castration-resistant Prostate Cancer.
Topics: Aged; Bridged-Ring Compounds; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Terminal Care; Treatment Outcome | 2019 |
Unravelling the anticancer efficacy of 10-oxo-7-epidocetaxel: in vitro and in vivo results.
Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Docetaxel; Female; Humans; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Taxoids | 2019 |
Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Antigens, Differentiation; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant | 2019 |
Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Heterografts; Humans; Leiomyosarcoma; Mice; Mice, Nude; Neoplasm Metastasis; Peritoneal Neoplasms; Recurrence; Salvage Therapy; Treatment Outcome; Tumor Burden | 2019 |
Nivolumab (Opdivo°) and metastatic or inoperable lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Neoplasm Metastasis; Nivolumab; Survival Rate | 2017 |
Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Netherlands; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2019 |
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Humans; Kallikreins; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Spain; Time Factors | 2019 |
Oligometastatic Prostate Cancer Should Be Studied and Treated Differently to High-volume Disease. Con: The Underlying Biology is the Same, So They Should Not Be Treated Differently.
Topics: Androstenes; Cost of Illness; Docetaxel; Humans; Male; Molecular Biology; Neoplasm Metastasis; Phenotype; Positron-Emission Tomography; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy; Tubulin Modulators; Whole Body Imaging | 2019 |
Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).
Topics: Androgens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prostatic Neoplasms, Castration-Resistant; Sensitivity and Specificity; Treatment Outcome | 2020 |
Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Republic of Korea; Retrospective Studies; Treatment Outcome | 2019 |
Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Standard of Care; Tumor Burden | 2019 |
Black Phosphorus-Based Multimodal Nanoagent: Showing Targeted Combinatory Therapeutics against Cancer Metastasis.
Topics: Animals; Antineoplastic Agents; Docetaxel; Female; Lung Neoplasms; Mammary Neoplasms, Animal; Mice; Nanoconjugates; Neoplasm Metastasis; Phosphorus; Polylactic Acid-Polyglycolic Acid Copolymer | 2019 |
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Topics: Aged; Aldo-Keto Reductase Family 1 Member C3; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Image-Guided Biopsy; Immunohistochemistry; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2019 |
Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Biopsy, Large-Core Needle; Bone Neoplasms; Docetaxel; Endosonography; Health Resources; Health Services Accessibility; Humans; Iraq; Kallikreins; Kuwait; Lebanon; Lymph Node Excision; Magnetic Resonance Imaging; Male; Margins of Excision; Middle East; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy, Adjuvant; Risk; Salvage Therapy; Saudi Arabia; Syria | 2020 |
Osteoclasts and tumor cells dual targeting nanoparticle to treat bone metastases of lung cancer.
Topics: Animals; Bone Neoplasms; Cell Proliferation; Docetaxel; Drug Delivery Systems; Drug Liberation; Heterografts; Humans; Lung Neoplasms; Mice; Nanoparticles; Neoplasm Metastasis; Osteoclasts; Osteolysis; RAW 264.7 Cells | 2019 |
Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Docetaxel; Female; Human Umbilical Vein Endothelial Cells; Humans; Matrix Metalloproteinase 14; Matrix Metalloproteinase Inhibitors; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Ovarian Neoplasms; Taxoids; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2013 |
Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1.
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Growth Differentiation Factor 15; Humans; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2013 |
VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Bevacizumab; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Survival Rate; Taxoids; Vascular Endothelial Growth Factor A | 2013 |
Ulinastatin exerts synergistic effects with taxotere and inhibits invasion and metastasis of breast cancer by blocking angiogenesis and the epithelial-mesenchymal transition.
Topics: Aged; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Glycoproteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Random Allocation; Taxoids; Trypsin Inhibitors; Xenograft Model Antitumor Assays | 2013 |
Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2014 |
Let-7c governs the acquisition of chemo- or radioresistance and epithelial-to-mesenchymal transition phenotypes in docetaxel-resistant lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Apoptosis; Base Sequence; bcl-X Protein; Caspase 3; Cell Line, Tumor; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; MicroRNAs; Molecular Sequence Data; Neoplasm Metastasis; Oligonucleotide Array Sequence Analysis; Phenotype; Proto-Oncogene Proteins c-akt; Radiation Tolerance; Signal Transduction; Taxoids; Up-Regulation | 2013 |
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2013 |
Chemotherapy and resection for gastric cancer with synchronous liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Female; Fluorouracil; Glycosylation; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pilot Projects; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2013 |
Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer?
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Taxoids | 2013 |
Epirubicin and docetaxel as first-line treatment for hormonal receptor positive metastatic breast cancer: the predictive value of luminal subtype: a retrospective cohort analysis.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Taxoids | 2013 |
Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Docetaxel; Humans; Male; Neoplasm Metastasis; Orchiectomy; Probability; Prostatic Neoplasms; Quality-Adjusted Life Years; Taxoids; Treatment Outcome | 2013 |
Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Castration; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Proportional Hazards Models; Prostatic Neoplasms; Risk Factors; Sarcosine; Taxoids | 2013 |
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Taxoids | 2014 |
First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Approval; Female; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Docetaxel (Taxotere®)-induced cavitary change of pulmonary metastatic lesions complicated by bilateral spontaneous pneumothoraces in a patient with primary adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Docetaxel; Female; Humans; Lung Neoplasms; Neoplasm Metastasis; Pneumothorax; Taxoids; Tomography, X-Ray Computed | 2013 |
New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Docetaxel; Erlotinib Hydrochloride; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Taxoids; Treatment Outcome | 2013 |
Metastatic castration-resistant prostate cancer: integrating new learnings to optimise treatment outcomes.
Topics: Antineoplastic Agents; Biomarkers; Decision Trees; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2013 |
Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Clinical Trials, Phase I as Topic; Cytochrome P-450 CYP3A; Docetaxel; Doxorubicin; Drug Interactions; Female; Half-Life; Humans; Intestine, Small; Lapatinib; Membrane Transport Modulators; Mice; Mice, Inbred Strains; Neoplasm Metastasis; Quinazolines; Taxoids; Tissue Distribution; Topoisomerase II Inhibitors; Tubulin Modulators | 2013 |
Single institutional experience of the treatment of angiosarcoma of the face and scalp.
Topics: Aged; Antineoplastic Agents; Chemoradiotherapy; Combined Modality Therapy; Docetaxel; Facial Neoplasms; Female; Hemangiosarcoma; Humans; Interleukin-2; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retrospective Studies; Scalp; Skin Neoplasms; Taxoids; Treatment Outcome | 2013 |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Survival Analysis; Taxoids | 2013 |
Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Breast Neoplasms; DNA Primers; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Taxoids; Vascular Endothelial Growth Factor A | 2014 |
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Ifosfamide; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2013 |
Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption.
Topics: Absorption; Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Cryoelectron Microscopy; Docetaxel; Drug Delivery Systems; Humans; Lung Neoplasms; Lymphatic System; Male; Mice; Mice, SCID; Microscopy, Electron, Scanning; Nanocapsules; Neoplasm Metastasis; Particle Size; Rats; Rats, Sprague-Dawley; Swine; Swine, Miniature; Taxoids; Tissue Distribution; Xenograft Model Antitumor Assays | 2013 |
[Assessment of the vulnerable elders survey as a predictive test for elderly patients with advanced or metastatic gastric cancer treated with combined S-1 and docetaxel therapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Data Collection; Docetaxel; Drug Combinations; Female; Humans; Male; Neoplasm Metastasis; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Proliferation; Cyclooxygenase 2; Docetaxel; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; NF-kappa B; Nitrobenzenes; Prostatic Neoplasms; Quinazolines; Sulfonamides; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
Safety and antitumor efficacy of (153)Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Organophosphorus Compounds; Prostatic Neoplasms, Castration-Resistant; Safety; Taxoids | 2014 |
First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Drug Costs; Female; France; Hospital Costs; Hospitals, Private; Hospitals, University; Humans; Kaplan-Meier Estimate; Middle Aged; National Health Programs; Neoplasm Metastasis; Paclitaxel; Public Sector; Retrospective Studies; Taxoids; Time Factors; Transportation; Trastuzumab; Treatment Outcome | 2014 |
Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.
Topics: Antigens, Neoplasm; Antigens, Surface; Antineoplastic Agents; Biomarkers, Tumor; Cell Adhesion Molecules; Cell Count; Cell Line, Tumor; DNA Methylation; Docetaxel; Epithelial Cell Adhesion Molecule; Flow Cytometry; Glutamate Carboxypeptidase II; Humans; Hyaluronan Receptors; Immunohistochemistry; Leukocyte Common Antigens; Male; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Vimentin | 2014 |
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
Topics: Active Transport, Cell Nucleus; Androstenes; Androstenols; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Nucleus; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Green Fluorescent Proteins; Humans; Male; Microscopy, Confocal; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Time-Lapse Imaging | 2013 |
Anti-tumor efficacy of c(RGDfK)-decorated polypeptide-based micelles co-loaded with docetaxel and cisplatin.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Cell Survival; Cisplatin; Docetaxel; Endocytosis; HeLa Cells; Humans; Hydrodynamics; Magnetic Resonance Spectroscopy; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Micelles; Molecular Sequence Data; Neoplasm Metastasis; Peptides; Polyethylene Glycols; Polyglutamic Acid; Taxoids; Tissue Distribution; Tumor Burden | 2014 |
Complete pathological response in a patient with metastatic esophageal cancer treated with a regimen of capecitabine, oxaliplatin and docetaxel: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Taxoids | 2014 |
Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma.
Topics: Adult; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Mammary Neoplasms, Animal; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Taxoids; Transplantation, Heterologous; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Docetaxel and cisplatin in first line treatment of patients with unknown primary cancer: a multicenter study of the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Unknown Primary; Retrospective Studies; Taxoids; Treatment Outcome | 2014 |
Prognostic factors on overall survival of newly diagnosed metastatic nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Carcinoma; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Nasopharynx; Neck; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Radiotherapy, Conformal; Survival Rate; Taxoids; Young Adult | 2014 |
Epigenetic silencing of DACH1 induces the invasion and metastasis of gastric cancer by activating TGF-β signalling.
Topics: Animals; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; DNA Methylation; Docetaxel; Dose-Response Relationship, Drug; Epigenesis, Genetic; Eye Proteins; Female; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Stomach Neoplasms; Taxoids; Transcription Factors; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2014 |
The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Docetaxel; Drug Synergism; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome; Venous Thromboembolism; Warfarin | 2015 |
PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Epirubicin; ErbB Receptors; Female; Follow-Up Studies; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; ras Proteins; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids | 2014 |
Prostate cancer: the best fit for enzalutamide in metastatic prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Patient Selection; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2014 |
CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2015 |
Active targeting docetaxel-PLA nanoparticles eradicate circulating lung cancer stem-like cells and inhibit liver metastasis.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Glycoproteins; Lactic Acid; Liver; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Nanomedicine; Nanoparticles; Neoplasm Metastasis; Neoplastic Cells, Circulating; Peptides; Polyesters; Polymers; Taxoids | 2015 |
Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Ifosfamide; Karnofsky Performance Status; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Salvage Therapy; Taxoids; Thrombocytopenia; Treatment Outcome; Urologic Neoplasms | 2015 |
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lipocalin-2; Lipocalins; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Taxoids | 2015 |
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Biomarkers, Tumor; Disease-Free Survival; DNA Copy Number Variations; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation, Missense; Neoplasm Metastasis; Neoplastic Cells, Circulating; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids | 2015 |
Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T.
Topics: Aged; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tissue Extracts; Treatment Outcome | 2015 |
[A case of metastatic cancer of unknown primary origin that progressed rapidly after complete remission via second-line chemotherapy].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Docetaxel; Fatal Outcome; Humans; Male; Neoplasm Metastasis; Neoplasms, Unknown Primary; Remission Induction; Taxoids | 2015 |
The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax).
Topics: Aged; Antineoplastic Agents; Diarrhea; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Germany; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasms; Patient Selection; Prospective Studies; Quality of Life; Risk Factors; Severity of Illness Index; Surveys and Questionnaires; Taxoids; Time Factors; Treatment Outcome; Vomiting | 2015 |
Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle.
Topics: Animals; Antineoplastic Agents; Carboxymethylcellulose Sodium; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Female; Fibroblasts; Humans; Mice; Mice, Inbred C57BL; Nanoparticles; Neoplasm Metastasis; Pancreas; Pancreatic Neoplasms; Polyethylene Glycols; Taxoids; Xenograft Model Antitumor Assays | 2015 |
Why Chemotherapy Should be Given Early for Men with Metastatic Prostate Cancer.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2015 |
Evaluation of Docetaxel-Sensitive and Docetaxel-Resistant Proteomes in PC-3 Cells.
Topics: Antineoplastic Agents; Calreticulin; Cathepsin D; Cell Line, Tumor; Cofilin 1; Docetaxel; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Male; Mass Spectrometry; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Proteome; Proteomics; Taxoids; Up-Regulation | 2015 |
Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.
Topics: Aged; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Endpoint Determination; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Failure | 2015 |
E10A, an adenovirus carrying human endostatin gene, in combination with docetaxel treatment inhibits prostate cancer growth and metastases.
Topics: Adenoviridae; Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Docetaxel; Endostatins; Genetic Therapy; Genetic Vectors; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Nude; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2010 |
GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Male; MAP Kinase Signaling System; Membrane Proteins; Mice, Nude; Neoplasm Metastasis; Neoplasm Proteins; Nerve Tissue Proteins; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Receptors, CXCR4; Sequence Deletion; Taxoids; Time Factors; Xenograft Model Antitumor Assays | 2015 |
Establishment of a highly metastatic model with a newly isolated lung adenocarcinoma cell line.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Proliferation; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Neoplasm Metastasis; Neoplasms, Experimental; Proteomics; Taxoids; Tumor Cells, Cultured | 2015 |
Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Pemetrexed; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; C-Reactive Protein; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factors; Humans; Indoles; Interleukin-6; Middle Aged; Neoplasm Metastasis; Oxindoles; Propionates; Pyrroles; Taxoids; Vascular Endothelial Growth Factor A | 2016 |
Should docetaxel be administered earlier in prostate cancer therapy?
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Time Factors | 2015 |
Upregulation of KPNβ1 in gastric cancer cell promotes tumor cell proliferation and predicts poor prognosis.
Topics: Antineoplastic Agents; beta Karyopherins; Biomarkers; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Immunohistochemistry; Male; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Proportional Hazards Models; Protein Binding; Signal Transduction; STAT1 Transcription Factor; Stomach Neoplasms; Taxoids; Up-Regulation | 2016 |
Docetaxel for hormone-sensitive metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2015 |
Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Receptor Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Kallikreins; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Brachytherapy; Clinical Decision-Making; Docetaxel; Humans; Male; Neoplasm Metastasis; Pain; Pain Measurement; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radium; Taxoids | 2015 |
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Brachytherapy; Clinical Decision-Making; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Treatment Outcome | 2015 |
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Viscera | 2015 |
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
miR-138-Mediated Regulation of KINDLIN-2 Expression Modulates Sensitivity to Chemotherapeutics.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Integrin beta1; Male; Membrane Proteins; MicroRNAs; Neoplasm Metastasis; Neoplasm Proteins; Prostatic Neoplasms, Castration-Resistant; Signal Transduction; Taxoids; Treatment Outcome | 2016 |
Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Count; Cell Line, Tumor; Disease-Free Survival; Docetaxel; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Predictive Value of Tests; Prednisone; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Real-Time Polymerase Chain Reaction; Reproducibility of Results; Risk Factors; Serum Albumin; Serum Albumin, Human; Taxoids; Time Factors; Treatment Outcome | 2015 |
Will chemotherapy change the management of prostate cancer?
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Risk Assessment; Taxoids; Treatment Outcome | 2016 |
Metastatic prostate cancer in 2015: The new and the old that is new again.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Molecular Targeted Therapy; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids | 2016 |
Translating Clinical Evidence-Based Medicine into the Real World: Single-Center Experience with Cabazitaxel in Metastatic Prostate Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Evidence-Based Medicine; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2016 |
The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate
Topics: Androgen Antagonists; Docetaxel; Drug Therapy, Combination; Humans; Male; Medical Oncology; Neoplasm Metastasis; Oncologists; Practice Guidelines as Topic; Prognosis; Prostatic Neoplasms; Standard of Care; Surveys and Questionnaires; Taxoids | 2016 |
Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Docetaxel; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Outcome Assessment, Health Care; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Registries; Statistics as Topic; Survival Analysis; Taxoids; United Kingdom | 2016 |
Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.
Topics: Aged; Antineoplastic Agents; Dexamethasone; Docetaxel; Drug Therapy, Combination; Glucocorticoids; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2016 |
Prostate cancer: Validating early PSA response to enable improved treatment decisions.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Docetaxel; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Outcome Assessment, Health Care; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Registries; Statistics as Topic; Survival Analysis; Taxoids; United Kingdom | 2016 |
Graphene oxide-wrapped PEGylated liquid crystalline nanoparticles for effective chemo-photothermal therapy of metastatic prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Docetaxel; Drug Liberation; Graphite; Humans; Liquid Crystals; Male; Microscopy, Electron, Transmission; Nanoparticles; Neoplasm Metastasis; Oxides; Photochemotherapy; Polyethylene Glycols; Prostatic Neoplasms; Spectroscopy, Fourier Transform Infrared; Taxoids | 2016 |
Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Drug Interactions; Humans; Male; Mice; Mice, Nude; Neoplasm Metastasis; Prostatic Neoplasms; Random Allocation; Taxoids; Xenograft Model Antitumor Assays | 2016 |
[Predictive and prognostic value of monitoring lymphocyte subsets in peripheral blood before and after chemotherapy in patients with metastatic breast cancer].
Topics: Breast Neoplasms; Docetaxel; Female; Flow Cytometry; Humans; Lymphocyte Count; Neoplasm Metastasis; Prognosis; Survival Rate; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Taxoids | 2016 |
Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Decision Support Techniques; Dexamethasone; Disease-Free Survival; Docetaxel; Drug Costs; Humans; Male; Markov Chains; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Quality-Adjusted Life Years; Taxoids; Treatment Outcome | 2017 |
Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Taxoids | 2016 |
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Benzamides; Biomarkers, Tumor; Disease-Free Survival; DNA; Docetaxel; Drug Resistance, Neoplasm; Gene Dosage; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Chromatin Regulators as a Guide for Cancer Treatment Choice.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Chromatin; Chromatin Assembly and Disassembly; Cluster Analysis; Computational Biology; Databases, Genetic; Docetaxel; Gene Expression Profiling; Genes, Essential; Humans; Models, Biological; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Pharmacogenomic Testing; Protein Interaction Mapping; Protein Interaction Maps; Taxoids; Tubulin Modulators | 2016 |
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2016 |
Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Recurrence; Taxoids; Trastuzumab; Treatment Outcome | 2016 |
Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2016 |
Dual Drug Loaded Biodegradable Nanofibrous Microsphere for Improving Anti-Colon Cancer Activity.
Topics: Abdominal Neoplasms; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Curcumin; Docetaxel; Drug Carriers; Drug Screening Assays, Antitumor; Flow Cytometry; Hemolysis; Humans; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred BALB C; Microspheres; Molecular Weight; Nanofibers; Nanoparticles; Neoplasm Metastasis; Poloxamer; Polymers; Spectroscopy, Fourier Transform Infrared; Taxoids; Thermogravimetry; X-Ray Diffraction | 2016 |
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Topics: Abiraterone Acetate; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Practice Patterns, Physicians'; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids | 2017 |
Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever.
Topics: Antineoplastic Agents; Chemotherapy-Induced Febrile Neutropenia; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids | 2016 |
[Drug therapy of hormone-sensitive metastatic prostate cancer : Consensus paper of the AKO/AUO].
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Castration; Combined Modality Therapy; Docetaxel; Evidence-Based Medicine; Germany; Humans; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Practice Guidelines as Topic; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Urology | 2016 |
Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Tumor Burden | 2016 |
A biodistribution study of solid lipid-polyethyleneimine hybrid nanocarrier for cancer RNAi therapy.
Topics: Animals; Cell Line, Tumor; Docetaxel; Epidermal Growth Factor; Genetic Therapy; Humans; Lipids; Liver Neoplasms; Male; Mice; Nanomedicine; Nanoparticles; Neoplasm Metastasis; Neoplasm Transplantation; Polyethyleneimine; Prostatic Neoplasms; Random Allocation; RNA Interference; RNA, Small Interfering; Taxoids; Transfection | 2016 |
Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Carcinoma, Transitional Cell; Disease-Free Survival; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Retrospective Studies; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2016 |
Ecotropic viral integration site 1, a novel oncogene in prostate cancer.
Topics: Antineoplastic Agents; Cell Proliferation; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Gene Expression; Gene Knockdown Techniques; Humans; Immunohistochemistry; Male; MDS1 and EVI1 Complex Locus Protein; Models, Biological; Neoplasm Grading; Neoplasm Metastasis; Oncogenes; Prostatic Neoplasms; Proto-Oncogenes; Spheroids, Cellular; Taxoids; Transcription Factors; Tumor Cells, Cultured | 2017 |
The Utility of Serum CA9 for Prognostication in Prostate Cancer.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carbonic Anhydrase IX; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Phenotype; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2016 |
Silencing of CDC20 suppresses metastatic castration-resistant prostate cancer growth and enhances chemosensitivity to docetaxel.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cdc20 Proteins; Cell Proliferation; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer.
Topics: Aged; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2016 |
A comparison of the CARG tool, the VES-13, and oncologist judgment in predicting grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Decision Support Techniques; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Judgment; Male; Neoplasm Metastasis; Oncologists; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Risk Assessment; Taxoids | 2017 |
Synergistic Anticancer Effect of Peptide-Docetaxel Nanoassembly Targeted to Tubulin: Toward Development of Dual Warhead Containing Nanomedicine.
Topics: Antineoplastic Agents; Docetaxel; Drug Delivery Systems; Humans; MCF-7 Cells; Mucin-1; Nanomedicine; Nanoparticles; Neoplasm Metastasis; Neoplasms; Peptides; Taxoids; Tubulin | 2017 |
Avoiding Undertreatment of Aggressive Prostate Cancer by Early Use of Chemotherapy.
Topics: Docetaxel; Humans; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2017 |
Should Chemotherapy Be Used in Nonmetastatic Prostate Cancer?
Topics: Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Drug Therapy; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2017 |
Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Immunohistochemistry; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; SOX9 Transcription Factor; Taxoids; Time Factors; Tissue Array Analysis; Transcriptional Regulator ERG; Treatment Outcome | 2016 |
Prognostic Differences: Epstein-Barr Virus-Associated Primary Leiomyosarcoma of the Spine Versus Spinal Leiomyosarcoma Metastases.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Docetaxel; Epstein-Barr Virus Infections; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Immunocompromised Host; Leiomyosarcoma; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Metastasis; Prognosis; Retroperitoneal Neoplasms; Spinal Neoplasms; Taxoids | 2017 |
Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.
Topics: Aged; Alaskan Natives; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Asian; Black or African American; Disease-Free Survival; Docetaxel; Ethnicity; Hispanic or Latino; Humans; Indians, North American; Male; Native Hawaiian or Other Pacific Islander; Neoplasm Metastasis; Neoplasm Staging; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; SEER Program; Survival Rate; Taxoids; Treatment Outcome; White People | 2017 |
Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Polyethylene Glycols; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2017 |
[CR of All Target Lesions in a Patient with Metastatic Esophageal Cancer and Generalized Weakness Treated with Systemic Chemotherapy after Nutritional Support].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoplasm Metastasis; Parenteral Nutrition; Taxoids | 2016 |
Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Time Factors; Treatment Outcome | 2017 |
How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer?
Topics: Antineoplastic Agents; Bayes Theorem; Clinical Decision-Making; Decision Support Techniques; Docetaxel; Humans; Male; Neoplasm Metastasis; Patient Selection; Principal Component Analysis; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2017 |
The effects of 1,4-dimethylpyridine in metastatic prostate cancer in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Models, Animal; Docetaxel; Humans; Male; Mice; Neoplasm Metastasis; Niacinamide; Prostatic Neoplasms; Pyridines; Taxoids | 2017 |
The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome; Young Adult | 2017 |
[A Case of Resected Advanced Esophageal Cancer That Responded to Combination Therapy Comprising Docetaxel, Cisplatin, and 5-Fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2017 |
Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline.
Topics: Angiogenesis Inhibitors; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Oxindoles; Propionates; Pyrroles; Quality of Life; Taxoids | 2017 |
Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations.
Topics: Adult; Aged; BRCA1 Protein; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Taxoids | 2008 |
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Neoplasm Metastasis; Pilot Projects; Prostatic Neoplasms; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Taxoids; Zoledronic Acid | 2008 |
[Low dose-intensity docetaxel monotherapy for patients with anthracycline-resistant metastatic breast cancer in poor physical status].
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukopenia; Lymphatic Metastasis; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids | 2008 |
Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Delivery Systems; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2008 |
[Docetaxel-Cisplatin-5-Fu Combination Chemotherapy as a First-line Treatment in Patients with Metastatic or Recurred Gastric Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Stomach Neoplasms; Taxoids; Treatment Outcome | 2007 |
[Combination therapy consisting of gemcitabine, docetaxel and carboplatin as a second-line chemotherapy for patients with MVAC-treated metastatic urothelial carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Gemcitabine; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Retrospective Studies; Taxoids; Urologic Neoplasms; Vinblastine | 2008 |
Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease Models, Animal; Docetaxel; Drug Synergism; Female; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Taxoids; Xenograft Model Antitumor Assays | 2009 |
Combining 153Sm-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: first experience.
Topics: Aged; Analgesics, Non-Narcotic; Antineoplastic Agents; Body Weight; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Organophosphorus Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Taxoids; Time Factors; Treatment Outcome | 2008 |
Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
Topics: Adult; Albumins; Antineoplastic Agents; Attitude of Health Personnel; Breast Neoplasms; Canada; Cost-Benefit Analysis; Docetaxel; Drug Costs; Female; Humans; Meta-Analysis as Topic; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2009 |
[Chemotherapy of hormonorefractory and hormonoresistant metastatic prostate cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2008 |
Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Hospitalization; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Retrospective Studies; Taxoids; Treatment Outcome | 2009 |
3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Survival; Docetaxel; Down-Regulation; Drug Therapy, Combination; Female; Humans; Indoles; Inhibitor of Apoptosis Proteins; Luciferases; Male; Mice; Microtubule-Associated Proteins; Neoplasm Metastasis; Plasmids; Prostatic Neoplasms; Survivin; Taxoids | 2009 |
Reversal of docetaxel resistance with bevacizumab and thalidomide.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Taxoids; Thalidomide | 2009 |
Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Disease-Free Survival; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Taxoids; United Kingdom | 2009 |
Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Etoposide; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Failure | 2010 |
Downmodulation of Bcl-2 sensitizes metastatic LNCaP-LN3 cells to undergo apoptosis via the intrinsic pathway.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Docetaxel; Down-Regulation; Humans; Male; Neoplasm Metastasis; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Receptors, Androgen; RNA, Small Interfering; Signal Transduction; Taxoids | 2010 |
The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Docetaxel; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies; Skin Neoplasms; Taxoids; Temozolomide; Treatment Outcome | 2010 |
Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Chemistry, Pharmaceutical; Cytarabine; Deoxycytidine; Docetaxel; Drug Design; Drug Screening Assays, Antitumor; Fatty Acids; Humans; Inhibitory Concentration 50; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Taxoids | 2010 |
Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Comment on pegylated liposomal Doxorubicin plus docetaxel in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Neoplasm Metastasis; Polyethylene Glycols; Survival Analysis; Taxoids | 2010 |
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Endothelium, Vascular; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
[Efficacy of FEC and trastuzumab/docetaxel combination therapy for metastatic breast cancer].
Topics: Adenocarcinoma, Scirrhous; Adult; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Trastuzumab | 2010 |
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Diphosphonates; Docetaxel; Double-Blind Method; Drug Synergism; Female; Genes, erbB-2; Humans; Incidence; Jaw Diseases; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Oral Hygiene; Osteonecrosis; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2010 |
Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Docetaxel; Estrogen Receptor alpha; Female; Humans; Middle Aged; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Taxoids | 2010 |
Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2010 |
Photosensitive rash in association with porphyrin biosynthesis possibly induced by docetaxel and trastuzumab therapy in a patient with metastatic breast carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dermatitis, Phototoxic; Docetaxel; Exanthema; Female; Humans; Middle Aged; Neoplasm Metastasis; Porphyrins; Taxoids; Trastuzumab | 2010 |
[Chemotherapy in early stage of hormone-resistant metastatic prostate cancer: what are the indications?].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prostatic Neoplasms; Taxoids | 2010 |
[Safety and tolerance of docetaxel (especially 75 mg/m2) with cyclophosphamide (TC therapy) as adjuvant chemotherapy for Japanese patients with operable breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Taxoids | 2010 |
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quality of Life; Quinazolines; Retrospective Studies; Salvage Therapy; Taxoids | 2010 |
Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression.
Topics: Adult; Aged; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Basigin; Biomarkers, Tumor; Cell Line, Tumor; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Hyaluronan Receptors; Male; Middle Aged; Monocarboxylic Acid Transporters; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Up-Regulation | 2010 |
CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Division; Disease Models, Animal; Docetaxel; Immunohistochemistry; Male; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Neoplasm Metastasis; Peptides; Receptors, CXCR4; Taxoids; Vascular Endothelial Growth Factor A | 2011 |
Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Genes, BRCA1; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Repressor Proteins; Retrospective Studies; RNA, Messenger; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
The First Description of Docetaxel-Induced Recall Inflammatory Skin Reaction After Previous Drug Extravasation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Docetaxel; Drug Eruptions; Erythema; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Neoplasm Metastasis; Recurrence; Taxoids | 2011 |
Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Epidemiologic Methods; Humans; Immunotherapy; Male; Neoplasm Metastasis; Orchiectomy; Prednisone; Prognosis; Prostatectomy; Prostatic Neoplasms; Retreatment; Taxoids; Treatment Outcome | 2011 |
Docetaxel as a vital option for corticosteroid-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Docetaxel; Drug Resistance, Neoplasm; Humans; Karnofsky Performance Status; L-Lactate Dehydrogenase; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2011 |
Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Synergism; Female; Fluorouracil; Humans; Models, Theoretical; Neoplasm Metastasis; Taxoids | 2011 |
Successful multimodal treatment of a breast cancer patient with a recurrence invading the chest wall.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Plastic Surgery Procedures; Polyethylene Glycols; Ribs; Taxoids; Thoracic Wall | 2011 |
Novel approaches to treatment of leiomyosarcomas.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Gemcitabine; Humans; Ifosfamide; Leiomyosarcoma; Molecular Targeted Therapy; Neoplasm Metastasis; Poly(ADP-ribose) Polymerase Inhibitors; Taxoids | 2011 |
Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids | 2011 |
Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Remission Induction; Stomach Neoplasms; Taxoids; Treatment Outcome | 2012 |
Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Clusterin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Neoplasm Metastasis; RNA Interference; Taxoids; Transcription, Genetic | 2012 |
Absolute quantification of [(11)C]docetaxel kinetics in lung cancer patients using positron emission tomography.
Topics: Adult; Aged; Antineoplastic Agents; Carbon Radioisotopes; Dexamethasone; Docetaxel; Female; Humans; Kinetics; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Perfusion; Positron-Emission Tomography; Reproducibility of Results; Taxoids; Treatment Outcome; Tumor Burden | 2011 |
Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk; Taxoids; Treatment Outcome | 2013 |
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Thrombocytopenia; Treatment Failure | 2012 |
Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Castration; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Feasibility Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2011 |
Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study.
Topics: Aged; Androgen Antagonists; Androgens; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Orchiectomy; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models.
Topics: Animals; Antineoplastic Agents; Carboxymethylcellulose Sodium; Disease Models, Animal; Docetaxel; Drug Screening Assays, Antitumor; Intracellular Space; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Neoplasms; Polyethylene Glycols; Polymers; Taxoids; Tissue Distribution; Treatment Outcome | 2012 |
Reducing endothelial NOS activation and interstitial fluid pressure with n-3 PUFA offset tumor chemoresistance.
Topics: Animals; Cell Movement; Cells, Cultured; Coloring Agents; Disease Progression; Docetaxel; Docosahexaenoic Acids; Drug Resistance, Neoplasm; Eicosapentaenoic Acid; Endothelial Cells; Evans Blue; Extracellular Fluid; Fatty Acids, Omega-3; Female; Human Umbilical Vein Endothelial Cells; Humans; Mammary Neoplasms, Animal; Neoplasm Metastasis; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Permeability; Phosphorylation; Rats; Rats, Sprague-Dawley; Signal Transduction; Taxoids; Vascular Endothelial Growth Factor A | 2012 |
Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cell Line; Cell Line, Tumor; Diphosphonates; Docetaxel; Drug Carriers; Humans; Imidazoles; Lactic Acid; Mice; Nanoparticles; Neoplasm Metastasis; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Taxoids; Zoledronic Acid | 2012 |
Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Squamous Cell; Palliative Care; Remission Induction; Retrospective Studies; Survival Rate; Taxoids | 2012 |
[Combination chemotherapy using docetaxel, cisplatin, and S-1 for far advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2011 |
Targeting aurora kinases: a novel approach to curb the growth & chemoresistance of androgen refractory prostate cancer.
Topics: Androgens; Animals; Aurora Kinases; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Male; Mice; Mice, Transgenic; Neoplasm Metastasis; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Real-Time Polymerase Chain Reaction; RNA Interference; Taxoids | 2012 |
Systemic taxotere chemotherapy for metastatic tumor pleurisy in cats with spontaneous breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cats; Disease Progression; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Mammary Neoplasms, Experimental; Neoplasm Metastasis; Pleura; Pleurisy; Taxoids; Treatment Outcome | 2011 |
A case report of putative autoimmunity to prostate cancer after immune-mediated rejection of melanoma through a shared tumor antigen.
Topics: Adenocarcinoma; Aged, 80 and over; Antibodies, Neoplasm; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Docetaxel; Fatal Outcome; Glutamate Carboxypeptidase II; Humans; Immunotherapy; Male; Melanoma; Neoplasm Metastasis; Neoplasms, Second Primary; Prostate-Specific Antigen; Prostatic Neoplasms; Skin Neoplasms; Taxoids | 2012 |
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Radiation-Sensitizing Agents; Taxoids | 2012 |
[Docetaxel plus S-1 as a second-line chemotherapy for metastasis or recurrence of esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Recurrence; Salvage Therapy; Taxoids; Tegafur | 2012 |
Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Costs and Cost Analysis; Cyclophosphamide; Databases, Factual; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Health Care Costs; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors; Taxoids | 2012 |
CXCR4 expression in prostate cancer progenitor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cell Adhesion; Cell Proliferation; Chemokine CXCL12; Cyclams; Docetaxel; Heterocyclic Compounds; Humans; Male; Mice; Neoplasm Metastasis; Neoplastic Stem Cells; Prostatic Neoplasms; Receptors, CXCR4; Taxoids | 2012 |
[A case of gastric cancer treated with modified docetaxel, cisplatin and 5-fluorouracil(mDCF)with ingestion inability].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Feeding and Eating Disorders; Fluorouracil; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Stomach Neoplasms; Taxoids; Tomography, X-Ray Computed | 2012 |
Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Genotype; Humans; Middle Aged; Neoplasm Metastasis; Pharmacogenetics; Prognosis; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2012 |
Choroidal metastasis as the sole initial presentation of metastatic lung cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Choroid Neoplasms; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Taxoids | 2012 |
Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Taxoids; Treatment Outcome; Young Adult | 2012 |
[A case of advanced gastric cancer successfully treated with docetaxel and S-1 combined therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Positron-Emission Tomography; Remission Induction; Stomach Neoplasms; Taxoids; Tegafur | 2012 |
Dual HER2 blockade slows metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
A combined therapy with docetaxel and nedaplatin for relapsed and metastatic esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids | 2012 |
Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75 years old.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Asian People; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2012 |
Pertuzumab (Perjecta) for HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Approval; Female; Humans; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab; United States; United States Food and Drug Administration | 2012 |
First-line bevacizumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimisation analysis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2012 |
In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147.
Topics: Animals; Antineoplastic Agents; Basigin; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Monocarboxylic Acid Transporters; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Muscle Proteins; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Taxoids; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2012 |
ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Receptor, ErbB-2; Receptors, IgG; Survival Rate; Taxoids; Trastuzumab | 2012 |
Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Turkey | 2012 |
Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care.
Topics: Antineoplastic Agents; Continuity of Patient Care; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2012 |
A novel monomethoxy polyethylene glycol-polylactic acid polymeric micelles with higher loading capacity for docetaxel and well-reconstitution characteristics and its anti-metastasis study.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Guinea Pigs; Hemolysis; Lactic Acid; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Micelles; Neoplasm Metastasis; Polyesters; Polyethylene Glycols; Polymers; Rats; Taxoids | 2012 |
Optimize administration protocol of capecitabine plus docetaxel combination in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Databases as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Models, Statistical; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2012 |
Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Dendritic Cells; DNA-Binding Proteins; Docetaxel; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; HMGB1 Protein; Humans; Immunomodulation; Neoplasm Metastasis; Peptides, Cyclic; Taxoids | 2012 |
Interferon-alpha improves docetaxel antitumoral and antimetastatic efficiency in Lewis lung carcinoma bearing mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cell Line, Tumor; Docetaxel; Immunologic Factors; Interferon-alpha; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Taxoids | 2012 |
Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids | 2013 |
Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; China; Docetaxel; Hemoglobins; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Taxoids | 2013 |
Abiraterone and its place in the treatment of metastatic CRPC.
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2013 |
Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cell Division; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Fibroblast Growth Factor 2; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Polyethylene Glycols; Prostatic Neoplasms; Random Allocation; Recombinant Proteins; Taxoids; Xenograft Model Antitumor Assays | 2002 |
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Transitional Cell; Cyclohexanes; Docetaxel; Drug Synergism; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Sesquiterpenes; Taxoids; Time Factors; Transplantation, Heterologous; Urinary Bladder Neoplasms | 2003 |
Measurement of volumetric and vascular changes with dynamic contrast enhanced MRI for cancer therapy monitoring.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Contrast Media; Docetaxel; Female; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Paclitaxel; Radiography; Rats; Rats, Inbred F344; Taxoids; Time Factors; Treatment Outcome | 2002 |
Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Docetaxel; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Middle Aged; Multicenter Studies as Topic; Narcotics; Neoplasm Metastasis; Paclitaxel; Pain; Pain Measurement; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Taxoids | 2003 |
[Cylindroma of the trachea, a rate tumor with unusual evolution].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carcinoma, Adenoid Cystic; Cisplatin; Combined Modality Therapy; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Radiography, Thoracic; Radiotherapy Dosage; Taxoids; Tracheal Neoplasms; Treatment Outcome | 2003 |
Calcitriol and alopecia--is it the hair apparent?
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Docetaxel; Humans; Male; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Taxoids | 2003 |
Extraorbital sebaceous carcinoma with rapidly developing visceral metastases.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Fatal Outcome; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Orbit; Paclitaxel; Sebaceous Gland Neoplasms; Taxoids; Viscera | 2003 |
Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Taxoids | 2003 |
Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Retreatment; Taxoids | 2004 |
[New: gemzar plus taxan in metastatic breast carcinoma. Optimal combination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2003 |
Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Genes, erbB-2; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Taxoids; Trastuzumab; Treatment Outcome | 2003 |
Influence of dosing schedule on toxicity and antitumor effects of a combination of adriamycin and docetaxel in mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Granulocyte Precursor Cells; Leukocytes; Male; Mice; Mice, Inbred ICR; Neoplasm Metastasis; Radiometry; Taxoids; Time Factors | 2004 |
[Therapeutic options and controversies in the management of prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Agents, Phytogenic; Brachytherapy; Combined Modality Therapy; Cryotherapy; Docetaxel; Forecasting; Humans; Male; Neoplasm Metastasis; Palliative Care; Patient Selection; Prognosis; Prostatectomy; Prostatic Neoplasms; Taxoids; Ultrasonic Therapy | 2003 |
Docetaxel extravasation into the normal breast during breast cancer treatment.
Topics: Antineoplastic Agents, Phytogenic; Blister; Breast; Breast Neoplasms; Docetaxel; Extravasation of Diagnostic and Therapeutic Materials; Female; Histamine H1 Antagonists; Humans; Hydrocortisone; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Taxoids | 2004 |
Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Taxoids; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2004 |
Use of LeVeen pleuroperitoneal shunt for refractory high-volume chylothorax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chylothorax; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Fatal Outcome; Fluorouracil; Humans; Ligation; Male; Middle Aged; Neoplasm Metastasis; Parenteral Nutrition, Total; Peritoneovenous Shunt; Pleural Effusion; Postoperative Complications; Respiration, Artificial; Taxoids; Thoracostomy; Thoracotomy; Tissue Adhesives | 2004 |
Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Prospective Studies; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
[Adjuvant chemotherapy with taxoid-containing drugs in breast cancer: soon to be expected in the Netherlands].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2004 |
[Role of taxanes in treatment of breast cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Data Interpretation, Statistical; Disease Progression; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Taxoids; Time Factors; Trastuzumab | 2004 |
Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and docetaxel in a human prostate cancer PC-3 model.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Apoptosis; Cyclohexanes; Docetaxel; Drug Interactions; Humans; Male; Neoplasm Metastasis; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Prostatic Neoplasms; Sesquiterpenes; Taxoids; Tumor Cells, Cultured | 2005 |
[Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids | 2005 |
[An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Male; Neoplasm Metastasis; Neoplasms, Unknown Primary; Paclitaxel; Pancreatic Neoplasms; Taxoids | 2005 |
A modified weekly docetaxel schedule as first-line chemotherapy in elderly metastatic breast cancer: a safety study.
Topics: Age Factors; Aged; Bone Neoplasms; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Geriatric Assessment; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Risk Assessment; Skin Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer.
Topics: Adipocytes; Animals; Breast Neoplasms; Cell Death; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Humans; Interferon-gamma; Interleukin-6; Interleukin-8; Lactones; Mice; Mice, Nude; Neoplasm Metastasis; Sesquiterpenes; Survival Rate; Taxoids; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2005 |
[Hormone-refractory metastatic prostate carcinoma -- combination improves survival].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Clinical Trials, Phase III as Topic; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Time Factors | 2005 |
Early onset of oral aphthous ulcers with weekly docetaxel.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Stomatitis, Aphthous; Taxoids | 2005 |
Tumor lysis syndrome after treatment with docetaxel for non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Fatal Outcome; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Taxoids; Tumor Burden; Tumor Lysis Syndrome | 2006 |
A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229).
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Vaccines; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Poxviridae; Randomized Controlled Trials as Topic; Research Design; Taxoids | 2006 |
A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Recurrence; Taxoids; Tegafur | 2006 |
Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Docetaxel; Female; Genotype; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Genetic; Taxoids | 2006 |
Pharmacokinetics and toxicity of weekly docetaxel in older patients.
Topics: Aged; Aging; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2006 |
Trastuzumab/docetaxel-induced nail dystrophy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Fatal Outcome; Female; Humans; Middle Aged; Nail Diseases; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2006 |
Chemoimmunotherapy in the treatment of metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; CD4-CD8 Ratio; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Endpoint Determination; Female; Fluorouracil; Humans; Immunotherapy; Killer Cells, Natural; Leucovorin; Lymphocyte Count; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Survival Analysis; Taxoids; Vascular Endothelial Growth Factor A | 2007 |
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Synergism; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2007 |
Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Keratin-18; Models, Genetic; Necrosis; Neoplasm Metastasis; Reproducibility of Results; Taxoids; Time Factors; Treatment Outcome | 2007 |
Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Quality of Life; Stomach Neoplasms; Taxoids; Treatment Outcome | 2007 |
Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Tolerance; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Taxoids; Treatment Outcome | 2007 |
Docetaxel weekly with metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2007 |
Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancer.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukopenia; Lymphatic Metastasis; Middle Aged; Nausea; Neoplasm Metastasis; Retrospective Studies; Taxoids; Treatment Outcome; Vomiting | 2007 |
[Docetaxel-cisplatin-5-FU combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Taxoids | 2007 |
Acute lung injury associated with docetaxel and bevacizumab.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Docetaxel; Female; Humans; Lung Diseases, Interstitial; Neoplasm Metastasis; Respiratory Distress Syndrome; Taxoids; Tomography, X-Ray Computed | 2007 |
Retroviral integration site analysis and the fate of transduced clones in an MDR1 gene therapy protocol targeting metastatic breast cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Hematopoietic Stem Cells; Humans; Neoplasm Metastasis; Retroviridae; Taxoids; Virus Integration | 2007 |
Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.
Topics: Animals; Antibodies; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Chemokine CCL2; Docetaxel; Humans; Immunization, Passive; Immunoglobulin G; Male; Mice; Mice, SCID; Neoplasm Metastasis; Prostatic Neoplasms; Receptors, CCR2; Receptors, Chemokine; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: a retrospective analysis of 12 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Docetaxel; Esthesioneuroblastoma, Olfactory; Female; Follow-Up Studies; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neuroblastoma; Retrospective Studies; Taxoids | 2008 |
[An advanced metastatic breast cancer patient successfully treated with combination therapy including docetaxel, doxorubicin and cyclophosphamide (TAC) as salvage therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Salvage Therapy; Taxoids; Tomography, X-Ray Computed; Treatment Failure | 2008 |
The postchemotherapy PSA surge syndrome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Estramustine; Gonadotropin-Releasing Hormone; Humans; Kinetics; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Sesquiterpenes; Syndrome; Taxoids; Treatment Outcome | 2008 |
European oncologists' preferences for the management of breast cancer: case presentations and expert commentary.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Genes, erbB-2; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Tamoxifen; Taxoids; Trastuzumab | 2008 |
Paclitaxel in doxorubicin-resistant metastatic breast cancer patients.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
An overview of phase II studies of docetaxel in patients with metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
Effect of microtubule disruption on cell adhesion and spreading.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Adhesion; Cell Size; Docetaxel; Dose-Response Relationship, Drug; Humans; Integrins; Microtubules; Neoplasm Metastasis; Nocodazole; Paclitaxel; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 1998 |
Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Neoplasms; Paclitaxel; Taxoids | 1998 |
[Tumor therapy. New concepts for advanced cases].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids | 2000 |
Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Dexamethasone; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids | 2000 |
Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; Breast Neoplasms; Cell Survival; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Flow Cytometry; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Immunohistochemistry; Immunomagnetic Separation; Keratins; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Risk Factors; Stem Cells; Taxoids; Time Factors; Tumor Cells, Cultured | 2001 |
[Combination of taxotere and doxorubicin in chemotherapy of disseminated breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 2001 |
[Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |